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Summary 
In the past two decades, liposomes have been employed extensively as vehicles to modify and 
enhance the delivery of drugs, vaccines, and biomolecules. This highly versatile drug delivery 
system lends itself to a plethora of applications, providing both safety and efficacy. Within this 
thesis, the potential of liposomes to deliver challenging drugs has been explored, including the 
co-delivery of drugs of divergent solubility and an anti-respiratory syncytial virus (RSV) peptide. 
Prior to the formulation development, the HPLC based method for simultaneous analysis of the 
drugs metformin HCl and glipizide was developed and validated. The formulation development 
initially considered the production of multi-lamellar vesicles using the conventional thin film 
hydration method, where the effect of lipid chain length and cholesterol content on liposome 
attributes was considered. After optimising the concentration of cholesterol, the capacity of 
liposomes to load drugs was determined by a pilot escalation study for both the drugs. The 
synergistic effect of drugs on in-vitro drug release was studied using USP-IV dissolution 
apparatus. Furthermore, the similar composition of lipids was used to prepare liposomes with 
the emerging technique, microfluidics. Here, for the first time, simultaneous co-encapsulation 
of hydrophilic and lipophilic drug was demonstrated. Following the optimisation of microfluidics 
process parameters necessary for the production of small unilamellar liposomes with narrow 
polydispersity index (PDI), the effect of single or co-drug encapsulation on particle 
characteristics and drug encapsulation was investigated, with a subsequent pilot drug 
escalation study to determine the drug loading capacity of liposomes produced by 
microfluidics. Finally, in-vitro studies were performed to study the synergistic effect of 
simultaneously co-encapsulated drugs. Also, the potential of the 1,2-disteroyl-sn-glycero-
phosphocholine (DSPC): cholesterol formulation as a carrier of anti-RSV protein and the empty 
formulation itself as anti-RSV agent were investigated using bio-analytical techniques.  
The co-encapsulation of drugs of divergent solubility was achieved by both the conventional 
thin film hydration and the emerging microfluidics technology. However, microfluidics proved 
advantageous with regards to time required for liposome production, one-step production of 
small unilamellar vesicles (SUV), narrow PDI and effective drug encapsulation with lower 
amounts of lipids. The liposomes of DSPC: cholesterol were also discovered to be a potential 
carrier of anti-RSV peptide, as well as potential anti-RSV agent itself, compared with the 
reported gold nanoparticles (GNPs).  
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Chapter 1: Realising the potential of liposomes: a carrier for 
chemical and biological molecules 
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1 Introduction to delivery systems 
To improve the therapeutic profile and efficacy of drugs, various carrier systems have been 
developed, including nano-particulate systems  to microelectronic carriers (Balmayor et al., 
2011). These systems can be used for a wide range of delivery routes, from topical delivery 
through to crossing the blood brain barrier (BBB), with the aim of targeted, timed and dose 
specific delivery of chemical and biological molecules.  
The aim of delivery systems is to enhance the delivery of active pharmaceutical ingredients to 
the target site and overcome limitations in the stability and/or solubility of the ingredient. 
There are various designs, methodologies and process optimisations involved in the 
development of these drug delivery systems; for example, 1) transdermal delivery systems, 2) 
colloidal carriers and 3) drug-conjugates and prodrug technology. Furthermore, technical 
development of these novel drug delivery systems (NDDS) involves the use of methodologies 
such as hot melt extrusion (e.g. Bioadhesive hot-melt extruded film (Repka et al., 2002)), dry 
powder inhalers (e.g. drug delivery to the respiratory tract using dry powder inhaler (Timsina et 
al., 1994)), lyophilisation (e.g. lyophilised paclitaxel magneto liposomes (Zhang et al., 2005)) and 
microfluidisation (e.g. Preparation of nano-emulsions (Tadros et al., 2004)). Of these various 
systems, colloidal carriers of drugs, peptides and genes have been the choice for many 
researchers, due to advantages including their ease in cell penetration and protection against 
biodegradation (Hung, 2006). 
Nanoparticles and nanotechnology generally refers to the particles that have one or more 
dimensions between approximately 1 and 100 nm; however, the US Food and Drug 
Administration (FDA) consider 1000 nm as the upper limit for screening of materials for 
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consideration as nanotechnology and a key consideration is their small size and high surface 
area to volume ratio. Due to their size, nanoparticles tend to be more accessible to target sites 
within the body and less susceptible to recognition and removal by the mononuclear phagocyte 
system (MPS) after administration. Examples of nanoparticles commonly used within 
pharmaceutical research include liposomes, niosomes, and the metal/polymeric nanoparticles. 
 
1.1 Liposomes 
Liposomes were first discovered by (Bangham et al., 1965), who described these ‘Bangosomes’ 
as swollen phospholipid systems. The term ‘liposome’ was subsequently adopted, which came 
from a combination of two Greek words, ‘lipos’ and ‘soma’, meaning ‘fat’ and ‘body’, 
respectively (Çağdaş et al., 2014). The application of liposomes in drug and vaccine delivery was 
first proposed in the 1970s by Gregoriadis (Gregoriadis et al., 1971; Gregoriadis and Ryman, 
1972a) and their medical uses became perceptible during the 1990s; the European Medicines 
Agency (EMA) approved the first liposomal drug product, ‘AmBisome’, with the active 
ingredient amphotericin-B for human use in 1990, and subsequently the FDA approved it in 
1997 (Cornier et al., 2016). It is produced as small negatively charged liposomes, containing the 
lipophilic drug Amphotericin B, used against systemic fungal infections.  
 
Since these early developments, countless researchers have studied and looked to 
commercialise liposome drug delivery systems, with more than a dozen liposomal formulations 
already marketed (Table 1.1). Whilst previous dosage forms were dose limited due to toxicity 
 and poor aqueous solubility, incorporation into liposomes allows for targeted delivery 
Doxil) and improved solubility (e.g. AmBisome) and, due to this formulation approach, l
and longer dosage regimens are now possible with reduced toxicity 
composed of lipids, that when forced into an aqueous environment, align to form bilayered 
vesicles, which can be single or multi
 
Figure 1.1 Liposomes made up where 
exist as unilamellar or multi-lamellar structures
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(Lasic, 1998
-lamellar in nature (Figure 1.1).   
 
hydrophilic core is surrounded by lipid bilayer. Liposomes 
 (Kastner et al., 2015). 
(e.g. 
arger 
). Liposomes are 
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Table 1.1 Examples of marketed liposomal formulations. 
No Product Drug Therapeutic use Lipids 
1 Ambisome Amphoteracin 
B 
Antifungal (fungal infections and 
leishmaniasis) 
Hydrogenated soy PC(HSPC), 1,2-
dioctadecanoyl-sn-glycero-3-phospho-
(1'-rac-glycerol) (DSPG), cholesterol 
2 Myocet Doxorubicin Anti-cancer (leukemia, lymphoma, and 
different types of carcinoma as well as soft 
tissue sarcomas) 
Egg PC (EPC) and cholesterol  
3 Doxil Doxorubicin Anti-cancer (leukemia, lymphoma, and 
different types of carcinoma as well as soft 
tissue sarcomas) 
HSPC, cholesterol and PEG 2000 
4 Caelyx Doxorubicin Anti-cancer (leukemia, lymphoma, and 
different types of carcinoma as well as soft 
tissue sarcomas) 
HSPC, cholesterol and PEG 2000 
5 LipoDox Doxorubicin Anti-cancer (leukemia, lymphoma, and 
different types of carcinoma as well as soft 
tissue sarcomas) 
1,2-distearoyl-sn-glycero-3-
phosphocholine 
(DSPC), cholesterol , PEG 2000-DSPE  
Thermodox Doxorubicin Anti-cancer (leukemia, lymphoma, and 
different types of carcinoma as well as soft 
tissue sarcomas) 
1,2-dipalmitoyl-sn-glycero-3-
phosphocholine 
(DPPC), mono steroyl PC (MSPC) and 
7 DaunoXome Daunorubicin Anti-cancer (leukemia, lymphoma, and 
different types of carcinoma as well as soft 
tissue sarcomas) 
DSPC and cholesterol 
8 Marqibo Vincristine Anti –cancer (leukaemia, lymphoma, 
myeloma, breast, head as well as neck 
cancer) 
Egg sphingomylin and cholesterol 
9 Visudyne Verteporfin Macular degeneration (To eliminate the 
abnormal blood vessles in the eye). 
BPD-MA:EPG:1,2-dimyristoyl-sn-glycero-
3-phosphocholine (DMPC) 
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10 DepoCyt  Cytarabine Anti-cancer (myeloid leukemia, acute 
lymphocytic leukemia, chronic myelogenous 
leukemia, and non-Hodgkin's lymphoma) 
1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), 1,2-
dihexadecanoyl-sn-glycero-3-phospho-
(1'-rac-glycerol)(DPPG) and cholesterol 
11 DepoDur Morphine 
sulphate 
Opioid Analgesic  DOPC, DPPG and cholesterol 
12 Arikace Amikacin Bacterial infections (joint infections, intra-
abdominal infections, meningitis, 
pneumonia, sepsis, as well as urinary tract 
DPPC and cholesterol 
13 Lipoplatin Cisplatin Anti-cancer (testicular, ovarian , breast, 
bladder, head, neck , cervical cancer and 
lung cancer) 
DPPG, Soy PC, cholesterol and PEG2000-
DSPE 
14 LEP-ETU Paclitaxel Anti-cancer (Kaposi sarcoma and ovarian, 
breast, lung,  cervical as well as pancreatic 
cancer) 
DOPE and cholesterol  
15 Epaxal  Hepatitis A 
vaccine 
Hepatitis A DOPC and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) 
16 Inflexal V Influenza 
vaccine 
Influenza 
 
DOPC and DOPE 
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1.1.1 Classification of liposomes 
Liposomes can be classified in a range of ways. Based on the interaction of liposomes with cell 
and other blood components, liposomes are broadly classified into five categories: 1) 
conventional liposomes; 2) pH sensitive liposomes; 3) cationic liposomes; 4) immuno-
liposomes; and 5) non-interactive sterically stabilised liposomes (also known as long circulating 
liposomes)(Storm and Crommelin, 1998b). Sterically stabilised liposomes are prepared by using 
long-chain polymers in the lipid bilayer of liposomes (Bakker-Woudenberg et al., 2005). These 
polymers form a coat on the surface and help in blocking opsonin adsorption as well as 
penetration (Sharma and Sharma, 1997). This reduced opsonisation results in slower uptake of 
these long circulating liposomes by mononuclear phagocytes (MPS). Hence, these types of 
liposomes are different from conventional liposomes because of their extended half-life in vivo 
(Chonn and Cullis, 1995; Ricci et al., 2000). 
 
Liposomes can be prepared in the range of approximately 50 nm to several microns and can be 
single or multi-lamellar in nature. Both the size and number of lamella or lipid bilayer can 
influence drug entrapment efficiency within liposomes. Therefore, based on their size and 
structure liposomes are classified into three major categories: 1) multilamellar vesicles (MLV); 
2) large unilamellar vesicles (LUV); 3) small unilamellar vesicles (SUV) (Figure 1.2).            
 
 
 
 Figure 1.2 Classification of liposomes based on their size. SUV and LUV can be prepared from 
MLV using techniques like sonication (for 
 
 
1.1.2 Considerations in building liposomes
Lipids are molecules made up of prominently hydrocarbon moieties 
ranging from 150 to 3000 (Small, 1981
aliphatic or aromatic (cyclic), and normally
lipids are also available and these are known as triacylglycerols
1981). Fahy et al (2005) have defined a lipid as hydrophobic or 
may originate entirely or in part by carbonium
carbocation-based condensation of isoprene units 
based condensation of thioesters are fatty acids and polyketides
condensation of isoprene units includes phenols
functional backbone, lipids could be categori
prenols, or saccharolipids (Fahy et al., 2005
main categories; simple and complex lipids
H and O in their structure, whereas complex lipids include extra elements like phosphorous, 
sulfur and nitrogen in their structure. Phospholipids are the most common type of lipids used in 
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SUV), thawing (LUV), etc (Kastner et al., 2015
 
, having molecular weight
). This hydrocarbon portion of the lipid molecule could be 
 they have one or two carbon chains. Three chained 
 (Perrie and Rades, 2012b
amphiphilic small molecules that 
-based condensation of thioesters and/or 
(Fahy et al., 2005). Examples of carbonium
, whereas carbocation
 and sterols. Depending on the chemically 
sed as polyketides, acylglycerols, sphingolipids, 
). Moreover, lipids may be categorised 
 (Fahy et al., 2005). Simple lipids contain elements C, 
). 
s 
; Small, 
-
-based 
into two 
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liposome preparation, due to the variability of head group, degree of hydrocarbon chain 
saturation and variability in chain length, which provides a wide range of options in the 
formulation of liposomes. 
 
1.1.2.1 Mechanism of liposome vesicle production 
 
Phospholipids have two hydrophobic tails and a hydrophilic head. Liposomes are generally 
produced upon hydration of thin lipid films or lipid cakes and layers of liquid crystalline bilayers 
fluidise and swell. These hydrated bilayers detach and self-transform to a large multi lamellar 
vesicle upon mechanical agitation.  
 
The process of vesicle formation is largely dependent of energy input. Basically, an energy is 
associated with a patch of thin film where the phospholipids are layered (Figure 1.3a) and the 
energy associated with the thin film is higher towards the edges and near the hydrophobic tails. 
The significance of the energy effect minimises when these hydrophobic tails get exposed to 
the hydration media and forms a spherical vesicle (Patil and Jadhav, 2014). During the process 
of vesicle formation, the ‘bending energy’ is responsible for the bending of the lipid layer into 
the disc shape and this causes an increase in the total energy of the system (Patil and Jadhav, 
2014); this, at a subsequent stage, starts decreasing and vanishes upon vesicle formation after 
attachment of the bilayer edges (Patil and Jadhav, 2014).  
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In other words, phospholipids are molecules, which can be dissolved in organic solvent but 
form stacks of lipid upon removal of the solvent (Lasic and Barenholz, 1996). As described in 
Figure 1.3b, these stacks upon hydration swell and with the help of bending energy turn into 
multi-lamellar vesicles (MLV).  
37 
 
 
                        
 
   a           b 
Figure 1.3 a) Arrangement of a single molecule of lipid to lipid bilayer. b) Diagrammatic illustration of the mechanism of liposomal 
vesicle formation.
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1.1.2.2 Effect of transition temperature in bilayer formation 
 
There are two key components within liposomes: phospholipids (normally a phosphatidyl 
choline) and cholesterol. Phospholipids are available with a range of fatty acid chains and this 
impacts on the resulting liposome characteristics. Indeed, the physico-chemical characteristics 
of liposomes is principally determined by their lipid, as well as other constituents and 
formulation techniques, which include size reduction methods to produce smaller, more 
homogeneous liposome suspensions. Traditional examples include sonication, whereby 
disruptive energy causes large vesicles to rearrange into smaller ones, and size-extrusion, in 
which vesicles are forced through defined pore sizes. As shown in Figure 1.4, lipids are 
composed of two main sections: a hydrophobic section and a hydrophilic head-group. Due to 
the hydrophobic and hydrophilic nature of the tail and head respectively, the polar head group 
is directed outwards and the non-polar tails form the inner bilayer phase. Due to this biphasic 
nature, both water soluble and lipophilic drugs can be loaded into liposome systems. Table 1.2 
lists a selection of phospholipids and their characteristics.   
 
As can be seen from Table 1.2, increasing the hydrophobic chain length of lipids increases their 
transition temperature. Transition temperature (Tc) plays crucial role in formation, as well as 
membrane fluidity of liposomes (Mabrey and Sturtevant, 1976). The lipid transition 
temperature is the temperature where the lipid changes its phase from an ordered solid state 
of lipid to disordered liquid crystalline state (Figure 1.4). In the ordered solid state, the 
hydrocarbon chains are extended and packed; whereas in the disordered state, the chains are 
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randomly oriented. The Tc of lipid bilayers can be determined by calorimetric analysis; when a 
substance experiences a transition from a solid to a liquid state, the energy is gained by the 
system to break the intermolecular chains without causing a consistent increase in the 
temperature of the substance, and this change in phase can be observed as a sharp peak in the 
thermogram (Kolusheva et al., 2003). Microcal-high sensitivity colorimeter is widely used in 
determination of Tc, through calculation of change in temperature (∆Hcal) and Van’t Hoff 
enthalpies (∆Hvaf). The position of peak representing excess heat capacity versus temperature is 
considered as the transition temperature (Tc) (Savva et al., 1999). 
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Table 1.2 Examples of lipids along their full form, molecular structure, molecular weight (MW) 
and transition temperature (Tc). 
Lipid Structure MW Tc, °C 
Phosphatidylcholine  (PC) 
 
770.12 -2 
Phosphatidylglycerol (PG) 
 
782.28 -3 
Hydrogenated 
phosphatidylcholine (HSPC) 
 
783.77 53  
1,2-disterol-sn-
phosphatidylcholine (DSPC) 
 
790.15 55 
1,2—Dimyristoyl-sn-glycero-3-
phosphatidyl choline (DMPC) 
 
677.93 24 
1,2—Dipalmitoyl-sn-glycero-3-
phosphatidyl choline (DPPC) 
 
734.04 41 
Distearoyl-phosphatidylglycerol 
(DSPG) 
 
801.06 55 
Dipalmitoylphosphatidylglycerol 
(DPPG) 
 
744.95 41 
Dioleoylphosphatidylglycerol 
(DOPC) 
 
786.11 -17 
1,2-disteroyl-sn-glycero-3-
phosphoethanolamine (DSPE) 
 
748.07 74 
1,2-dipalmitoyl-sn-glycero-3-
phosphate (DPPA) 
 
670.87 -20 
41 
 
The formation of liposomes can be described as a two-step process; the first step is bilayer 
formation and the second is the closing of the bilayer to form liposomes. The transition 
temperature of lipids is responsible for their phase change and lipids, when at temperatures 
above their transition temperature, will initially orientate into parallel alignment and form a 
sheet like structure (Figure 1.4); subsequently liposomes form by the bilayer sheet closing onto 
a vesicle structure to reduce tension (Antonietti and Förster, 2003).  
 
 
Figure 1.4 Diagrammatic illustration of effect of change in the transition temperature on the 
lipid bilayer. (modified from (Monteiro et al., 2014)). 
 
In the consideration of their application, the liposomal transition temperature is a key factor. 
Employing lipids with transition temperatures about body temperature (>37⁰C) make lipid 
bilayers less prone to leakage and uptake by the MPS at physiological temperature (Gregoriadis 
et al., 1984). On the other hand, liposomes with lower Tc (<37⁰C) are more susceptible to 
leakage at physiological temperature and may experience quick uptake by MPS or lose their 
original structure at that temperature (Bhandary et al., 2010; Sharma and Sharma, 1997). 
Commonly 1,2-disteroyl-sn-phosphatidylcholine (DSPC) is used to prepare liposomes (Table 
1.2). The long saturated alkyl chains of DSPC result in a transition temperature of 55°C and this 
property of DSPC is beneficial for drug retention in vivo compared to 1,2-dipalmitoyl-sn-glycero-
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3-phosphocholine (DPPC) (Webb et al., 1998). Furthermore, the long saturated chains of DSPC 
increase probability of high drug loading, especially for lipid soluble drugs (Anderson and Omri, 
2004; Mohammed et al., 2004).  
 
1.1.2.3 Role of cholesterol in liposome formation, stability and activity 
In addition to the choice of phospholipid, cholesterol content is a key factor in liposome 
formulation. Cholesterol plays a vital role in animal cells, modulating physical as well as 
functional properties of the bilayer (Gallová et al., 2004). Cholesterol is a large lipophilic 
molecule with a very small polar region at the hydroxyl end. It is poorly water-soluble and 
incorporates itself between acyl chains of the phospholipid bilayer (Figure 1.5). Cholesterol is 
often incorporated into liposomes to improve bilayer fluidity and permeability (Socaciu et al., 
2000) and brings profound changes to physical properties of membranes (Wang and Quinn, 
2002). In particular, inclusion of cholesterol improves bilayer stability. Indeed, during early 
investigations of liposomes (Gregoriadis and Davis, 1979), it was discovered that the optimal 
concentration of cholesterol is 1:1 mol/mol, lipid:cholesterol, and not only increases the 
stability but also reduces permeability of the bilayer. The key factor making cholesterol more 
promising is its planar steroid ring (Figure 1.5), imparting a rigid structure to the molecule and 
this makes lipid-cholesterol interactions more prominent. 
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a)           b) 
 
               
Figure 1.5 a) Steroid ring in its structure makes it more promising to makes it prominent in its activity. b) 3D structure of 
cholesterol. The 3D structure adopted from Avanti Polar (AvantiPolar, 2014).
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Cholesterol provides rigidity to liposomal membranes (Mohammed et al., 2004; Nomura et al., 
2005), but high concentrations of cholesterol may impact on the size of the vesicles (Nomura et 
al., 2005). The miscibility, as well as promising action of cholesterol depends on the polar head 
groups of lipid being used, in addition to the saturated or unsaturated nature of the lipid 
(Mohammed et al., 2004; Wang and Quinn, 2002). For example, research performed by Wang 
and Quinn (2002) describes the interaction of cholesterol with phospholipids and found it 
decreased in the order sphingomyelin > phosphatidylcholine > phosphatidylserine > 
phosphatidylethanolamine. Through these interactions, cholesterol actively participates in 
bilayer formation due to its relatively small head group. In the case of saturated phospholipids 
like phosphatidylethanolamine, the strong intermolecular interaction can result in elimination 
of cholesterol from the bilayer. However, in the case of unsaturated phosptidylethanolamine, 
the intermolecular interaction is weak and, hence, there is non-lamellar phase formation (Wang 
and Quinn, 2002). Indeed, it has been observed that for the mixture containing cholesterol less 
than 30 mol %, the  gel to liquid crystalline transition shifted towards the lower temperature  
i.e. from lamellar to non lamellar and began to increase for cholesterol proportions more than 
30 mol % (Wang and Quinn, 2002). 
 
1.1.2.4 Solubility of the payload 
Due to their biphasic nature, liposomes can deliver both water soluble and lipid soluble drugs 
by a range of routes, including the intravenous route (Douroumis and Fahr, 2012). However, 
with respect to analyte encapsulation, the solubility of the analyte is an important aspect of 
liposomal encapsulation, with lipophilic molecules encapsulated into the lipid bilayer and the 
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hydrophilic moieties into the hydrophilic core of the liposomes (Figure 1.6). On the other hand, 
the solubility of the encapsulated drug can also control release rate from the liposomes; during 
the in-vitro studies, the analyte with least water solubility elutes slower than the analyte with 
greater solubility. If the drug is loaded passively, then the encapsulation of the lipophilic drug is 
higher with slow drug release and vice versa for the hydrophilic drug.  
 
Figure 1.6 Compartmentalisation of the drugs into the liposomes with respective solubility.  
 
1.1.2.5 Vesicle properties contributing towards liposomal structure and behaviour 
Changes in size directly affect entrapment efficiency and, thereby, drug delivery (Kazi et al., 
2010). For intravenous injection of liposomes, it is important to reduce the size range between 
100 nm to 200 nm (Allen et al., 1988). This range of vesicle size is small enough to enter 
inflamed areas of tissues and tumour sites and the small size is less prone to clearance by the 
macrophages in the MPS and, thus, tend to reside longer in the blood (Gregoriadis et al., 1996; 
Waterhouse et al., 2005). A key factor controlling vesicle size is the method of manufacture, as 
already discussed. However, there are various other contributing factors that can influence 
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vesicle size. The incorporation of drugs within bilayer vesicles can influence their properties; for 
example, in recent studies by Essa (2010), mannitol was taken as water soluble drug, whereas 
estradiol was selected as poorly water soluble drug, and it was observed that hydrophilic drug 
can increase the size by approximately 6.5 %, whereas lipophilic drug increased the vesicle size 
by 35 % of the size of empty liposomes. The influence of encapsulation of lipophilic drug was 
possibly due to the interaction with the head groups or due to the mutual repulsion, whereas 
the influence of hydrophilic drug encapsulation was insignificant (Essa, 2010a).  
 
Another factor influencing vesicle size is the packing of vesicles. Geometry of amphiphiles can 
be analysed by determining the critical packing parameter (CPP). CPP is a dimensionless 
number illustrating tendency of any amphiphiles to form micellar or vesicular aggregates. CPP 
values below 0.5 indicate the spherical micelle formation and CPP=1 indicates formation of 
vesicles. However CPP above 1 gives indication of reverse micelle formation.   The increase in 
alkyl chain length would result in an increased CPP and, hence, minimal permissible vesicle size 
increases (Uchegbu and Florence, 1995; Uchegbu and Vyas, 1998a). Also, the molecular 
structure of the amphiphiles can influence the assembly of lipids as well as crystalline phase 
formation. Amphiphiles have two major non-polar (Anp) and polar (Ap) areas. When these 
areas are stable, the stable bilayer is formed, whereas an imbalance (i.e. CPP less than ½ and 
more than 1)  in Anp and Ap gives random aggregated structures (Figure 1.7).  
47 
 
                         
Figure 1.7 Structural representation of possible structure for a range packing parameter value. 
 
Bigger vesicles form when small head and long chain length molecules are used (Bayindir and 
Yuksel, 2010). Indeed, the type and amount of lipid play a vital role in vesicle size as well as 
entrapment efficiency. A well-defined structure of liposomes is determined by the arrangement 
of lipid molecules and this appropriate arrangement of lipid molecules depends on the 
interaction between the non-polar lipid tails directed away from the polar head groups placed 
in contact with the water. This results in optimisation of surface area and brings reduction in 
surface energy due to increases in hydrophobicity, which leads to smaller particle size (Kazi et 
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al., 2010; Yoshioka et al., 1994). Therefore, the vesicle size is directly proportional to the 
hydrophobicity  (Uchegbu and Florence, 1995).  
 
1.1.2.6 Surface charge 
Daneshpouret. al. (2011) have recently shown that the addition of the negatively charged lipid 
phosphatidyl serine (PS) in the formulations has a substantial effect on both the size as well as 
zeta potential of the liposomes, regardless of the PC or cholesterol content employed 
(Daneshpour et al., 2011). On the other hand, Felgner et. al (1994) mentioned that cationic 
liposomes were able to deliver contents by fusion with cells (Daneshpour et al., 2011; Felgner 
et al., 1994; Mohammed et al., 2004). The presence of charge increases the distance between 
consecutive bilayers in multilamellar vesicle structure(Kazi et al., 2010). However, charges are 
sometimes necessary to avoid aggregation (Uchegbu and Florence, 1995). Also, in recent 
research, it was found that found that addition of negative charges make niosomes (non-ionic 
surfactant vesicles) less stable (Fang et al., 2001). Therefore, it is important to know vesicle 
charge, not only for stability purposes, but also for the in-vivo activity. 
 
1.1.2.7 Steric Hindrance 
The presence of appropriate coats such as polyethylene glycol (PEG) or carboxymethylchitin 
(CMC) on the surface of liposomes can sterically hinder opsonin (an antibody producing 
immune response) adsorption, thereby resulting in reduced uptake by MPS. The molecules of 
water forms the organised vesicle via hydrogen bonding to the ether oxygen molecules of the 
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PEG, and these tightly bound water molecules form a film around the vesicle, repelling the 
protein interactions. This covering of the PEG on the surface of the vesicle could increase the 
hydrodynamic size, prevent aggregation, favour the formation of mono-dispersed liposomal 
suspension and increase the enhanced permeation and retention (EPR) effect due to prolonged 
circulation (Bozzuto and Molinari, 2015). Hence, sterically stabilised liposomes are more stable 
in the blood stream than conventional liposomes (Sharma and Sharma, 1997). 
 
1.1.3 Method of liposome production 
Although  liposomes were discovered nearly half century ago, the developments in preparation 
of these vesicles is still limited and in need advanced research. A variety of methods are 
described in an exhaustive number of reviews (Akbarzadeh et al., 2013; Bramwell and Perrie, 
2005; Dua et al., 2012; Mansoori et al., 2012; Perrie et al., 2008; Perrie and Rades, 2012a; 
Sharma and Sharma, 1997; Storm and Crommelin, 1998a; Wagner and Vorauer-Uhl, 2010) and 
there are  nearly half a dozen methods of liposome preparation available in pharmaceutical and 
cosmetic research (Figure 1.8). 
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Figure 1.8 Classification of methods of liposome production. (Modified from (Dua et al., 2012). 
 
 
1.1.3.1 Thin film hydration 
 Production  of multilamellar liposomes by a thin film preparation followed by hydration was 
first achieved by Banghamet.al. (Bangham et al., 1965). However, carrying forward this 
research, a range of methods have been established for the preparation of liposomes. 
Preparation of multilamellar liposomes can be achieved remarkably simply. Briefly, lipids are 
dissolved in the organic solvents to form a thin film on the wall of a round bottom flask by 
rotary evaporation under maintained and reduced pressure. When mixtures of lipids are used, 
then those lipids must be amply mixed in the organic solvents before subjecting to the rotary 
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evaporation. Water or any other aqueous buffer is then added to the round bottom flask and 
the lipids get hydrated at a temperature above the transition temperature (Figure 1.9). This 
method is based on the principle of passive loading and a maximum 50 % of lipophilic drug and 
upto 15 % hydrophilic drug loading has been reported in past research (Cullis et al., 1989). Size 
reduction of these vesicles can be achieved by various methods (Figure 1.9) and probe 
sonication is the most common approach used in laboratory research. This method uses sonic 
energy to rupture the bilayer and form small unilamellar liposomes. However, possible 
contamination with titanium particles from the probe is one of the disadvantages of this 
method. Centrifugation of the sonicated suspension is an approach to remove these titanium 
particulates.  
 
As discussed earlier in this chapter, MLV exhibit particle diameters above 1 µm. Due to uneven 
number of lamellas, these large particle diameters bring heterogeneity in the particle size 
distribution and may develop multi compartmentalisation (Hope et al., 1993). Extrusion is one 
of the many techniques available to overcome this issue; during the process of extrusion, a 
moderate amount of pressure is applied to force the liposomes through a mesh of defined pore 
size. During the passage through the mesh, the MLVs deform and reseal. Multiple numbers of 
passes of the same liposomal suspension through this extrusion assembly reflects on the 
particle size distribution, where the multiple extrusion as well as the pore size reduced the 
particle size from 1 µm to 100 nm (Hope et al., 1993; Hunter and Frisken, 1998).   
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Figure 1.9 Diagrammatic illustration of thin film hydration process for liposome production (Bangham et al., 1965). 
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1.1.3.2 Microfluidics 
Microfluidics is one of the recently emerging technologies that allows reproducible mixing on 
the nanolitre scale in milliseconds to seconds (Kastner et al., 2014) and is cost-effective in 
liposome production. Microfluidics is based on laminar fluid flow and involves diffusion mixing; 
where the nano-precipitation and nanoparticles production can be achieved in a single step 
using micro-mixing (Bally et al., 2012). There are different types of micromixers involved in 
current microfluidic research and most common are the T & Y shaped mixromixers, parallel 
lamination micromixers, sequential micromixers and droplet generators (Erbacher et al., 1999; 
Gobby et al., 2001; Kastner et al., 2014; Lee et al., 2003; Quevedo et al., 2005). The T and Y 
shaped micromixers are slower than other types but due to ease of operation they are widely 
used. The parallel lamination micromixers enhance the mixing efficiency by increasing the 
surface area and reducing the diffusion length. However, the sequential micro-mixer works on 
rearrangements of fluid streams; whereas the droplet mixromixer generates droplets using 
electric field.  
  
Microfluidics is a novel method to prepare liposomes that are reproducible, in a one-step and 
high throughput method compared to the traditional thin film hydration method (Hood et al., 
2014). Microfluidics is presented by a low Reynold’s number (‘Re’), which is a non-dimensional 
number to determine whether the flow is turbulent or laminar. A threshold value for this is 
2000 and ‘Re’ below 2000 is considered as laminar flow. This ‘Re’ can be expressed as follow.  
                                                          =
ὠ^	


                                                                        Equation 1.1 
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Here µ is the viscosity of the fluid, ρ is the density, V is velocity scale and ὠ2 is the diameter of 
the pipeline. Microfluidics allows distinct mixing organised exclusively by interfacial diffusion, 
where multiple flow streams get injected into a microchannel (Pradhan et al., 2008). It is a 
promising way to obtain a mono-disperse population of particles (Belliveau et al., 2012). The 
small width of the short length microfluidic channels is the reason for the fast mixing (Riahi et 
al., 2015). The diffusive mixing time plays a vital role in particle size distribution and rate of 
particle formation, whilst the channel width (ὠ2), diffusivity (D) of the solvent in the core 
stream, and the ratio of the core stream flow rate to the total flow rate of the surrounding 
streams (R) also contribute (Lo et al., 2010). 
                                      Tmix= ὠ
2/9D(1+1/R2)                                                                          Equation 1.2 
Microfluidics is based on laminar fluid flow and involves diffusion mixing.  Flow rates, aqueous 
to solvent ratios, total sample volumes and waste volumes can be manipulated as needed. A 
provision in the form of a heating block is provided under the microfluidic chip to create a 
special environment for high transition temperature lipids. The device can be divided in 3 
different sections, namely a syringe holder assembly, a chip holder and a chip. The syringe 
holding assembly is designed to hold two syringes; one filled with solvents, in which lipids 
and/or drug is dissolved, and another filled with buffer, in which drug may be dissolved. The 
suspension is dispensed through an outlet of the cartridge connected to chip holder. One side 
of this chip holder is metal, with 2-inlets as well as one outlet, whilst the other side is a separate 
plastic cover to hold the chip within this metal case. The third and important part of the 
microfluidic device is the chip. The chip is engraved with two channels, one for the buffer and 
other for the solvent. These channels carry different solution and mix at a particular point from 
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which mixture of these two solutions elutes from an outlet on the other end. Also, a staggered 
herringbone micromixer (SHM) is a micro-mixer engraved in patterns on the bottom of the 
channel (Figure 1.10). This initiates turbulent  mixing a series of repetitive flow profiles (Stroock 
et al., 2002).  
                                        
Figure 1.10 Microscopic image of a staggered herringbone micro-mixer engraved in patterns on 
a channel floor. 
 
Briefly, the method involves mixing of buffer and solvent phases coming from two different 300 
µm diameter channels joined at a point in a planner chip. From the point of joining, the fully 
solvated lipids self-assemble as liposomes when the two phases interdiffuse (Pradhan et al., 
2008). Preparation of liposomes by a microfluidic device is based on 2 important parameters; 
namely flow rate ratio (FRR) and total flow rate (TFR) (Kastner et al., 2014).  
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1.1.4 Characterisation of liposomes 
 
The quality of the liposomal formulation is determined by the size, shape, zeta-potential, 
entrapment efficiency and quantitative analysis of the amount of lipid, cholesterol as well as 
other excipient, such as α-tocopherol, etc. For this, use of techniques such as dynamic or 
diffraction light scattering, microscopy, high performance liquid chromatography (HPLC) and 
UV/Visible-spectrophotometry is common. However, further and detailed analysis includes 
liposomal lamellarity, geometry of lipid and lipid bilayer and the role of cholesterol in liposomal 
assembly. This can be performed by the use of small-angle x-ray scattering (SAXS) or small angle 
neutron scattering (SANS), Fourier transform infra-red spectroscopy (FT-IR) differential 
scanning colorimetry (DSC) and Langmuir–Blodgett trough. 
 
1.1.4.1 Size and surface analysis 
When analysing liposomal drug delivery systems, size is considered as a critical parameter; the 
lower the size of liposomes, the better the bioavailability of drugs as the size of liposomes 
significantly affects the absorptions and thereby the bioavailability (Ong et al., 2016). There are 
different techniques used to reduce size of liposomes (e.g. sonication, extrusion and micro-
fluidisation) and dynamic and diffraction light scattering are the best available tools for 
liposomal size analysis. It is fast and reasonably accurate, although factors such as particle 
aggregation and multiple scattering could affect particle size measurements. The diffusion 
caused due to the Brownian motion of the particle/liposomes measured by these techniques.  
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Microscopy is another tool for the structural elucidation of liposomes. There are various 
microscopic techniques available in current research, depending on the size of liposomes, but 
generally scanning electron microscopy (SEM) and transmission electron microscopy (TEM) are 
the most commonly used. Size analysis of MLVs is possible with optical microscope. However, 
for analysis of SUV and LUV below 1 µm, the SEM and TEM are suitable. Also, for lipid bilayer 
analysis or drug entrapment analysis, fluorescent or confocal microscopy is used. Sample 
preparation is a crucial stage of microscopic analysis. For example, Bibi et. al. (2011) described 
three ways of sample preparation for microscopic study; 
1) Using a cover-slip as a conventional way of microscopic study 
2) Using a micro-slide: here an external micro-slide mounted on top of a normal glass-slide 
with glue(Bibi et al., 2011). This idea of sample preparation keeps the sample safe from 
mechanical damage, and the end of the microscopic slides can be sealed, which prevent 
sample from drying..  
3) Using a frame seal chamber: this strategy of sample preparation gives greater chance 
for better resolution, with advantages similar to the micro-slide, where sample drying 
can be avoided.  
 
Another consideration in the characterisation of liposomes is their surface potential. The zeta 
potential is a quantification of the relative electrostatic potential due to surface charge density 
on the surface of the particle, conductivity of the solvent and depends on the velocity of 
particles mobility in electric field. The change in frequency of a moving particle is measured 
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when an electric field is applied across the cell. This change in frequency is usually a result of 
charges on the particles. 
To consider the liposomal structure, Bhaleraoet al. (2003) have described a 31P-NMR method to 
determine lamellarity of liposomes (Bhalerao and Raje Harshal, 2003). They have used Mn2+ions 
from magnesium chloride (MnCl2), which interact with the periphery of the outmost bilayer, 
resulting in enlarged peal. This reduced signal then can be used to correlate with the lamellarity 
of the liposomes. In general, a 50%, reduction in NMR signal may be interpreted as unilamellar 
liposomes, whilst a 25% reduction in the signal intensity of the original NMR signal suggests two 
bilayers of liposome.Ristori et al. (2005) have studied physiochemical characterisation of 
cationic liposomes loaded with sugar-based carboranes. Carboranes are famous for their anti-
cancer neutron capture therapy and liposomes are famous for non-toxic drug delivery (Ristori 
et al., 2005). Using SAXS and SANS, the size, shape and bilayer composition of liposomes has 
been studied. The targeting effect toward the nucleus by cationic lipids and the availability of 
the sugar moieties on the liposome surface, were the major constructive properties of this 
loaded liposomes that were established (Ristori et al., 2005). The data obtained from X-ray or 
neutron scattering can reveal if any subtle changes occurred in the bilayer of the liposomes.   
1.1.4.2 Drug encapsulation and release 
Target specific and controlled drug release represents one of the many key attributes of 
liposomes. To consider drug loading, a range of methods are used to quantify the drug. For 
example, Mohammed et al. (2004) in their research have determined entrapment efficiency of 
ibuprofen within MLV by measuring non-incorporated drug separated by centrifugation, then 
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analysed by UV-spectroscopy and validated by HPLC (Mohammed et al., 2004). In general, the 
drug entrapment efficiency can be calculated with the following formula (Mitra et al., 2013).   
                                      % Entrapment efficiency=
  
 
 × 100                           Equation 1.3 
 
The method mentioned by Mohammad et al. (2004) also includes incubation of drug loaded 
liposomes in phosphate saline buffer (PBS) at 37°C in a water bath with constant agitation. At 
constant intervals, samples were removed and analysed spectrophotometrically to determine 
amount of drug release in a particular time interval (Mohammed et al., 2004).  
 
Use of dialysis for in vitro drug release has been widely adopted at laboratory scale research 
(Cosco et al., 2012; Kastner et al., 2015; Laouini et al., 2012). Appropriate dialysis membrane 
selection is a key factor in this study, since the pore size of the membrane determines the 
separation and the membrane should be free to active ingredients and there must not be any 
adsorption of active ingredient. The molecular weight cut-off (MWCO) specifications must be 
taken into consideration and this depends on the average molecular mass of molecules in the 
solution (Paul et al., 2013). In other words, MWCO is the smallest average molecular mass of 
the standard molecule which will not diffuse across the membrane. Sample molecules larger 
than the pores remain on the sample side, whereas sample molecules smaller than the pore 
size cross the membrane. A dialysis bag containing a few millilitres of liposomal suspension can 
be placed in a receptor compartment at 37°C by tying it hermetically and under constant 
stirring. The receptor compartment must be closed in order to avoid evaporation of contents 
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present. At particular and predetermined time intervals, samples are withdrawn from the 
receptor compartment (i.e. the media outside the dialysis tube) and analysed 
spectrophotometrically or chromatographically. Sink conditions are maintained by the addition 
of fresh buffer to the receiver phase. However, the method needs skills as well as extreme care 
of the dialysis tubing to avoid contamination and sample loss. Precise and rugged experimental 
arrangement is the doorstep to achieve precision in multiple experimental outcomes. The 
percent drug release then can be calculated using the equation below.  
                                      % Release=
   
 
 × 100                                                      Equation 1.4 
 
1.1.4.3 Phase transition studies 
DSC is the technique used widely to determine the phase transition behaviour of the lipid. This 
is useful to know the phase transition temperature of the lipid, as it is necessary to hydrate the 
lipid suspension above its transition temperature to form liposomes. Along with this use, it is 
beneficial to record the activity of cholesterol when present in the formulation. As 
mentionedearlier, presence of cholesterol more than 30 mole % can completely diminish the 
phase transition temperature and makes the lipid bilayer less prone to leakage (Wang and 
Quinn, 2002).  
 
In typical DSC experiment, the liposome formulation with recorded weight is placed into the an 
aluminium pan, followed by sealing with an aluminium lid. The cuvette was then mounted in to 
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the DSC chamber and heated from 20 to 200°C at the heating rate of 10°C/min in nitrogen 
atmosphere (Bhalerao and Raje Harshal, 2003).  Another method described a DSC approach for 
the commonly used lipid distearoyl phosphatidylcholine (DSPC) (Terada et al., 2006). Here, 50 
microlitre of suspension is placed for DSC analysis at 3°C /minute from ambient temperature to 
75 °C.   
 
1.1.4.4 Microbial assay 
The total microbial count (TMC) determination is performed and this is done using the plate 
count method. Selection of appropriate media is crucial here. The method mentioned in United 
States Pharmacopoeia (USP)-29, <61>, states that for a fluid specimen that consists of a true 
solution or a suspension in water or a hydroalcoholic vehicle containing less than 30 % of 
alcohol, the specimen is suspended in pH 7.2 PBS (Pharmacopoeia, 2002). This sample is then 
analysed by appropriate method e.g. plate method where the numbers of colonies are counted 
from two plates and the average of this is reported as results.  
 
1.1.5 Applications of liposomes 
The structural as well as physiological characteristics of the liposomes are diverse and so are 
their applications. Liposomes with their broad range of applications are involved in the 
multidisciplinary research. More than a dozen fields in the science have applications of 
liposomes (Table 1.3).  
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Table 1.3 Overview of applications of liposomes in science. 
Number Discipline  Application 
1 Arithmetic  Studying bilayer elasticity the topology of two dimensional structures can 
be explored in 3-dimensioal space(Sackmann, 1995) 
2 Physics and 
biophysics  
Softening, hardening, aggregation, elasticity and fractals, phase-transition, 
permeability  (Blok et al., 1975; Sackmann, 1995) 
3 Chemistry and 
biochemistry  
Artificial photosynthesis, micro and nano-compartmentalisation, catalysis 
and photochemistry (Landfester and Ostafin, 2008; Lipowsky and 
Sackmann, 1995) 
4 Physical 
chemistry  
Colloidal chemistry, aggregation forces (inter and intra), DLVO(Lipowsky 
and Sackmann, 1995; Sabın et al., 2006) 
5 Pharmaceutics Pharmacodynamics, colloidal suspension compounding. (Perrie and Rades, 
2012a) 
6 Medicine and 
pharmacology 
Therapeutics and diagnostics(Rahman et al., 1985) 
7 Biology and 
microbiology 
Cell function, fusion as well as  recognition and representation of artificial 
biological membrane (Gregoriadis, 1993) 
 
These liposome vehicles can be tailored in variety of applications such as: 
1) distribution: passive or active targeting of the molecules by site specification or site 
avoidance(Perrie and Rades, 2012a); 
2) duration: liposomes can act as a reservoir, helping towards delayed or controlled release of 
molecules(Kastner et al., 2015); 
3) protection: it is a shell that protects molecules such as proteins and peptides from biological 
degradation(Vabbilisetty and Sun, 2014); 
4) internalisation: liposomes due to their size and/or surface characteristics can be internalised 
into the cells and deliver the active ingredient (Hadjidemetriou et al., 2015); 
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5) amplification: liposomes can work as immunological adjuvant vaccines (Schwendener, 2014). 
 
Liposomal applications in medicine and pharmacology can be separated as diagnostic and 
therapeutic applications. Liposomes containing drug or marker can be used as a tool to study 
cell interactions, recognition or mechanism of action of certain molecules. In the case of drugs 
with limited therapeutic index, their toxicity can be lowered by using liposomes as a carrier 
giving a temporal and spatial effect to the delivery of the drug molecules. In other words, 
liposomes can be used to alter the bio-distribution and pharmacokinetics. For example, the 
clinically approved oncological agent doxorubicin, demonstrated reduced toxicity with better 
therapeutic outcome when packaged within liposomes (O’brien et al., 2004). Some other 
medicinal benefits of liposomes include improved solubility of poorly water soluble drugs, 
passive targeting to the immune system cells, and sustained release upon systemic or local 
administration, site bypassing and better tissue penetration. Indeed, applications of liposomes 
in the biochemical field are prolific and liposomes have remarkably influenced the 
understanding of membrane proteins and cell functions. Many processes such as exo-and endo-
cytosis, transportation to and from golgi apparatus, internalisation or fusion and 
neurotransmission are largely dependent on travel of the vesicles. Hence, vesicles are the 
biggest source of internal communication. 
 
Indeed, liposomes can be used depending on the need of research. Due to the structural 
attributes, liposomes can be used in combinational therapy. Drugs prescribed in combinational 
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therapy, such as metformin and glipizide, gemcitabine and tamoxifen, doxorubicin and 
paclitaxel, irinotecanandfluxoridine,etc. (Cosco et al., 2012; Liu et al., 2014; Tardi et al., 2007) 
can be compartmentalised depending on the solubility of the analyte; i.e. a lipophilic drug can 
be encapsulated into the phospholipid bilayer and at the same time a hydrophilic drug can be 
encapsulated into the hydrophilic core of the liposomes. Similarly, for the delivery of the 
biomolecules such as proteins and peptides, liposomes are advantageous. Depending on the 
characteristics of the peptide, this can be encapsulated or attached to the surface of the 
liposomes e.g. Trans-activating transiscriptional peptide can be attached to the surface of 
liposomes (Hadjidemetriou et al., 2015; Torchilin et al., 2001; Vabbilisetty and Sun, 2014). 
 
1.2 Other particulate systems for the delivery of chemical and biological substances 
 
Similar to liposomes, niosomes are bilayered vesicles constructed from the non-ionic 
surfactants. They offer advantages over other vesicle forming structures, as they have relatively 
economical production and can offer enhanced stability (Vora et al., 1998). There are different 
types of non-ionic surfactants that can be used in the formulation of niosomes, ranging from 
fatty alcohols, ethers, esters and poloxamers (Karim et al., 2010).Surfactants with hydrophilic 
lipophilic balance (HLB) between 14 and 17 can’t form vesicles due to high aqueous solubility, 
but with optimised cholesterol concentration can produce vesicles from these surfactants 
(Seleci et al., 2016). These surfactants, as well as the cholesterol, can help to attain the required 
shape and can be particularly useful for those surfactants with a HLB around 10 (Marianecci et 
al., 2014). Common surfactants used in the formulation of niosomes include Spans, Tweens, 
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Brij, Steryl alcohol and Poloxamers and the choice of surfactant can impact upon the properties 
of the vesicles, including their size, tapped volume, and surface charge (Diljyot, 2012). As with 
other nano and microparticles, niosomes have been used in controlled release preparations 
and have shown to be able to target a range of organs, such as the skin, brain, liver, respiratory 
system, ocular systems and certain tumours (Uchegbu and Vyas, 1998b). Niosomes have also 
shown promise as drug carriers for dermal indications. This includes acting as a local 
anaesthetic, use in psoriasis and as a skin tone lightener in the cosmetics industry. Metal or 
polymeric particles have been involved in the mimicking or altering the biological process (Singh 
and Lillard, 2009). Most of these particle based delivery systems are biodegradable, designed 
for drug delivery and stabilising molecules like proteins, peptides and DNA (Singh and Lillard, 
2009). In oncological studies, it was found that these particles can get accumulated at target 
site and show the depot effect depending on the make-up of the carrier and provide a constant 
supply of the loaded active ingredient (Desai et al., 1997). Metal nanoparticles came into focus 
as imaging agent and diagnostic biosensors (Arvizo et al., 2011; Mody et al., 2010), but metal 
particles such as gold nanoparticles have been shown to have a role in the transport of an anti-
cancer agents (Chen et al., 2008). 
 
1.3 Current challenges in pharmaceutical industry 
 
As mentioned earlier, liposomes are the most common and investigated delivery systems used 
for delivery of variety of chemical and biological molecules (Lasic, 1993; Perrie and Rades, 
2012a). The first generation of liposomes  experienced rapid clearance by MPS due to structural 
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imperfections but the optimisation made longer circulation and enhanced EPR effect (Sawant 
and Torchilin, 2012). Although the optimisation increased the availability of molecule and 
enhanced EPR effect, the endocytosed material is prone to degradation by acidic environment 
in the lysosol and the enzymes. This results in the reduced biological activity of molecules that 
are sensitive, for example peptides and peptidic drugs (Connor and Huang, 1986).  
 
Furthermore, prolonged retention at the target site would not be important if the drug is 
rapidly lost on storage. The correct choice of lipid and formulation component would be a 
solution, but optimisation of component concentration and process parameters is equally 
important, especially for hydrophilic drugs, as they may suffer low membrane permeation and 
low retention (Cullis et al., 1989). 
 
Studies have described that discovery of new drugs is not sufficient for the growth of 
therapeutic excellence; therefore, developments in delivery of existing drugs is necessary 
(Kalepu and Nekkanti, 2015). 40 % of the marketed drugs are hydrophilic and, therefore, 
remaining are the  significant number of marketable drugs are poorly water soluble (Kalepu and 
Nekkanti, 2015). Hence, the pharmaceutical market is significantly interested in developing 
strategies to deliver poorly water soluble molecules.  
 
Moreover, recent research has exploited the co-delivery of hydrophilic and lipophilic drugs 
(Cosco et al., 2012; Tardi et al., 2007). Surprisingly, very little research has been reported about 
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the delivery of multiple drugs in one liposomal formulation. This may be a result of challenges 
associated with encapsulation, stability and release of two therapeutic agents in one liposomal 
composition (Tardi et al., 2007).  
Liposomes are not only preferred in the pharmaceutical but also in the biopharmaceuticals (Van 
Slooten et al., 2001). Liposome based vaccines such as hepatitis C virus vaccine, tuberculosis 
vaccine, etc. are being evaluated extensively (Schwendener, 2014; Schwendener et al., 2010; 
van Dissel et al., 2014). Similar to other deadly diseases, respiratory syncytial virus (RSV) is 
affecting millions of children and adult around the world (AR et al., 2005a; Borchers et al., 2013; 
Rappuoli et al., 2011). First line of treatment for treatment of RSV infection is use of 
bronchodilators such as α and/or β adrenergic agonist (Borchers et al., 2013) but there is no 
active prophylaxis available for this virus. Recently, anti-RSV peptide RF-482 found capable of 
inhibiting the virus (Singh et al., 2014) and this anti-RSV peptide was carried by gold 
nanoparticles (GNPs). Considering available RSV inhibitor and potential of liposomes in vaccine 
development, liposome based vaccine against RSV could be safe and effective candidate.          
 
1.4 Aim and Objectives 
Given the need of optimal use of liposomal structural benefits, the overall aim of this thesis was 
to investigate the role of liposomes to enhance the delivery of  different classes of drugs (small 
active pharmaceutical ingredients and bio-molecules). To achieve this, the objectives of the 
thesis were: 
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1. Develop appropriate methodical tools for the preparation, quantification and 
characterisation of a range of liposomal formulations. 
2. Investigate the role of liposomes for the delivery of hydrophilic and low solubility 
drugs alone and as part of a combination therapy.  
3. Investigate and develop a new high-throughput one-step process for the 
manufacture of liposomes simultaneously entrappinghydrophilic and lipophilic 
drugs.  
4. Investigate potential of liposomes to deliver peptides and exploit their use to control 
RSV infection. 
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Chapter 2: Materials and methods 
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2.1 Materials and chemicals 
*All the materials, chemicals used were of analytical grade. 
Material/Chemical/Instrument Vendor/Supplier 
1,1'-dioctadecyl-3,3,3'3'-
tetramethylindocarbocyanine perchlorate (Dil C)  
Sigma-Aldrich Company Ltd. (Poole, UK) 
1,2-disteroylphosphatidylcholine (DSPC) Avanti Polar Lipids, Inc. (Alabaster, AL) 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC) 
Sigma-Aldrich, St. Louis, MO, USA 
12-Well Plates Life Technologies, CA, USA 
1X PBS: 0.01M Phosphate buffered saline, pH 7.4 Life Technologies, CA, USA 
75 cm2 Flasks Life Technologies, CA, USA 
8-well chamber slides Life Technologies, CA, USA 
96-well Reaction plates Life Technologies, CA, USA 
Acetonitrile Fisher Scientific UK (Loughborough, UK) 
BCA-assay Kit Thermo scientific, Rockford, IL, USA 
Cell counter Thermo scientific, Rockford, IL, USA 
Centrifugation tubes for MLV Sigma-Aldrich Company Ltd., Poole, UK 
Centrifuge Apparatus DJB Labcare Ltd,. Buckinghamshire UK 
Chloroform Fisher Scientific, Loughborough, UK 
Cholesterol Sigma-Aldrich Company Ltd., Poole, UK 
Confocal Microscope Leica Microsystems, Milton Keynes, UK 
Cryo-Electron Microscope Tecnai 12 G2 electron microscope (FEI, 
Eindhoven, USA).  
Crystal Violet Life Technologies, CA, USA 
DAPI Life Technologies, Carlsbad, CA, USA 
Dialysis Tubing/Membrane Medicell membranes Ltd, London, UK 
Diffraction light scattering-Sympatec-HELOS Sympatec, Bury, UK 
Dulbecco’s Modified Eagle’s Media (DMEM)  Life Technologies, CA, USA 
dye MTT (3-(4, 5-dimethyl-thiazol-2-yl)-2, 5-
diphenyl-tetrazolium bromide) 
Promega Corp, Madison, WI, USA 
Dynamic light scattering-Malvern-ZS-Nano Zetasizer Nano-S, Malvern instruments, 
Westborough, MA, USA 
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Dynamic light scattering-Malvern-ZS-Nano Malvern Instruments, Worcestershire, 
UK 
Egg-Phosphotidyl Choline (PC) Avanti Polar Lipids, Inc., Alabaster, AL 
Electron Microscope EM10A/B, ZEISS, Germany. 
Ethanol Fisher Scientific, Loughborough, UK 
Fetal Bovine Serum (FBS) Life Technologies, CA, USA 
Filter Units-Ultracel- 50K Millipore Ireland Ltd., Cork, Ireland 
FITC (goat) Life Technologies, CA, USA 
FITC-labelled-RF-482 Bachem Americas Inc., Santa, Clara, CA, 
USA 
Fluorescence Microscope Nikon Inc. Melville, NY, USA 
Gas Chromatography (GC) CSi 200 Cambridge Scientific Instruments Ltd, 
Witchford, UK 
GC column GC column TRACE, 15 m x 0.25 mm x 
0.25 μm 
Glipizide Discovery Chemicals, UK 
Gold Nanoparticles (GNPs) Nanopartz™, Loveland, CO, USA 
Hank’s balanced salt solution (HBSS) Life Technologies, CA, USA 
High performance liquid chromatography (HPLC) Shimadzu 2010-HT, Milton Keynes, UK 
HPLC-column Phenomenex, Macclesfield, UK 
Human epidermoid type-2 (HEP-2) cells American Type Culture Collection 
(ATCC®, Manassas, VA, USA) 
Kanamycin Sigma-Aldrich Co., St Louis, MO, USA 
Metformin Sigma-Aldrich Co. St Louis, MO, USA 
Methanol Fisher Scientific, Loughborough, UK 
Methyl Cellulose Sigma-Aldrich Co., St Louis, MO, USA 
NanoAssemblrTM benchtop  Precision Nanosystems, Agronomy Rd, 
Vancouver 
Microslide Cam lab, Cambridge, UK 
Minimum Essential Medium (MEM) Life Technologies, CA, USA 
Ortho-phosphoric acid Sigma-Aldrich Company Ltd., Poole, UK 
Osmium Tetroxide (4 % Solution) Electron Microscopy Sciences, Hatfield, 
PA, USA. 
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Paraformaldehyde-glutaraldehyde Sigma-Aldrich Co., St Louis, MO, USA 
Penicillin Sigma-Aldrich Co., St Louis, MO, USA 
Peptide RF-482 Bachem Americas Inc., Santa, Clara, CA, 
USA 
Phosphate Buffered Saline (PBS) Sigma-Aldrich Company Ltd., Poole, UK 
Plastic syringes Sigma-Aldrich Company Ltd., Poole, UK 
Plate reader TECANTM, Morrisville, NC, USA 
Primers(forward & reverse) and Probes Life Technologies, CA, USA 
Probe Sonicator MSE Ltd., London, UK 
Real-time PCR instrument Biosystems® ViiA™ 7 real time PCR ,Life 
Technologies, CA, USA. 
Respiratory Syncytial Virus (RSV) American Type Culture Collection 
(ATCC®, Manassas, VA, USA) 
RNA-Extraction Kit Life Technologies, CA, USA 
DNA-Extraction Kit Qiagen, Germantown, MD, USA 
RNA-Free Water Qiagen, Germantown, MD, USA 
Rota evaporator BuchiLabortechnik GmbH, Essen, GE 
Rota Evaporator Roavaps, Atkinson, NH, USA. 
Simvastatin Sigma-Aldrich Company Ltd., Poole, UK 
Spin Columns Sartorius AG, Goettingen, Germany 
Streptomycin Sigma-Aldrich Co. St Louis, MO, USA 
SuperScript  II Life Technologies, CA, USA 
TaqMan® Master Mix 2 Life Technologies, CA, USA 
USP-4 SOTAX, FTC SOTAX AG, Switzerland 
UV-Visible Spectrophotometer Beckman Coulter spectrophotometer, 
Brea, CA, USA 
Water Milli-Q, MB-328, Aston University 
β-mercaptoethanol Sigma-Aldrich Co., St Louis, MO, USA 
 
 2.2 Methods of liposome production
2.2.1 Thin film hydration 
Multi-lamellar vesicles (MLVs) 
method (Bangham et al., 1965) (Figure 2.1). Briefly, the
0r 5:2 w/w)  were dissolved in an
with the addition of lipophilic drug,
film.  To remove the solvent residue
was then hydrated with 2.0 mL 
drug and vortexed for 1 minute, which produces a
lipids from the wall of the round bottom flask.  The milky suspension
minutes at the temperature above the ‘Tc’ of lipid used
sample was vortexed for 1 minute
resulted in the formation of MLV
cholesterol ratios of 5:1 and 5:2 
Figure 2.1 Thin-film hydration method for the production of MLV.
with lipids in the organic phase and hydrophilic drug was added during hydration of thin lipid 
film. 
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were prepared using the conventional thin film hydration 
 lipid components (DSPC cholesterol, 5:1 
 organic solvent mixture of chloroform and methanol
 followed by solvent evaporation to obtain a thin dry 
, the film was then flushed with Nitrogen (N
phosphate saline buffer (PBS) with the addition of hydrophilic 
 milky suspension, suggesting detachment of 
 was then heated for 30 
   and at an interval of 10 minutes
. This step-by-step treatment to the thin film of lipids 
s, which were prepared at two different 
w/w, respectively. 
 Lipophilic drug was combined 
 (9:1 v/v) 
2).  The film 
 the 
DSPC-
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2.2.2 Probe sonication 
Probe sonication is one of the many methods to reduce the size of MLVs produced by the thin 
film hydration method. Time of sonication and amplitude at which sonication is performed are 
the factors responsible for the size reduction of MLV. Titanium probe was used for this size 
reduction. The probe was immersed into the milky MLV suspension and the sonication was 
performed maintaining the temperature above the transition temperature of the lipid. A 
change in colour (i.e. from milky to a clear suspension) was observed during the process of the 
sonication. The suspension was cooled for 20 minutes prior to the next treatment. Probe 
sonication leaves debris of the probe immersed into the suspension (Mizuguchi et al., 2015); 
therefore, the debris was removed before analysing the size of the obtained vesicles.  
 
2.2.3 Protein loading 
The fusion protein RF-482 is a small and heat sensitive protein (39 amino scids, molecular 
weight: 4361.8, theoretical iso-electric point: 4.95, net charge: -2, atomic formula: 
C192H303N53O63 and total number of atoms 611). Therefore, a slight modification was done in the 
thin film hydration method (Figure 2.2), where in spite of the hydrophilic nature of the protein, 
it was not added to the hydration buffer but was added post sonication when SUVs were 
obtained. Briefly, a predetermined concentration of protein was added to the SUV suspension 
and mounted on a shaker for 30 minutes. This was done to facilitate the fusion of protein on to 
the liposomal surface.  
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Figure 2.2  Illustration of thin film hydration based SUV production and loading of fusion 
protein RF-482. 
 
2.2.4 Microfluidics based one step SUV production 
Liposomes were manufactured using a microfluidic device manufactured by Precision 
NanoSystems Inc., Vancouver, Canada, using a microfluidic chip with a 300 micron Staggered 
Herringbone Micromixer (Figure 2.3). The design introduces a turbulent flow in a micro-
channels by subjecting the fluid to a repetitive series of rotational flow profiles, which is 
achieved by alteration of the grooves as a function of the axial position in the channel(Stroock 
et al., 2002). Other parts of this bench top instrument include plastic syringes, which carry 
buffer and solvent that are pumped into the microfluidic channels by moveable stages. The 
movement of these stages can be programmed through a computer based program, which also 
control TFR, FRR, initial as well as end waste volumes.  
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Figure 2.3 Diagrammatic illustration of microfluidic chip inlet and outlet and a microscopic 
image of cycles of herringbone micromixer.(modified from (Kastner et al., 2014)). 
 
The aqueous buffer used in all studies was PBS, 10 mM, pH 7.4. The flow rate ratio (FRR) 
between the aqueous and solvent stream was varied from 5:1 to 1:1 (aq:solvent ratio) and the 
total flow rate (TFR) was varied from 5 to 15 mL/min. Through this method, liposome formation 
and incorporation of the drugs was performed simultaneously by addition of the drug into the 
appropriate phase; within these studies, the lipophilic drug glipizide (anti-diabetic, molecular 
weight: 445.6 gm/mol, pKa: 12.4, logP: -1.8) was dissolved in the solvent, whilst the hydrophilic 
drug metformin (anti-diabetic, molecular weight: 165.7 gm/mol, pKa: 5.6, logP: 1.9) was 
dissolved in PBS prior to microfluidic mixing. The liposome formulations were collected from 
the chamber outlet and dialysed using dialysis tubing (Section 2.3.2) at room temperature 
against PBS buffer for removal of residual solvent as well as the non-loaded drug. 
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2.3 Purification of liposomes, separation of unloaded analyte and quantification of loading 
2.3.1 Centrifugation 
For the purpose of purification to remove the titanium debris after the size of MLV was reduced 
by probe sonication, as well as separation of non-entrapped drug, liposomes were subjected to 
centrifugation. Each sample was centrifuged at 2500 rpm for 30 minutes and this procedure 
repeated twice by re-suspending the same sample in PBS. Without disturbing the pellet, visual 
observation was performed to check for the presence of unusual or unexpected supernatant. 
For water soluble drugs, the centrifugation process is simple and involves centrifugation of 
liposomal suspension directly and analysis of non-entrapped drug present in supernatant. For 
lipid soluble drugs, media preparation is needed, which depends on the extent of its water 
solubility. In the case of metformin, 1.0 mL of the suspension was centrifuged directly. As the 
solubility of glipizide in PBS is 37 mg/L, the suspension was diluted in 40 mL PBS to achieve 
maximum solubility of glipizide and to avoid its sedimentation along with liposomes.  
 
2.3.2 Dialysis 
Empty as well as drug loaded liposomes were dialysed using (3500Da) membrane for 15 minute 
for the removal of residual solvent as well the non-encapsulated drug. The dialysis tubing 
(Medicell membranes Ltd, London, UK) was soaked under running water to remove the traces 
of preservatives. The tubing was cut into 10 cm length pieces and secured with clips on both 
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ends ensuring no sample leakage. The 60 mL PBS outside the dialysis tubing and the sample 
inside the tubing was then analysed by HPLC for quantification of drug and the residual solvent.  
 
2.3.3 Spin columns 
Although the process of dialysis is used widely for the removal of solvent as well as the free 
drug, it requires skilled operation and is prone to environmental contamination. Therefore, as 
an alternative approach, disposable spin columns (Sartorius-Vivaspin 2, Surrey, UK) were tested 
for the removal of residual solvent as well the non-encapsulated drug. Here, the membrane of 
the spin column was pre-soaked with water and centrifuged at 2000 rpm for 5 minutes. 
Following this, the required volume (1.0 mL) of sample was placed in to the spin column and 
then centrifuged for 15 minutes at 3000 rpm. The sample was washed once again with 1.0 mL 
PBS for 15 minutes at 3000 rpm to achieve the maximum removal of non-encapsulated drug as 
well as residual solvents. The eluent as well as the sample inside the spin column was then 
tested for quantification of drug using HPLC and the residual solvent using GC.  
To separate unloaded peptide RF-482, a similar approach was used. The peptide was removed 
using centrifugal filter units (Ultracel- 50K, Millipore Ireland Ltd., Cork, Ireland). The eluent as 
well as the sample inside the spin column was then tested for quantification of unloaded and 
loaded peptide, respectively, using the BCA assay (Section 2.4.4.2). 
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2.4 Characterisation of liposomes 
2.4.1 Laser diffraction 
Characterisation of MLVs was performed using laser diffraction method (Sympatec-HELOS, 
Sympatec, Bury, UK), using samples within an optical concentration range of 15-25 %. The size 
was reported as volume mean diameter (VMD) and the particle size distribution is reported in 
terms of span value. The span value was generated using equation 2.1 based on the particle 
distribution percentile (D0.1, D0.5 and D0.9) (Kirby et al., 2008). 
                             =
D0.9 − D0.1
D0.5
                                                                          E()*+,-. /. 0 
 
2.4.2 Dynamic light scattering 
Characterisation of small unilamellar vesicles (SUVs) was performed using dynamic light 
scattering (Malvern Zetasizer Nano-ZS). Intensity based mean particle size was reported as Z-
average for the monomodal distribution. In the case of multimodal distribution, the Z-average 
was reported based on the intensity as well as the size based distribution of vesicles. The 
sample analysis was carried out at 25°C and in the attenuation range of 6 to 10. To achieve this 
attenuation range the sample was diluted with water. The width of particle distribution was 
reported as polydispersity index (PDI).  
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2.4.3 Surface charge measurement 
Characterisation of the surface charge of the vesicles was performed using particle 
electrophoresis (Malvern Zetasizer Nano-ZS). in this instrument uses laser doppler micro-
electrophoresis to measure zeta-potential. Briefly, the velocity of particles according to their 
zeta-potential is measured, as a result of an dc electric field being applied across the sample. 
The sample was diluted 1:100 in diluted PBS (1 in 300).  
 
2.4.4 Determination of unknown concentration using calibration curve 
Using area under curve (AUC) (HPLC) and absorbance (BCA assay), percent recovery of the 
unknown concentration of drug and peptide was determined statistically by using a calibration 
curve. Intensity was considered as the response (y) from the detector, which is directly 
proportional to the concentration (x) of analyte present in the unknown solution. Linearity of 
standards as well as its slope (c) and intercept (m) also contribute in determination of sample 
concentration. It was observed that the ‘R2’ value, which is measure of linearity between 
detector signals and sample concentration, is >0.99. This shows good correlation between 
detector signals and sample concentration. 
For both HPLC and BCA assays, the quantification of unknown concentration was performed by 
plotting a calibration curve which was presented as a linear function of concentration of API or 
peptide.  
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2.4.4.1 High performance liquid chromatography (HPLC) 
A validated HPLC method was used to determine the entrapped and non-entrapped drug. 
Briefly, simultaneous quantification of metformin and glipizide (both liposome entrapped and 
non-entrapped) was performed using reversed-phase high performance liquid chromatography 
(RP-HPLC, Shimadzu 2010-HT, Milton Keynes, UK) connected with an ultra-violet detector at 
233 nm to allow simultaneous quantification of both drugs. Isocratic elution was performed 
using a mobile phase composition of acetonitrile:PBS (65:35, pH 5.75) at constant flow rate of 
1.0 mL/minute, using a Luna column (C-18, 5µ, i.d. 150 X 4.6 mm) from Phenomenex 
(Macclesfield, UK)(Kar and Choudhury, 2009). Mobile phase acetonitrile: PBS (65:35, pH 5.75) 
was used as sample diluent. However, to determine drug encapsulated into the liposome, the 
liposomes were dissolved in ethanol followed by a second dilution with the mobile phase.  
Considering analyte properties and foreseeing the co-encapsulation of drugs, the method was 
developed in-house and validated following ICH guidelines (FDA, 1994). The method 
development and validation is further described in chapter3. Briefly, the determination of 
loading was performed by separating non-entrapped drug. This was done by centrifugation for 
the MLV and by dialysis for the SUV. The percent encapsulation and non-encapsulation was 
then determined by using equations 2.2 &2.3, whilst the percentage recovery of the drug was 
calculated by equation 2.4.  
      % 23456789 =
Amout of drug in the sample (i. e. in liposome) X 100
Amount of drug used initally
                            O()*+,-. /. / 
   % P9 − 3456789 =
Amout of drug in the sample (i. e. outside liposome) X 100
Amount of drug used initally
             O()*+,-. /. Q 
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%39RST =
(Amount of drug encapsulated + Amount of drug non − encapsulated)X 100
Amount of drug used initally
      O()*+,-. /. W 
 
2.4.4.2 Bicinchoninic acid (BCA) assay 
After separation of liposome associated and non-associated peptide molecules (RF-482), the 
eluent and the liposome suspension were tested for peptide presence by BCA assay, using a 
Micro BCA assay kit (Thermo scientific, Rockford, IL, USA). PBS (pH 7.4) was used as sample 
diluent. However, ethanol (Fisher scientific, Fair lawn, NJ, USA) was used to separate liposome 
associated protein and this was further diluted with PBS.  Five standards of peptide RF-482 
were prepared for linearity and calibration curve. Working reagent was prepared following the 
protocol provided (Thermo scientific, Rockford, IL, USA). 150 µL of standards and samples were 
added to the 96-well plate. To all the standards and samples, 150 µL of working reagent was 
added and incubated for 2 hours, after which the plate was cooled to room temperature and 
tested for peptide quantification using a plate reader (TECANTM, Morrisville, NC, USA) at 562 
nm. Apart from the standards and samples, ethanol, buffer as well as ‘empty’ liposomes were 
tested for BCA interference. Percent loaded protein, unloaded protein and percent recovery of 
the protein was calculated using the same equations 2.2, 2.3 &2.4, respectively.  
 
2.4.5 Removal of residual solvent and quantification 
Two different approaches, dialysis and using spin columns, were used to remove residual 
solvent in the SUV suspension obtained from the microfluidic device. ‘Empty’ as well as drug 
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loaded liposomes were dialysed using (3500Da) membrane (Medicell membranes Ltd., London, 
UK) for 15 minutes for the removal of residual solvent as well the non-encapsulated drug. 
Dialysis was performed using PBS (composition: phosphate buffer 0.01 M, 0.0027 M potassium 
chloride and 0.137 M sodium chloride, pH 7.4). On the other hand, disposable spin columns 
(Sartorius-Vivaspin 2, Surrey, UK) were also used for the removal of residual solvent as well the 
non-encapsulated drug. 
Gas chromatography (200 series gas chromatograph, Ellutia, Cambs, UK) was used to test the 
presence of residual solvents in liposome samples obtained from the microfluidic device. The 
specifications of the method are described in table 2.1.  
 
Table 2.1 Method parameters of gas chromatographic method used for residual solvent 
analysis. 
Specification Description  
Gas chromatography 200 series gas chromatogrph, Ellutia,  Cambs, UK) 
Column  Capillary column. Dimensions:15 m x 0.25 mm x 0.25 μm. 1.5 µm 
film thickness. 
Carrier gas Hydrogen 
Injector temperature 210°C 
Detector temperature 280°C 
Over temperature Oven temperature was controlled by a 5-ramp temperature elevation 
program. The temperature was initially set at 45°C for 3 min, elevated to 
250C at the rate of 20°C/min. 
2.4.6 In-vitrodrugrelease 
The majority of in-vitro drug release studies are based upon dialysis of liposomal formulation 
against large volumes of buffers or other simulated media at physiological temperatures; yet, 
this excess buffer could lead to leakage of drug out of liposomes (Shabbits et al., 2002).    
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The CE7smart USP-4 system (SOTAX AG, Switzerland) was used to create an incubating 
environment for the release of drug encapsulated within liposomes. The method is widely used 
for the drug release study of novel drug delivery systems (Burgess et al., 2004; Siewert et al., 
2003). Dialysed samples were subjected for the drug release. Briefly, the method is based on a 
dialysis adaptor placed in a flow-cell. Through this flow-cell, PBS (pH 7.4) was used in a closed 
loop system and was circulated at constant temperature (37 ± 1°C) at a constant flow of 8.0 
mL/minute. The method was developed in-house and the release of drug was quantified using 
the validated HPLC method for the individual and simultaneous determination of glipizide and 
metformin. Samples were withdrawn at time intervals of 10, 30, 60, 90, 120, 180, 360, 540, 720 
and 1440 minutes. The setup of the USP-4 and its operation is described further in chapter3.  
 
2.4.7 Microscopic analysis of liposomes 
2.4.7.1 Confocal microscopy for the visualisation of MLV 
1,1'-dioctadecyl-3,3,3'3'-tetramethylindocarbocyanine perchlorate (Dil C), a lipophilic dye, was 
used for this analysis.Liposomes were produced using the thin film hydration method (section 
2.2.1), with the addition of 0.2 mole % of the DilC dye. This dye has excitation wavelength 540 -
552 nm and emission wavelength 565 – 640 nm. When in the emission wavelength, the dye 
emits a red colour. A microslide (Cam lab, Cambridge, UK) was mounted on a clean glass slide to 
avoid the possible squeezing of liposomes caused by the usage of conventional coverslip. 10 µL 
of the suspension of DilC dye encapsulated liposomes was then injected in to the microslide 
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using a micropipette. Due to the lipophilic nature of the dye, it was expected to be 
encapsulated into the bilayer of liposomes, thereby allowing imaging of the multiple red 
coloured layers of the MLV.   
 
2.4.7.2 Cryo-electron microscopy for the visualisation of SUV 
All the samples were freshly prepared on the day of analysis. Empty, single and co-drug loaded 
liposomes were prepared using the method described before (section 2.2). A 3 µL aliquot of 
each sample was placed onto a pre-cleaned lacey carbon coated grid and flash frozen by 
plunging into liquid ethane cooled by liquid nitrogen. Samples were stored in liquid nitrogen 
and conveyed to a cryo-holder and observed under the electron microscope at liquid nitrogen 
temperatures. Grids were observed using Tecnai 12 G2 electron microscope (FEI, Eindhoven) at 
80 kV and the evaluation was performed in the magnification range of 40000 X to 135000 X. 
 
2.4.7.3 Fluorescence microscopy for the visualisation of RF-482 
Fluorescein isothiocyanate FITC labelled peptide RF-482 was used to demonstrate the 
association of peptide with liposomes. Liposomes were produced using the method described 
in section 2.2.3. The unloaded fluorescent peptide was removed by using filter units (Ultracel- 
50K, Millipore Ireland Ltd., Cork, Ireland) and centrifugation. A drop of SUV suspension was 
then placed on a glass slide and dried in a desiccator, which was covered to avoid the 
interference of light with the fluorescent peptide. The slide with the dried SUV was then 
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observed under FITC channel of the Nikon Ti Eclipse fluorescence microscope (Nikon Inc. 
Melville, NY, USA).  
 
2.4.7.3 Electron microscopy for the analysis of peptide loaded liposomes 
Osmium tetroxide is commonly used for the fixative stain for cells; since the liposome structure 
resembles cell structure, a similar fixative staining was performed. Briefly, a drop of each 
liposome sample was placed on to the carbon film mesh copper grid and the excess suspension 
was removed using filter paper. Staining was performed using 4 % osmium tetroxide solution. 
Images were captured using high resolution electron microscope (EM10A/B, ZEISS, Germany). 
 
2.5 Production and analysis of gold nanoparticles (GNPs) 
2.5.1 Functionalisation of gold nanoparticles 
Using apre-developed and validated protocol for the functionalisation of GNPs (Tiwari et al., 
2014), 50 nm in sized carboxyl-polymer coated spherical GNPs (Nanopartz™, Loveland, CO, 
USA), were functionalised with RF-482 (Bachem Americas Inc., Santa Clara, CA, USA) with the 
aid of 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, Sigma Aldrich, St. Louis, MO, USA) 
chemistry. The carboxylated GNPs were conjugated by mixing with peptide (17 mM) and EDC 
followed by shaking on an auto-shaker for an hour. The peptide concentration was higher than 
free carboxyl groups on the GNPs. The whole solution was then centrifuged at 18000  rpm for 
60 min to separate unbound protein and repeated once for maximum removal of unbound 
87 
 
protein. Finally, the pellet of functionalised GNPs was re-suspended in sterile deionised water 
up to 5 mL. 
The copyrights of the fuctionalisation are reserved but available information confirms that the 
peptide was first reacted to [(2-amino-ethoxy)-ethoxy]-acetic acid (H-AEEAc) by N-terminatal 
addition reaction and  conjugation of this to the GNPs was facilitated by the carboxyl group (-
COOH) of the polymer coated on the surface of the GNPs (Singh et al., 2014).    
 
2.5.2 Particle characteristics 
Dynamic light scattering (DLS) (Zetasizer Nano-S, Malvern instruments, Westborough, MA, USA) 
was used for size determination of GNPs, F-GNPs, empty and RF-482 encapsulated liposomes. 
Zeta potential was determined using laser Doppler velocimetry (Zetasizer Nano-S, Malvern 
instruments, Westborough, MA, USA. The analysis was performed for both GNPs and FGNPs. 
Samples were diluted 1:100 in distilled water for both size and surface charge analysis.  
 
2.5.3 UV/visible-spectrophotometry for the confirmation of conjugation 
GNPs functionalisation was evaluatedby UV/Vis spectrophotometry (Beckman Coulter 
spectrophotometer, Brea, CA, USA). Confirmation of conjugation of peptide with GNPs was 
made upon the data analysis of DLS as well as US/Visible spectrometry (Beckman Coulter 
spectrophotometer, Brea, CA, USA); Chithraniet al. (2006) have reported that the 
functionalisation of GNPs can be confirmed by a shift in λmax (Chithrani et al., 2006b). 
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2.5.4 Quantification of GNPs-Peptide conjugation 
As mentioned earlier in section 2.5.1, the peptide concentration was higher than free carboxyl 
groups on the GNPs; therefore, the whole sample was then centrifuged at 18000 rpm for 60 
min to separate unbound protein and repeated again for maximum removal of unbound 
protein. Finally, the pellet of functionalised GNPs was re-suspended in sterile deionised water 
up to 5 mL. The supernatant obtained after F-GNPs washing was subjected to BCA assay and 
tested for quantification of protein conjugated with GNPs, using an indirect approach by 
quantifying non-conjugated protein. 
  
2.6 Analysis of RSV inhibition 
The evaluation of GNPs and functionalised GNPs was established to prove their potential of 
inhibiting RSV (Tiwari et al., 2014). Following the established protocols of the GNPs conjugate 
system, the liposomes alone as well as liposomes loaded with peptide was evaluated for their 
potential to inhibit RSV.   
 
2.6.1 Cell culture and subculture 
Human epidermoid type-2 (HEP-2) cells (American Type Culture Collection (ATCC), Manassas, 
VA 20110 USA) were used throughout this study.  Cells stored into the liquid nitrogen vapour 
phase were sub-cultured using the protocol provided by the supplier. Cells were thawed and 
centrifuged at 1500 rpm for 5 minutes to remove the organic solvent in the medium. The pellet 
was re-suspended using growth medium (MEM-10) supplemented with 2 mM L-Glutamine, 10% 
89 
 
FBS, 75U/mL Penicillin, 100 μg/mL Kanamycin as well as 75 μg/mL Streptomycin and stored in 
75 cm2 flask inside the incubator at 37°C in 5 % CO2 environment. The flask was microscopically 
observed after 48 hours for the confluence. Upon observing the required confluence, the 
medium was discarded and the cells were detached from the wall of the flask using 
Trypsin0.53mM EDTA. The cell suspension was removed carefully and the flask was washed 
with the medium for maximum removal of the cells. The cell suspension was then centrifuged 
at 1500 rpm for 5 minutes and the cells re-suspended using MEM-10. The cells suspended in 
the medium were counted and sub-cultured if needed or preserved in liquid nitrogen vapour 
phase.2.6.2 Cell count 
Cells prior to experimentation/ sub-culture/ storage were counted using a cell counter 
(countess-II FL, automated cell counter, ThermoFisher scientific, NY, USA). 10 µL of trypan blue 
(ThermoFisher scientific, NY, USA) and 10 µL of the sample was mixed and pipetted into the 
disposable chamber slide (Countess cell counting chamber slide, ThermoFisher scientific, NY, 
USA). The slide was inserted into the instrument and readings of cell count were noted for 
further use.  
 
2.6.3 Cell viability assay/MTT assay 
Human epidermoid type-2 (HEP-2) cells were proliferated using minimum essential medium 
(MEM) supplemented with 10 % foetal bovine serum (FBS), 2 mM L-glutamine, 75 U/mL 
penicillin, 100 mg/mL kanamycin and 75 mg/mL streptomycin. Empty and functionalised 
liposomes as well as peptide RF-482 was tested for the cell toxicity by using dye MTT (3-(4, 5-
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dimethyl-thiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide). The reduction assay was performed 
using CellTiter 96® Non-Radioactive cell proliferation assay kit (Promega, Madison, WI, USA). 
25,000 cells per well were seeded using MEM-10 (10% FBS). Two different concentrations of 
peptide RF-482, empty liposomes and functionalised liposomes were tested for their celltoxicity 
72 hours post incubation. MTT assay was performed as per protocol provided (Promega, 
Madison, WI, USA). The absorbance was measured at 570 nm using the plate reader (TECANTM, 
Morrisville, NC, USA). 
 
2.6.4 Fluorescence microscopy for cell imaging 
FITC labelled peptide RF-482 was used to demonstrate the association of peptide with 
liposomes. However, to study the RSV inhibition, 30000 cells per well were chambered into an 8 
chambered slide. Cells were incubated with peptide RF-482, empty liposomes and 
functionalised liposomes for 48 h, followed by fixing in paraformaldehyde-glutaraldehyde and 
buffer (PBS) wash. The nuclei were stained using 4’, 6-Diamidino-2-phenylindole (DAPI) and cell 
membranes were stained using Cell Mask™ (Life Technologies, Carlsbad, CA, USA). Using the 
DAPI and FITC channel of the Nikon Ti Eclipse fluorescence microscope (Nikon Inc. Melville, NY, 
USA), all the slide chambers were imaged. 
2.6.5 Immunofluorescence imaging 
Viral fusion inhibition was observed under fluorescence microscopy. 30,000 Hep-2 cells were 
grown in 250 µL/ well - 8 well chamber slides for 24-48h (with >80 % confluency). These cells 
were infected with RSV-Peptide/GNPs/FGNPs/liposome/RF-482 encapsulated liposomes, 
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followed by incubation for 48-72 Hrs at 37°C in a humidified 5% CO2 atmosphere. Uninfected 
cells were then removed using 1X PBS washing and infected ones were fixed with methanol and 
permeabilised with cooled acetone for 1 minute at -20°C. Primary antibody was then added 
followed by removal of unattached antibody and addition of secondary antibody antibody-FITC 
(goat). Similar washing was performed to remove unused secondary antibody, followed by 
staining using DAPI (ProLong® Gold Antifade Reagents with DAPI, Life Technology). A cover-slip 
was fixed over the slide before observing under microscope.  
 
2.6.6 Plaque assay 
The plaque assay is one of the most common and reliable method of determination of 
viral/antiviral activity by counting plaques in the cell culture. The plaque assay was performed 
using HEP-2 cells (1.5×105/well) proliferated in MEM-10 for 48hours to achieve maximum 
confluency. A predetermined titre of RSV was used for the experiments. Mixtures of RSV and 
peptide/empty liposome/conjugated liposome/GNPs/FGNPs were prepared in Dulbecco’s 
modified eagle’s media (DMEM) prior to the infection. Post-infection, the cells were covered by 
immobilising overlaying medium (1.6 % methyl cellulose) and subsequently incubated for 5 
days at 37⁰C in 5 % CO2 environment. On the 5
th day, the overlaying medium was removed and 
the monolayer was fixed with cold methanol at -20⁰C followed by staining with 0.1 % crystal 
violet solution. Plaques were counted to determine the viral or antiviral activity. 
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2.6.7 Quantitative polymerase chain reaction (qPCR) analysis 
The whole experiment consisted of a set of small experiments starting from cell culture to gene 
quantification. To reduce the chances of cross-contamination, these small experiments were 
performed in different rooms. Similar to the plaque assay, this experiment was started by 
plating HEP-2 cells (1.5×105/well). After 48 hours proliferation, the cells were treated with viral 
dilutions with and without peptide/empty liposomes/conjugated liposomes/GNPs/FGNPs. 
These treated cells were then incubated for 48 hours at 37⁰C in 5 % CO2 environment. After 48 
hours incubation, the cells were harvested for RNA extraction. From the extracted RNA, using 
manufacturer’s protocols, 1 μg RNA was converted to cDNA using reverse transcriptase 
enzyme. The RSV-F gene specific primers, along with the probe as well the experimental 
procedures, were selected based on previously published research (Eroglu et al., 2013; Mentel 
et al., 2003). Each qPCR reaction was performed using a total reaction mixture volume of 20 μL, 
comprised of 2 μL cDNA, reverse and forward primers (both 1 μL each), 2 μL probe, 10 μL of 
TaqMan Master Mix and nuclease free water.  Water as a negative control and RSV-F gene 
amplicon dilutions (102 to 108) were used as standards to prepare a calibration curve. The qPCR 
for each sample was run in duplicate on Applied Biosystems® ViiA™ 7 real time PCR (Life 
Technologies). 
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2.7 Statistical analysis 
Unless stated otherwise, the results were calculated as mean ± standard deviation (SD). T-test 
alone or ANOVA followed by Dunnett’s post hoc analysis was performed for comparison and 
significance was acknowledged for p values less than 0.05. All the calculations were made using 
Graphpad version-6 (GraphPad Inc., La Jolla, CA). 
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Chapter 3: Method development for the simultaneous 
quantification of metformin and glipizide  
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3.1 Introduction 
Pharmaceutical analysis is a key element in the formulation of medicines and an important task 
within this is analytical assay development and validation. A wide range of instrumental 
techniques are in use to meet regulatory requirements, including spectroscopy and 
chromatography; these two techniques are the major tools for the qualitative, as well as 
quantitative analysis of APIs within products (Lawrence, 2008; Rozet et al., 2007). The present 
focus of the analytical method development is towards the development of precise, fast, 
reproducible, easy and cost effective methods. From the origins of pharmaceutical analysis, 
analytical assay methods have been included in the compendia of pharmacopoeias to 
characterise the purity of bulk drugs by finalising the limits of their active ingredient content. In 
recent years, the assay methods in the pharmacopeial monographs comprise in titrimetry, 
spectrophotometry, chromatography, capillary electrophoresis as well as the electro analytical 
methods (Pharmacopoeia, 2002). 
 
Of these methods, chromatography is considered as one of the most reliable tools for drug 
detection and quantification. Chromatography has a broad history, and has been practiced in 
several forms, ranging from thin layer chromatography (TLC) to Ultra performance liquid 
chromatography (UPLC).  Based on the physical sources which bring the mobile phase and the 
stationary phase together, chromatography is classified into two parts;first is planar 
chromatography, where the stationary phase is supported onto a plane or plate or paper and 
the mobile phase is driven by capillary action, gravity, pressure or electric field; the second is 
column chromatography, where the mobile phase is driven through the column by pressure, 
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gravity or electric field (Giddings, 1991). HPLC is the advanced type of column chromatography; 
in short, a mobile phase carrying drug for detection gets forced at high pressure through the 
column and the compound elutes according to its affinity towards the stationary phase (Snyder 
et al., 1979). Mainly, there are four different types of HPLC methods, namely normal phase-
HPLC (NP-HPLC), reverse-phase-HPLC (RP-HPLC), size exclusion chromatography and ion-
exchange chromatography. RP-HPLC is widely used in pharmaceuticals, as well as biomedical 
research, and is recognised for its excellent resolution, experimental ease, high recoveries and 
excellent reproducibility (Aguilar, 2004). Of the two, RP-HPLC is the most preferred, not only for 
the bulk drug analysis but also for the main compound analysis. Due to the non-polar nature of 
the stationary phase, molecule separation occurs according to their hydrophobicity. The elution 
of the compound can either be isocratic elution, where the concentration of organic phase is 
constant, or gradient elution, where the concentration of the organic solvent changes according 
to the programmed time (Aguilar, 2004). The assembly of RP-HPLC involves mobile phase, 
injector, pump, column, detector, instrument control and waste (Figure 3.1).  
 
A wide range of detectors are used in chromatographic science. However, the most widely used 
detector for RP-HPLC is ultra-violet (UV) detector e.g. UV/Visible detector, fluorescence 
detector etc. In this work, the RP-HPLC with UV detector was used for qualitative and 
quantitative analysis. 
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Figure 3.1 Schematic representation of an HPLC assembly. Three major sections of the HPLC are mobile phase, stationary phase and 
the detector. Pumps and injectors are equally important but their functioning are dependent on the quality of mobile phase and 
sample matrix respectively. 
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The aim of the work presented in this chapter was to develop and validate an HPLC assay for 
simultaneous detection of glipizide and metformin to allow quantification of drug loading 
within liposomes. To consider drug release from these liposomes, a USP-4 dissolution based 
method was developed and used in combination with HPLC to determine the release of single 
or co-encapsulated drugs. 
 
3.2 Method development 
3.2.1 Physicochemical properties of drug 
The basic criterion for HPLC assay development is to study the physicochemical properties of 
the drug substance that could influence the chromatographic separation, which involves 
consideration of the solubility, pKa and Log P of the drugs. Metformin has a pKa value of 12.4, 
whereas that of glipizide is 5.6 (Figure 3.2).  Similarly, log P represents drug lipophilicity (P)and 
is the partition coefficient of the molecule in a water-octanol system; metformin and glipizide 
represent log P values of -1.8 and 1.9, respectively (Figure 3.2). Subsequently, metformin is 
practically insoluble in organic solvent and glipizide is a poorly water soluble drug. Therefore, 
simultaneous determination of these compounds with divergent properties is challenging 
(Snyder et al., 1979; Snyder et al., 2012).  
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Figure 3.2 Representation of divergent nature of glipizide and metformin through their 
physicochemical properties. 
 
 
3.2.2 Selection of diluents and determination of analytical wavelength (λ max) 
The selection of solvent is a crucial part in this particular analysis development, due to the 
divergent solubility of the two drugs for analysis, with metformin requiring an aqueous media 
and, due to the poor water solubility of glipizide, use of organic solvent was preferred. 
Phosphate buffer is widely used due to its pKa values, prominent hydrophilic effect and better 
stability. In RP-HPLC, water is considered as a poor solvent but acetonitrile is well known for its 
organic modifier activity. Furthermore, acetonitrile has a low UV-cut off of 190 nm, which 
allows detection of compounds at lower wavelength. Apart from these properties of 
acetonitrile, an important characteristic is that it is less viscous than methanol and less bubble 
formation is observed when mixed with water; this reduces the back pressure on the RP-HPLC 
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system. Considering the above factors, a mixture of acetonitrile and phosphate buffered saline 
(65:35 v/v) was chosen as the diluent.  
 
The maximum absorption wavelength (λmax), was determined using UV-Visible 
spectrophotometer (Thermo Scientific Genesys 10S). For this qualitative analysis, two solutions 
of the two drugs were prepared separately at three different concentrations. Upon the 
spectrophotometric analysis, it was observed that both the drugs possess similar λ max of 233 
nm (results not shown).   
 
3.2.3 Selection of column, mode of elution and mobile phase 
Metformin is a polar molecule (Wanjari et al., 2008), which has led to researchers preferring 
ion-pair extraction or capillary electrophoresis for its separation from the matrix(Lai and Feng, 
2006; Song et al., 1998). In contrast, Glipizide belongs to anarylsulfonylurea, which is relatively 
non polar (Lebovitz, 1985).  Having this information about both the drugs, it was challenging to 
develop a RP-HPLC method for the separation of polar and non-polar molecules on the same 
column. Silica surface with octadecylsilane ligands are widely used in analytical separation with 
minor changes in the mobile phase (Ihara et al., 2006). Therefore, a Phenomenex Luna C-18 
column with the dimensions i.d. 250 X 4.6 mm, particle size 5 μm and pore size 100 Å was 
chosen for the separation. 
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Before selecting elution mode, it is necessary to understand the capacity factor (k’), also termed 
the capacity ratio, which is a measure of the retention time of the peak, independent of 
geometry of the column or flow rate of the mobile phase. If the retention of the final peak has 
k’ less than 5, then it is considered as weak retention (Schellinger and Carr, 2006). Considering 
the presence of a polar (metformin) and relatively non-polar (glipizide) molecule in the sample 
matrix, there was possibility of weak retention. To avoid interference of possible weak 
retention and baseline impediment, it is recommended to use isocratic elution. Given the 
versatility of acetonitrile and the hydrophilic effect as well as stability of phosphate buffer, it 
was preferred to have a mixture of these as mobile phase for the RP-HPLC separation. 
Therefore, the diluent (acetonitrile:PBS, 65:35 v/v) used earlier for spectrophotometric analysis, 
was finalised to be used for the RP-HPLC separation.  
 
To test the above selection, preliminary analysis was performed at 233 nm on Shimadzu HPLC 
with UV detector using Phenomenex Luna C-18 column (150 X 4.6 mm, 5 μm, 100 Å), and 
acetonitrile:PBS (65:35 v/v) mobile phase. There were two chromatographic peaks observed 
within 5 minutes. It was concluded that the 1st and 2nd peaks possibly represents metformin 
and glipizide, respectively; however, the peaks were not well separated (Figure 3.3).  
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Figure 3.3 Chromatogram representing preliminary analysis of glipizide and metformin. Analysis 
performed on Shimadzu HPLC at 233 nm using Phenomenex Luna C-18 column and acetonitrile: 
PBS (65 : 35 v/v) mobile phase. Y-axis = Area Under Curve (AUC) (Dependent of concentration 
of analyte) and X-Axis = Minutes (Retention time representing interaction of analyte with the 
stationary phase when dissolved in given mobile phase and flow rate). 
 
 
3.2.4 Impact of ion-pairing agent and pH on separation of compounds 
Given that the mechanism of HPLC is primarily based on the hydrophobic interactions of the 
analyte and the stationary phase, use of an ion pairing agent can be used to promote retention 
of polar compounds such as metformin (e.g. phosphoric acid). Whilst, the exact mechanism of 
action is under debate, it has been shown that ion-pairing agents enhance retention of such 
molecules (Tinner, 2016).  In terms of ion-pairing agents, a variety of ion-pairing agents are 
available e.g phosphoric acid, tri-fluoroacetic acid, penta-fluoroacetic acid etc. Using ortho-
phosphoric acid, the pH of the aqueous portion of the mobile phase was adjusted to acidic. An 
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experiment similar to section 3.2.3 was performed with increased metformin and glipizide 
concentration for better peak height, but the pH of the mobile phase was adjusted to 6.75. 
Using this set up, both peak separation and peak resolution was improved (Figure 3.4). 
 
Figure 3.4 Chromatogram representing preliminary analysis of glipizide and metformin. Analysis 
performed on Shimadzu HPLC at 233 nm using Phenomenex Luna C-18 column and acetonitrile: 
PBS (65 : 35 v/v) mobile phase. Y-axis = Area Under Curve (AUC) (Dependent of concentration 
of analyte) and X-Axis = Minutes (Retention time representing interaction of analyte with the 
stationary phase when dissolved in given mobile phase and flow rate). 
 
 
In section 3.2.3, it was observed that the smaller peak eluting first is metformin, whereas here 
it was observed that the smaller peak represents glipizide and the bigger peak represents 
metformin. This was confirmed by running a single analyte of the same concentration (Figure 
3.4).   
To further consider the impact of pH on peak separation, the pH was further reduced from 6.75 
(Figure 3.4) to pH 5.75 for both the drugs independently and simultaneously (Figure 3.5). This 
reduction in pH promoted improved separation and a reduction in retention time to1.5 and 2.4 
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minutes for metformin and glipizide, respectively (Figure 3.5). The retention of analyte in a 
mobile phase running on a stationary phase is dependent on the pH of the mobile phase, due to 
the impact on ionisation (Equation 3.1 and 3.2). 
HAH++A-                                                                                Equation 3.1 
B+H+BH+                                                                               Equation 3.2 
 
At the low pH, the concentration of the H+ ions causes an equilibrium shift and, hence, at 
higher pH the acidic analytes elute more rapidly (Fallon et al., 1987). Hence, both metformin 
and glipizide, which are weak acids and strong base respectively, elute slowly at higher pH 
of6.75 (Figure 3.4) and rapidly at lower pH of 5.75 (Figure 3.5). 
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Figure 3.5 Chromatogram representing preliminary analysis of glipizide and metformin. The effect of pH on the separation of 
analyte. Analysis performed on Shimadzu HPLC at 233 nm using Phenomenex Luna C-18 column and acetonitrile: PBS (65: 35 v/v, aq. 
pH 5.75) mobile phase. a) glipizide RT=2.3 minutes, b) metformin RT= 1.5 minutes, c) metformin at 1.5 and glipizide at 2.3 minutes. 
Y-axis = Area Under Curve (AUC) (Dependent of concentration of analyte) and X-Axis = Minutes (Retention time representing 
interaction of analyte with the stationary phase when dissolved in given mobile phase and flow rate). 
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Based on these studies, a final HPLC protocol for the simultaneous analysis of both glipizide and 
metformin was developed, as outlined in Table 3.1. 
Table 3.1 SOP for the RP-HPLC method for glipizide and metformin analysis. 
RP-HPLC Assay 
Aim: Simultaneous determination of glipizide and metformin using RP-HPLC. 
Method parameters  
Chemicals: Glipizide and metformin, phosphate buffered saline 
(PBS), acetonitrile (ACN), ortho-phosphoric acid, milli-Q 
water. 
Column: C18, 5 micron particle size, i.d. 150 × 4.6 mm, Pore size 
100 Å 
  
Mobile phase: Adjust the pH of PBS to 5.75. Then mix acetonitrile and 
PBS with adjusted pH in a proportion 65:35 v/v. Degas 
for 5 minutes before use.  
Diluent: Use mobile phase as diluent. 
Column 
Temperature: 
Room Temperature  
Sample 
Temperature: 
Room Temperature  
  
Flow: 1.0 mL / minute 
  
Run time: 5 minutes 
  
Wavelength: 233 nm 
  
Detector: Ultra-violet (UV) 
  
Retention time: Metformin-1.5 minutes, Glipizide-2.3 minutes. 
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3.3 Method validation 
The international conference on harmonization (ICH) recognises accuracy, precision, 
repeatability, intermediate-precision, specificity, limit of quantitation and detection as well as 
linearity as major parameters for the HPLC methodvalidation (FDA, 1994). Therefore, the 
method developed for the analysis of glipizide and metformin, as outlined in Table 3.1, was 
tested for these validation parameters.  
 
3.3.1 Specificity 
Specificity confirms no interference of the external components to the analyte with good 
chromatographic resolution (FDA, 1994). To confirm this, the chromatograms for each drug 
alone and in combination were generated (Figure 3.5). Apart from the sample analyte solutions, 
the buffer, as well as pH adjusted mobile phase and acetonitrile was injected separately. 
Neither single component analysis nor multi component analysis has observed interference of 
the extraneous entities (Figure3.5).  
 
3.3.2 Accuracy 
Accuracy represents how close the experimental concentration is to the true concentration of 
the analyte (FDA, 1994). Five samples of different concentration were prepared in triplicates 
and tested for the recovery, as outlined in Table 3.2. For concentrations of both drugs, the 
recovery observed was >95 % (Table 3.2).   
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Table 3.2 Percent recovery of metformin and glipizide representing accuracy of the RP-HPLC 
method (n=3). 
Metformin Glipizide 
Standard Concentration 
(µg/mL) 
Found 
concentration 
(µg/mL) 
% Recovery Standard Concentration 
(µg/mL) 
Found 
concentration 
(µg/mL) 
% Recovery 
1 100 97.8 
± 0.3  
97.8 
± 0.3 
1 20 19.8 
± 0.3 
98.8 
± 0.2  
2 200 191.4 
± 0.5  
95.7 
± 0.2  
2 30 30 
± 0.2  
100 
± 0.1  
3 300 311.5 
± 0.5  
103.8 
± 0.2  
3 40 40.4 
± 0.2  
100.9 
± 0.2  
4 400 411.8 
± 0.5  
102.9 
± 0.3  
4 50 50.3 
± 0.5  
100.6 
± 0.3  
5 500 487.6 
± 1.0 
97.5 
± 0.2  
5 60 56.6 
± 0.6 
99.3 
± 0.3  
 
 
3.3.3 Linearity 
In validating the assay method, it is recommended that samples used to determine the 
recovery must be used for the purpose of linearity determination (FDA, 1994), i.e. samples 
should demonstrate that the recovery is within limits and satisfy the requirement of linearity 
(Jain et al., 2011). Therefore, five different concentrations of glipizide and metformin were used 
to consider linearity and accuracy. The accuracy represented for both drugs in table 3.3 was 
obtained from a linear calibration curve with R2 ≥ 0.995 (Figure 3.6).  
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a)         b)  
 
 
Figure 3.6 R2≥ 0.995 representing linearity obtained from the detector response to the analyte concentrations. a) Linearity of 
metformin concentration range 50 µg/mL to 250 µg/mL; b) Linearity of glipizide concentration range 20 µg/mL to 100 µg/mL. (AUC= 
Area under curve) 
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3.3.4 Precision 
When a number of measurements are made under similar analytical conditions, the closeness 
of the measurements represents method precision  (FDA, 1994). Precision is recommended to 
be calculated from the samples satisfying the requirement of linearity and accuracy. The 
fulfilment of the precision requirement is determined by percent relative standard deviation (% 
RSD) and it is recommended to be less than 0.5 %.  
                     % X =
Y Z[[
\  ]  
^ 100                                                              Equation 3.3 
 
Three concentrations of both glipizide and metformin were prepared in pentaplicates. The 
closeness of value of those pentaplicate samples was then tested by determining % RSD from 
the average value.  It was observed that both glipizide and metformin can be precisely 
determined using this RP-HPLC assay, as for both the drugs the % RSD was <0.5 % (Figure 3.7).  
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a)         b) 
 
 
Figure 3.7 Percent RSD≤ 0.5 % representing preciseness of the method. Values obtained from the detector response to the analytes 
concentration. a) % RSD for 3 different concentrations of metformin representing concentration precision. b) % RSD for 3 different 
concentrations of glipizide representing concentration precision. (AUC= Area under Curve) 
% 
RSD=0.30 
% 
RSD=0.30 
% 
RSD=0.2 
% 
RSD=0.24 
% 
RSD=0.17 
% 
RSD=0.29 
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3.3.5 Intermediate precision 
Intermediate precision is also referred toas ruggedness. Determination of accuracy on different 
occasion is considered as intermediate precision (FDA, 1994). Therefore, experiments were 
performed during two different weeks and the data was collected. On both occasions, the 
recovery of both glipizide and metformin for all five samples was found >95 % (Table 3.3). This 
confirms the ruggedness of the method.  
Table 3.3 Percent recovery representing the ruggedness of the analytical method for both 
metformin and glipizide (n=3). 
Metformin Glipizide 
Standard Concentration 
(µg/mL) 
Found 
concentration 
(µg/mL) 
% 
Recovery 
Standard Concentration 
(µg/mL) 
Found 
concentration 
(µg/mL) 
% 
Recovery 
1 100 97.6 
± 0.3  
97.6 
± 0.3  
1 20 19.2 
± 0.4  
96 
± 0.3  
2 200 193.5 
± 0.5  
96.8 
± 0.2  
2 30 31.1 
± 0.2  
103.7 
± 0.4  
3 300 304.5 
± 0.4  
101.5 
± 0.4  
3 40 39.8 
± 0.2  
99.5 
± 0.2  
4 400 403.8 
± 0.5  
101 
± 0.3  
4 50 49.5 
± 0.2  
99 
± 0.2  
5 500 492.6 
± 1.0  
98.5 
± 0.2  
5 60 58.6 
± 0.4  
97.7 
± 0.3  
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3.3.6 Limit of detection (LOD) and limit of quantification (LOQ) 
These parameters of the validation are also known as sensitivity of the method (Jain et al., 
2011). LOD and LOQ are the two vital parameters of method validation and can be determined 
by plotting a calibration curve using different concentrations of the analyte. Using area under 
curve (AUC) percent recovery of standards, as well as unknown concentration of each drug was 
determined statistically. The AUC considered as response (y) is directly proportional to the 
concentration(x) of analyte present in the unknown solution. Linearity of standards as well as 
its slope (c) and intercept (m) also contribute in determination of sample concentration. 
Equation 3.4 represents the equation to calculate concentration (x) of sample (Nagaraja et al., 
1999).  
                                                   T = _` + 3                                                           Equation 3.4 
As a part of drug analysis it is equally important to determine limit of detection (LOD) and limit 
of quantification (LOQ), using equations 3.5and 3.6, respectively: 
                                                    abX = (3 × e) ÷ 4                                                    Equation 3.5 
                                                  abg = (10 × e) ÷ 4                                                   Equation 3.6 
Where e  is the standard deviation of standard deviation of y-intercept and s is slope 
(Chorachoo et al., 2013; Jamadar et al., 2011). Using the data obtained from the calibration 
curve (Figure 3.6), the LOD and LOQ of glipizide were calculated to be 2.2 μg and 6.6 μg, 
respectively, whereas for metformin these were 20.2 μg and 61.4 μg, respectively.  
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3.4 Development of drug release methods using USP-4 based SOTAX dissolution apparatus 
with flow through cell (FTC) 
3.4.1 USP-4 dissolution apparatus 
Dissolution testing is derived from the disintegration testing. Official dissolution testing was 
adopted in the British pharmacopoeia (BP) in 1945, followed by the United States 
pharmacopoeia (USP) in 1950. In the early development of dissolution testing, various methods 
were proposed (e.g. Basket stirrer method, beaker method and Vliet’s method), before the 
introduction in the 1970s of the first two USP dissolution apparatus, the paddle and basket. In 
the past two decades, there has been further expansion of compendial dissolution testing 
apparatus for a variety of applications (Table 3.4)  
Table 3.4 Different dissolution apparatus currently in use mentioned in USP. 
USP dissolution apparatus Name 
USP-1 Basket 
USP-2 Paddle 
USP-3 Reciprocating cylinder 
USP-4 Flow through 
 USP-5  Paddle over disk 
USP-6 Cylinder 
USP-7 Reciprocating holder 
 
Among these various dissolution testing systems, USP-4 is recommended for the analysis of  in-
vitro drug release from liposomes (Bhardwaj and Burgess, 2010; Yuan et al., 2016). USP-4 was 
first included in the USP in 1957 (chapter <711> dissolution), and has since been adopted by the 
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European pharmacopoeia (Ph. Eur.) (Ph.Eur. 2.9.3) and Japanese pharmacopoeia (JP) (JP, XV, 
6.10 dissolution test). 
 
 The FTC are marketed into two different dimensions: a large cell (22.6 mm-internal diameter) 
and a small cell (12 mm-i.d.) (Fotaki, 2011). These provide 19 mL and 8 mL volume for the 
dissolution testing (Figure 3.9A&B). Depending on the purpose of analysis, these FTC then can 
be a used in two different systems: open loop or closed loop system (Figure 3.8C&D). 
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a)      b)        c)     d) 
 
 
Figure 3.8 Type of FTC (a) Large and (b) small FTC. The FTC can be used in (c) Closed loop system and (d) open loop systems. Adopted 
from (Fotaki, 2011). Copyright 2011, The United States Pharmacopoeia. The FTC can be used in (c) Closed loop system and (d) open 
loop systems. 
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In this research, the CE7 smart USP-4 system (SOTAX AG, Switzerland) was used to create an 
incubating environment for the release of drug encapsulated within liposomes. The method is 
widely used for drug release studies from novel drug delivery systems (Burgess et al., 2004; 
Siewert et al., 2003). To measure drug release, samples were subjected to dialysis; briefly, the 
method is based on a dialysis adaptor placed in a flow-cell. Through this flow-cell, PBS (pH 7.4) 
was used in a closed loop system and was circulated at constant temperature (37 ± 1°C) at a 
constant flow of 8.0 mL/minute (Figure 3.9).  
 
Figure 3.9 Schematic representation of USP-4 closed loop system. Adapter, flow-cell and 
reservoir are the 3 main components of the closed loop system used for studying in-vitro drug 
release. 
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3.4.2 Efficacy of the dialysis membrane for the passage of drug 
As seen in the previous section, the assembly for in-vitro release drug study of liposomes has an 
adapter inside the FTC. To hold the liposomal suspension into this adapter, this advanced 
setting was wrapped by a dialysis membrane. To determine the efficacy of this system with the 
liposomes being developed, a predetermined concentration of both drugs was initially 
investigated to ensure effective ‘free’ drug removal. It was observed for both the drugs that 
>90% of the drug was diffused through the membrane in the initial 10 minute interval and 
complete removal was achieved within 20 minutes (Table 3.5). 
Table 3.5 Testing efficacy of the dialysis tubing for the drug passage (n=1). 
Time interval % Metformin released % Glipizide released 
10 Minute 96.6  93.4  
20 Minute 101.2 102.4  
30 Minute 102.1 102.6 
 
 
3.4.3 Selection of release medium for the in-vitro release of liposomal drugs 
In the GI tract, the duodenum and jejunum are ideal for the absorption of fats, whereas the 
colon is ideal for water, electrolytes as well as short-chain fatty acids. Therefore, it is expected 
that liposomal absorption can be achieved in the small and large intestine, especially in the 
duodenum, jejunum and colon. The pH of the duodenum and jejunum is neutral to slightly 
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basic. Therefore, preliminary studies were conducted using neutral to slightly basic release 
media.  
 
To study the effect of salts and pH, the release of drug was studied initially in two different 
mediums: simulated media (Table 3.6) and PBS (composition: phosphate buffer 0.01 M, 0.0027 
M potassium chloride and 0.137 M sodium chloride, pH 7.4).  
 
3.4.4 In-vitro release of liposome encapsulated drugs 
Liposomal drug release studies have often been performed using a large amount of buffers and 
it was also observed that excess buffer often results in inaccurate analysis due to leakage of 
drug(s) (Shabbits et al., 2002). Therefore, the in-vitro drug release was studied using USP-4, FTC 
based closed loop system (SOTAX, SOTAX Ltd., London, UK).  The USP-4 is well known for 
versatility, and has distinct advantages such as requiring low volume of media, precise as well 
as auto-temperature control and most important is the adaptor, which is especially designed 
for the submicron sized delivery systems.   
 
To develop a protocol for analysis of drug released from liposome in release media, initial trials 
were undertaken using individual drugs. The initial observations were aimed to spot peaks of 
active analyte; this was done to study the interference of the media or method. Release of drug 
is not only triggered by the pH of the environment but also by the presence of salts in the fed 
and fasted state. Recently Marques. et. al. (Marques et al., 2011) have described the simulated 
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biological fluids that may be used as dissolution media. Therefore, initial trails of liposomal drug 
were decided to be taken into simulated medium resembling colonic as well as duodenum and 
jejunum environment (Table 3.6). 
Table 3.6 Simulated biological fluid to use as dissolution media to study the release of liposome 
encapsulated drugs. (Adopted from (Marques et al., 2011)). 
Simulated colonic fluid 
Composition Amount (g/L) 
Potassium chloride 0.2 
Sodium chloride 8 
Potassium phosphate monobasic 0.24 
Sodium phosphate dibasic 1.44 
pH 7 
 
Although peaks of metformin and glipizide were spotted with good resolution, there was 
interference of the dissolution media observed during the chromatographic analysis (Figure 
3.10). An alternative approach to the simulated fluid was use of buffer solution at the required 
pH. Therefore, PBS solution of pH 7.4 was used for further trials, since there was no 
interference caused by the dissolution medium. Both metformin and glipizide peaks were 
detected on the same retention time as observed during drug loading quantification (Figure 
3.11). Further, the drug release was quantified using RP-HPLC (section 2.6.) and reported as % 
release relative to amount of drug entrapped within liposomes. 
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Figure 3.10 Chromatogram representing the analysis of released drug from liposomes into simulated biological dissolution media. 
The HPLC-UV method developed (section 3.3) for the quantification of drug encapsulation was applied for this analysis.Y-axis = Area 
Under Curve (AUC) (Dependent of concentration of analyte) and X-Axis = Minutes (Retention time representing interaction of 
analyte with the stationary phase when dissolved in given mobile phase and flow rate). 
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Figure 3.11 Chromatogram representing the analysis of released drug from liposomes into PBS (pH 7.4). The HPLC-UV method 
developed (section 3.3) for the quantification of drug encapsulation was applied for this analysis. Y-axis = Area Under Curve (AUC) 
(Dependent of concentration of analyte) and X-Axis = Minutes (Retention time representing interaction of analyte with the 
stationary phase when dissolved in given mobile phase and flow rate). 
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3.5 Conclusion 
Due to the divergent nature of both molecules, to develop a method for simultaneous 
determination was a challenging task. The developed RP-HPLC method is based on isocratic 
elution, which makes the method simple and retention time observed for both drugs is less 
than 3 minutes. The validation was carried out using ICH guidelines and this method has 
fulfilled all the validation requirements recommended by ICH. In short, the method is easy, 
precise, accurate, selective as well as sensitive. Also, this method of simultaneous 
determination of glipizide and metformin has been found to be effectively rugged and robust 
for both the drug determination.  
 
The simulated biological dissolution medium failed to meet the qualitative criterions for the 
chromatographic analysis of released drug. However, with PBS (pH 7.4) it was possible to 
maintain the intrinsic environment. 
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Chapter 4: Formulation of liposomes co-encapsulating 
hydrophilic and lipophilic drugs 
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4.1 Introduction 
Administration of multiple drugs simultaneously is usually possible with conventional dosage 
forms (e.g. tablets, capsules and liquids). However, their controlled delivery using novel drug 
delivery systems (e.g. liposomes, niosomes, polymer nanoparticles,etc.) has received limited 
attention. Therefore, the research reported within this chapter focused on co-encapsulation of 
drugs with divergent solubilities within liposomes. At present, although marketed liposome 
products have been prepared with either hydrophilic or lipophilic active ingredients 
encapsulated, currently there are no products on the market taking advantage of the potential 
to encapsulate both hydrophilic and lipophilic active ingredients in the same vesicles. Indeed, 
there is very limited research present about this concept of co-encapsulation.  
 
Co-encapsulation is an innovative approach, making liposomes a multi-drug carrier. In recent 
years, co-encapsulation has been reported for two drugs of divergent solubility inside 
liposomes (Cosco et al., 2012; Liu et al., 2014; Tardi et al., 2007). For example, Cosco et al. 
(2012) demonstrated liposomal co-encapsulation of gemcitabine (a water soluble drug) and 
tamoxifen (a lipid soluble drug), whereas, Tardi et al. (2007) and Liu et al. (2014) have shown 
co-encapsulation of irinotecan-floxuridine and doxorubicin-paclitaxel, respectively. In each of 
these studies, the method used was the thin film hydration method. However, to enhance the 
loading of the hydrophilic drug, a pH gradient was created. It can be seen from the drugs 
selected, these studies were mainly done with oncological agents and supplements the 
potential of this co-encapsulation in cancer research. However, the potential of liposomes to 
co-encapsulate drugs could also create a novel way of delivering drugs of divergent solubility 
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which are prescribed in combinational therapy, such as the above mentioned gemcitabine and 
tamoxifen, or metformin and glipizide, which can be prepared in a single dosage form and could 
improve patent concordance (Collier, 2012). 
 
4.2 Aim and objectives 
The aim of this work was to develop a formulation co-encapsulating divergent solubility drugs 
in liposomes manufactured by the conventional thin film hydration method. To achieve this, the 
objectives were to: 
1. Optimise the lipid concentration to be used for co-encapsulation; 
2. Study the impact of single and co-drug encapsulation on drug encapsulation efficiency; 
3. Study the drug retention capacity of liposomes encapsulating one or two drugs 
together; 
4. Study the in-vitro drug release behaviour of drugs individually and simultaneously 
encapsulated.  
4.3 Results and discussion 
4.3.1 Selection of drugs for co-encapsulation 
As mentioned above, drugs prescribed in combinational therapy and with contrasting solubility 
are ideal for this concept of co-encapsulation. Diabetes is a principal risk factor for those 
patients with cardiovascular (CVS) disease(Dokken, 2008) and the ‘statins’ are given as a 
preventive intervention (Ebrahim et al., 2014; Taylor et al., 2013). Statins such as simvastatin, 
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atorvastatin, etc., are prescribed in combination with metformin for the diabetic patients 
suffering from cardiovascular disorders. Therefore drugs considered for co-loading within 
liposomes were: 
• Metformin hydrochloride (Figure 4.1A) is water soluble and highly prescribed drug for 
treating type-2 diabetes (Setter et al., 2003). It is a water soluble compound and will be 
entrapped in the hydrophilic core of liposomes or niosomes. Metformin belongs to the 
biguanide anti-diabetic agents (Vigneri and Goldfine, 1987). Metformin is used in 
combination therapy glipizide and marketed products are available e.g. the tablet 
formulation ‘Metaglip’.  
• Glipizide (Figure 4.1B) is a poorly water soluble drug and a potent hyperglycemic drug 
from the family of sulfonylureas (Prendergast, 1983). Glipizide and metformin have 
contrast solubility and are used in combinational therapy.  
• Simvastatin (Figure 1C) is a poorly soluble drug and has no drug-drug interactions with 
the metformin. Therefore, two combinations metformin-glipizide and metformin-
simvastatin were selected for preliminary investigations.  
4.3.2 Selection of lipids 
Lipids are molecules made up of prominently hydrocarbon moieties and having molecular 
weights ranging from 150 to 3000 (Small, 1981).The hydrocarbon portion of the lipid molecule 
can be aliphatic or aromatic (cyclic) and can be of single chain or have multiple chains, with 
phospholipids and spingolipids having two hydrocarbon chains and triaclglycerols having three 
chains (Perrie and Rades, 2012b; Small, 1981). 
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Figure 4.1 Chemical structures of selected drug for co-encapsulation. A) Metformin hydrochloride (Water Soluble), B) Glipizide 
(Poorly water soluble), C) Simvastatin (Poorly water soluble). Sketches drawn and transferred from web.chemdoodle.com 
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Phospholipids are amphiphilic in nature and have both hydrophobic and hydrophilic parts 
within their structure, thus supporting the formation of lipid bilayers. Due to variability in their 
head group, degree of saturation of fatty esters and variability in chain length, phospholipids 
can be used to formulate a range of liposome systems. Phospholipids as a group are lipids with 
one or more phosphate groups. In the field of liposomes, both PC and DSPC are being used 
widely, since they form a predominant component of human cell membranes and because they 
are less prone to oxidation upon storage (Lasic, 1993). The polar head-group and non-polar tail 
of these lipids form structures resembling human cell membranes. Especially, due to the high 
transition temperature and longer chain length, 40 % of the marketed liposomal formulations 
have DSPC in the formulation (De Villiers et al., 2008). DSPC is a synthetic lipid having only 
saturated chains, whereas the Egg-yolk PC (EPC) is a natural PC-lipid with both saturated as well 
as unsaturated fatty acids in its structure.Therefore, during initial studies, liposomes were 
produced using the PC (Figure 4.2A) or DSPC (Figure 4.2B) and their particle characteristics 
compared (Table 4.1). Cholesterol (Figure 4.2C) is a major component of eukaryotic cell 
membrane. Cholesterol brings profound changes to physical properties of membranes (Wang 
and Quinn, 2002), e.g. as discussed in chapter 1 (Section 1.1.1.2). 
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A) PC      B) DSPC      C) Cholesterol  
Figure 4.2 Chemical structures of selected drug for co-encapsulation. A) PC (L-α-lysophosphatidylcholine), B) DSPC (1,2-distearoyl-sn-
glycero-3-phosphocholine), C) Cholesterol. Sketches adopted from the website of Avanti polar lipids Inc.
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To consider the effect of lipid chain length, MLVs were prepared using the thin film hydration 
method (Bangham et al., 1965). Two different formulations were prepared in PBS (pH 7.4) with 
either PC or DSPC and cholesterol (Table4.1).  The increase in alkyl chain length could result in 
an increase in CPP and, hence, impact on the liposome characteristics, including vesicle size 
(Uchegbu and Florence, 1995; Uchegbu and Vyas, 1998a). Indeed, the formation of bigger 
vesicles has been shown to be directly proportional to the lipid chain length (Bayindir and 
Yuksel, 2010).  
Table 4.1 Composition of formulations prepared for the preliminary study of effect of 
cholesterol concentration, type of lipid and hydration media. 
Formulation Concentration (w/w) 
 PC/DSPC CHOL 
PC:CHOL ( PBS, pH 7.4) 5 2 
DSPC:CHOL (PBS, pH 7.4) 5 2 
 
Figure 4.3 shows the sizes of MLV liposomes prepared using PC:Chol (7.5 ± 1.2 µm)are 
significantly (p < 0.05, t-test) smaller than their DSPC:Chol liposome counterparts (11.5 ± 2.2 
µm). This difference in size could be due to difference in their alkyl chain lengths (Figure 4.2). 
Furthermore, when taking into account the span value– which is measure of particle size 
distribution, where a span value >1.0 is considered as broader size distribution – here, both 
liposome formulations have a broad size distribution as the span value for PC:Chol liposomes is 
(Span: 1.6 ± 0.08 ) and DSPC:chol (Span: 2.0 ± 0.11) (results not shown). This heterogeneous 
size distribution is a common issue with liposomes formed by the lipid film hydration. 
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Figure 4.3 Comparison of size results obtained from analysis of PC:Chol and DSPC:Chol 
formulations prepared by thin film hydration method. PBS (pH 7.4) was used as hydration 
medium for these formulations (N=3± SD). 
 
Transition temperature (Tc) plays a crucial role in the formation of liposomes, as well as their 
membrane fluidity (Mabrey and Sturtevant, 1976) and this is usually determined by differential 
scanning colorimetry (DSC). In the production of liposomes, liposome formation can only 
happen above the transition temperature of the lipid mixture. Lipids with Tc >37⁰C make lipid 
bilayers less prone to leakage and uptake by mononuclear phagocyte system (MPS) at 
physiological temperature. On the other hand, liposomes produced with lipids having a Tc 
below physiological temperatures are more susceptible to leakage and clearance within the 
body, as they are more rapidly opsonised and taken up by MPS (Bhandary et al., 2010; Kirby et 
al., 1980; Sharma and Sharma, 1997). In addition to higher Tc lipids, the presence of cholesterol 
in the system can also improve membrane fluidity. Cholesterol concentrations of more than 30 
molar % have been shown to eliminate the phase transition of lipid membranes, making them 
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less leaky on systemic administration (Mohammed et al., 2004; Sharma and Sharma, 1997; 
Wang and Quinn, 2002). Given this information, using DSPC will give more robust liposomes 
(due to its transition temperature (Tc) and saturated long chains) and the use of higher 
transition temperature lipid could be beneficial in terms of storage of formulations; therefore, 
DSPC was selected for continued studies.  
 
4.3.3 Influence of cholesterol concentration on MLV particle characteristics 
Cholesterol is a common component of liposome formulations, because cholesterol brings 
profound changes to physical properties of membranes (Wang and Quinn, 2002). In particular, 
inclusion of cholesterol improves bilayer stability. The key factor making cholesterol more 
promising is its planar steroid ring imparting a rigid structure to the molecule, which makes 
lipid-cholesterol interaction more prominent (Mohammed et al., 2004; Nomura et al., 2005). 
However, the impact of cholesterol content on MLV formulations has been controversial; it has 
been reported that the cholesterol content in the MLV formulations does not make any 
significant changes in the size and surface charge (Ali et al., 2010), whilst contrasting reports 
state that the addition of cholesterol to the lipid membrane reduces the Na+ binding to the lipid 
head group, releasing the ions from the membrane interface to the water phase, resulting in 
significant reduction in surface charge (Magarkar et al., 2014), whereas it has also been 
suggested that high concentrations of cholesterol may impact on the size of the vesicles and 
possibly decrease the size by making the structure more rigid (Nomura et al., 2005). Therefore, 
to consider the impact of cholesterol concentration on liposome formulations, two ratios of 
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phospholipid:cholesterol were considered. Knowing that the absence of cholesterol makes the 
bilayer porous (Ali et al., 2010), presence of cholesterol condenses the bilayer by reducing 
permeability, and an excess of cholesterol can significantly influence bilayer loading (Bernsdorff 
et al., 1997); the cholesterol concentrations of 17 and 30 mol % were chosen for the 
formulation (based on previous studies, Ali et al. 2010) 
 
 
Figure 4.4 Comparison of the vesicle size from liposomes containing increased cholesterol 
concentration. DSPC:Cholesterol 5:1 and 5:2 w/w formulations. Results are expressed as the 
means of four experiments (N=3± SD). 
 
Confirming the findings of Ali et al. (2010), the results in Figure 4.4 show that there was no 
significant difference (p>0.05, t-test) in the size of liposomes prepared at different ratios of 
cholesterol (5:1 and 5:2). This is in contrast to the results reported by Magarkar et al. (2014) 
and Nomura et al. (2005). Within their study, they attribute the reduction in size of liposomes 
prepared from Di-oleoyl-phosphatidylcholine (DOPC) and varying cholesterol concentration up 
to 40 mol % on increasing concentration of cholesterol. Magarkar et al.(2014) have also 
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proposed that the elevated concentration of cholesterol reduces the zeta potential of DSPC and 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) membranes (Magarkar et al., 2014). 
PC and DSPC are zwitterionic lipids with net neutral surface charge. Zeta potential measures the 
potential difference between the dispersion medium (in this case PBS) and stationary layer of 
fluid attached to the liposomes; thus, resulting in a small negative charge on the vesicles. The 
charge on the liposomes of all formulations of both the lipids was neutral to very slightly 
negative (PC= -6.7 ± 1.2 mV (n=3), DSPC= -8.7 ± 2mV (n=3)) with cholesterol having no notable 
impact. 
 
4.3.4 Stability testing of DSPC liposomes 
To investigate the stability of liposomes and to inform how these systems can be stored during 
forthcoming studies, the stability (in terms of liposome size and zeta potential) of DSPC 
liposomes was considered, as well as the effect of cholesterol concentration. Formulations 
were stored in three different stability chambers: 1) 4⁰C; 2) 25⁰C/60 % RH; and 3) 40⁰C/75% RH. 
The purpose of stability testing under different environmental conditions was to provide 
substantiation of how the quality of the formulation varies with time under the influence of 
different environmental factors, such as temperature and humidity. The samples were tested 
for size and zeta potential at intervals over 21 days. 
It was observed for all the suspensions that for 21 days, the storage conditions have negligible 
effect on the liposome size or zeta potential (Figure 4.5 a, b, c &d). During the span of 28 days, 
there was no notable change in size or zeta potential observed for the suspensions stored at 
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4⁰C and 25⁰C/60% RH (Figure 4.5 a&c). However, significant increases (p<0.05, ANOVA post hoc 
Dunnett’s test) in size were observed after 21 days for the suspensions stored at 40⁰C/75% RH, 
with no change in the surface charge (Figure 4.5 a,b,c & d). These finding were the same, 
irrespective of the cholesterol concentration. Previous research has described that increasing 
the cholesterol concentration brings stability to the formulation, as instability was observed in 
the liposomal size for lower (<20 mol %) cholesterol concentrations (Briuglia et al., 2015).  
However, in this research no size change has been observed for two different formulations with 
varying cholesterol concentration. 
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a)               b) 
 
c)                        d) 
 
Figure 4.5 Comparison of particle characteristics obtained from analysis of formulation prepared with drug and with two cholesterol 
concentrations. Samples were stored at three different stability conditions. a & b)Size and zeta potential  analysis respectively, 
representing the formulation with ratio of DSPC:Cholesterol, 5:1 w/w (N= 3 ± SD). c&d) Size and zeta potential  analysis respectively, 
representing the formulation with ratio of DSPC:Cholesterol, 5:2 w/w (N= 3 ± SD). 
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4.3.5 Liposome encapsulation of drugs and short-term drug retention study 
Liposomes at this stage of the research were loaded with metformin, glipizide and simvastatin 
individually. Determination of drug loading, and effect of the drug loading on particle 
characteristics, determines the development of the formulation (Essa, 2010b).  
 
Lipid soluble drugs are expected to give high drug loading; however, it is dependent upon the 
nature of the drug and storage condition. The separation of encapsulated and non-
encapsulated drug was achieved by centrifugation, based on a previously validated indirect 
approach to determine the entrapment efficiency of ibuprofen in MLV by measuring non-
incorporated drug present in the hydration medium after separation by centrifugation 
(Mohammed et al., 2004). However, to study loss of drug and actual encapsulation, it is 
necessary to determine the drug recovery. This was achieved by determining the non-
encapsulated drug (in the supernatant) as well as the encapsulated drug (in the liposomes). This 
quantification was done by using a validated HPLC method (Chapter3). One of the key elements 
of liposomal encapsulation of API is the determination of non-encapsulated and encapsulated 
drug as to determine the total drug recovery. In other words, it is the evaluation of drug 
encapsulation and drug loss. All three drugs were subjected to this evaluation process, where 
the encapsulation, non-encapsulation and drug loss was determined. 
 
The passive encapsulation of drugs into liposomes is dependent of the properties of the drug to 
be encapsulated (Cullis et al., 1989). The hydrophilic drug, metformin, and the lipophilic drugs, 
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glipizide and simvastatin, were predicted for their percent encapsulation into the liposomes. 
The encapsulation is predicted here as a function of solubility, pH of buffer used, pKa and LogP 
values (Table 4.2). If the pKa of the drug is higher than the pH of the buffer used or <3, then it 
possibly results in higher exaggerated drug loading (Lasic, 1993; Lasic and Barenholz, 1996). On 
the other hand, sensitivity in drug loading can be expected if the pKa ranges between 3 and 7 
(Lasic and Barenholz, 1996). Drugs with log P value <1.7 are retained well in the hydrophilic 
core, whereas, the drugs with log P value >5 are retained well in the lipophilic bilayer. However, 
the drugs with LogP value between 1.7 and 5 can experience rapid loss from the lipid bilayer 
(Perrie and Rades, 2012a).   
Table 4.2 Properties of hydrophilic and lipophilic drugs used in the liposomal formulations. 
Parameter Glipizide Simvastatin Metformin 
Water Solubility (mg/mL) 0.03 0.01 Freely soluble as HCl 
salt soluble pH of buffer used 7.4 7.4 7.4 
pKa 5.6 4.5 12.4 
LogP 1.9 14.7 -1.8 
Predicted % drug loading 
encapsulation 
5 to 50  5 to 50  1 to 15 
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a)        b) 
   
c)        d) 
 
Figure 4.6 Comparison of data obtained from HPLC analysis of formulations prepared with the metformin, glipizide and simvastatin. 
a & b) percent drug entrapped and percent recovery, respectively, representing the formulation with ratio of DSPC:Cholesterol, 5:1 
w/w (N= 3 ± SD).  c & d) percent drug entrapped and percent recovery, respectively, representing the formulation with ratio of 
DSPC:Cholesterol, 5:2 w/w (N= 3 ± SD). 
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Table 4.3 Particle characteristics of drug loaded liposomes (N=3, ±SD).  
Lipids Drug Size, μm Span Zeta potential, mV 
DSPC:Cholesterol  
(5:1 w/w) 
Metformin 11.1 ± 0.9  2.1 ± 0.3 -5.6 ± 2.1 
Glipizide 7.7± 1.5  1.6 ± 0.5 -6.8 ± 0.9 
Simvastatin 15.3± 4.4  2.7 ± 0.9 -5.6 ± 1.3 
 
DSPC:Cholesterol  
(5:2 w/w) 
Metformin 12.1± 1.5  2.1 ± 0.6 -5.9 ± 1.5  
Glipizide 8.1± 1.8  1.6 ± 0.4 -5.9 ± 0.8 
Simvastatin 9.3± 4.4  2.1 ± 0.5 -9.6± 1.9  
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Metformin is a hydrophilic drug and passive encapsulation of hydrophilic drugs within 
liposomes is generally poor. It was reported that the percent encapsulation of most hydrophilic 
drugs subjected to passive encapsulation ranges between 1 to 15 % of the total weight of drug 
added (Cullis et al., 1989; Sharma and Sharma, 1997).  In contrast, loading of poorly soluble 
drugs into the bilayer tends to be higher and reported in the range of 5 to 50 % (Cullis et al., 
1989). The results in Figure 4.6 demonstrate that within the DSPC:Chol liposomes, metformin 
entrapment was approximately 20 % of the initial amount used (20 mg) irrespective to the 
cholesterol concentration used (Figure 4.6 a and c), with good total drug recovery noted (>95%; 
Figure 4.6 b and d). This is slightly higher than normally reported for hydrophilic drug loading 
within multilamellar vesicles and may result from bilayer interactions within the system. When 
considering loading within the bilayer, again there was no impact in terms of cholesterol 
content on drug loading with approximately 40 to 45 % for glipizide and simvastatin (Figure 4.6 
a and c). However, whilst drug recovery for glipizide was again >95%, total drug recovery for 
simvastatin fell below normal acceptable ranges (Figure 4.6 b and d).  
 
In terms of vesicle size, the results in Table 4.3 show that the lipophilic drug encapsulated 
liposomes are comparatively smaller at higher cholesterol concentration. In Figure 4.3 (section 
4.3.3), although the effect of cholesterol was not significant on size of liposomes but at higher 
concentration of cholesterol the size of liposomes was found slightly reduced. Similarly, after 
encapsulation of drug the size of liposomes was not affected significantly by concentration of 
cholesterol but there was slight reduction in size at higher cholesterol concentration, this is 
possibly due to the nature of cholesterol which provides rigidity to the bilayer.  
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Also, it has previously been reported that the increase or decrease in cholesterol concentration 
along with lipophilic drug had no significant on size of vesicles (Atyabi et al., 2009). This is true 
in the case of the lipophilic drug glipizide, but in the case of simvastatin, the size of liposomes 
was not only significantly increased upon encapsulation of drug at 5:1 DSPC:Cholesterol 
concentration, but also significantly decreased upon increasing the cholesterol concentration. 
This is possibly due to the lipid lowering nature of the simvastatin and represents a highly 
unstable formulation. On the other hand, the size of liposomes encapsulated with hydrophilic 
drug metformin had no significant impact on size compared to empty liposome (Figure 4.3, 
section 4.3.3). Overall, there was no significant impact on size or surface charge of liposomes 
due to the encapsulation of metformin or glipizide. 
 
Encapsulation of a lipophilic drugs within liposomes has been reported to be dependent on 
factors such as drug-lipid interaction, cholesterol content, size of the drug molecule and drug-
to-lipid ratio (Ali et al., 2013). It was reported that the inclusion of 30 to 50 mol % cholesterol in 
phosphatidylcholine liposomes could potentially influence the drug loading in the bilayer by 
increasing the hydrophobicity of the bilayer interface (Bernsdorff et al., 1997). For example, 
DSPC has previously been shown to promote high drug loading due to its long chain structure, 
which may allow for enhanced hydrophobic interactions within the bilayer. This was 
demonstrated with the encapsulation of ibuprofen in the liposomes, which increased with 
increasing lipid chain length of the order dilignoceroyl phosphatidylcholine (D24PC)> DSPC > 
DMPC > PC (Mohammed et al., 2004). 
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From Figure 4.7, it can be seen that the percent loading of metformin was observed to be 
approximately 5 % higher than that of reported loading for hydrophilic drugs (Sharma and 
Sharma, 1997). It was reported that cholesterol reduces the moving of the phospholipid 
hydrocarbon chains, which helps to decrease the leakage of the encapsulated hydrophilic drugs  
and  stabilises the lipid bilayer (Eloy et al., 2014; Manojlovic et al., 2008). Apart from this, it is 
also believed that the cholesterol suppresses the passage of water through the polar heads of 
the lipids, increasing lipid hydrophobicity; this could further result in the accumulation of the 
hydrophilic drug in this part of the liposomal structure (Eloy et al., 2014; Kępczyński et al., 
2008). This phenomenon was first reported by Subczynski et al (1994), where it was reported 
that the inclusion of cholesterol not only influences polarity of the head groups, but also 
increased the hydrophobicity of the central region of the bilayer (Subczynski et al., 1994); this 
potentially results in stopping the leakage of entrapped water. The size of the sterol molecules 
measures half of the lipid molecule and, in the bilayer, the position of sterol molecules is 
towards the head groups (Richter et al., 1999); it was reported that for DSPC:Choleterol the 
hydration effect starts at 5:1 (molar ratio) and reaches a crest at 2:1 (molar ratio), where the 
polar heads could form hydrogen bonds with the water or cholesterol (Deniz et al., 2010). 
Therefore, the drug loading of metformin via the passive entrapment method reported in 
Figure 4.6 may be a result of either some bilayer interaction of the metformin with the vesicles 
and/or the reduced loss of the drug from the MLV systems.  
 
It was also reported that at low fractions of cholesterol in the formulations (below 33 mole %), 
the cholesterol molecules engage the half the area of the phosphocholine (PC) molecule and 
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considering this fact, no change in the size of the liposomes can be expected until a relatively 
high amount of cholesterol incorporation has happened (Melzak et al., 2012). Therefore, the 
amount of cholesterol used to produce empty or metformin or glipizide loaded liposomes was 
not sufficient enough to cause changes in the liposomal size.  
 
The bulky appearance of cholesterol is the main reason of immobility of hydrophobic tails (Deol 
and Khuller, 1997) and this is the reason of high drug entrapment in the lipid bilayer. However, 
it was observed that a change in cholesterol concentration has not made any significant 
difference on drug loading. This may be because the formulation used, DSPC:Chol, 5:1 w/w, is 
minimum required concentration to achieve high drug loading.  Formulations of both drugs 
were shown to have similar stability, with higher levels of cholesterol in the liposome 
formulation adding no advantage. 
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a)        b) 
 
c)        d) 
 
Figure 4.7 Drug retention study performed with the metformin and glipizide samples. Samples were stored at three different 
environmental conditions to investigate the leakage of the drug due to environmental factors. a & b) Metformin loading 
representing two different formulations with ratio of DSPC:Cholesterol, 5:1 w/w (N= 3 ± SD) and DSPC:Cholesterol, 5:2 w/w (N= 3 ± 
SD). c & d) Glipizide  loading representing two different formulations with ratio of DSPC:Cholesterol, 5:1 w/w (N= 3 ± SD) and 
DSPC:Cholesterol, 5:2 w/w (N= 3 ± SD) respectively. 
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Figure 4.7 a & b considers the stability in terms of drug retention of the two different 
formulations (DSPC:Chol, 5:1 w/w and 5:2 w/w) incorporating metformin. Both the 
formulations show good drug retention over time. Over 28 days, the drug loss was found to be 
less than 7 %, which demonstrates their capability to withstand various temperature and 
humidity conditions (Figure 4.7).From a starting loading of 19.9 ± 0.6 % metformin for 
DSPC:Chol, 5:1 w/w, there was very little drug loss after 28 days when stored at 4⁰C (15.9 ± 1.2 
%), 25⁰C (16.6 ± 2.4 %) and 40⁰C (16.1 ± 1.5 %) (Figure 4.7a), whereas for DSPC:Chol, 5:2, w/w, 
from a starting loading of 20.0± 1.1% metformin, again there is very little drop in drug 
entrapment when stored at 4⁰C (15.6 ± 1.4 %), 25⁰C (14.4 ± 0.2 %) and 40⁰C (15.9 ± 2.8 %) 
(Figure 4.7b). 
 
Similarly, the glipizide loaded liposomes prepared with different cholesterol content, exhibited 
very good encapsulation and, for DSPC:Chol, 5:1 w/w, from a starting loading of 36.8 ± 0.4 % 
glipizide, there was very little drug loss after 28 days when stored at 4⁰C (33.8 ± 3.5 %), 25⁰C 
(34.7 ± 4.2 %) and 40⁰C (37.0 ± 3.6 %) (Figure 4.7c). Similarly for DSPC:Chol, 5:2 w/wfrom a 
starting loading of 36.1 ± 0.4 % glipizide, very little drop in drug entrapment (4⁰C (30.4 ± 2.3 %), 
25⁰C (27.2 ± 2.2 %) and 40⁰C (29.3 ± 1.6 %) (Figure 4.7d)) was noted. 
In recent research performed on conventional liposomes versus PEGylated DSPC liposomes, 
Muppidi et al. (2012) have demonstrated that for an initial 28 days at lower temperature, the 
conventional liposomes were equally stable to the PEGylated liposomes and the instability of 
the higher temperature could be due to the swelling or aggregation of the liposomes (Muppidi 
et al., 2012). Therefore, from the above Figure 4.7, it can be concluded that the loss of drug at 
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higher temperature could be due increased fluidity within the bilayers and/or liposome fusion, 
resulting in drug permeation out of the liposomes.  
 
4.3.6 Effect of drug encapsulation on particle characteristics 
The size of the liposomes can also be an important indicator for the stability of liposomes, as 
whilst retention of drug is important, aggregation and precipitation of liposomes can also 
present issues in the use of the product. Similarly, zeta potential is sensitive to changes in pH; 
therefore, any significant change could cause a change in the cholesterol conformation 
(Sulkowskiet al., 2005), due to protonation potentially affecting stability, ultimately leading to 
flocculation and coagulation. Therefore, to study this, the size and zeta potential of liposomes 
loaded with either metformin or glipizide were also tracked over time when stored at: 4⁰C, 
25⁰C/60 % RH and 40⁰C/75% RH (Figure 4.8 & 4.9).  
 
Metformin containing liposomes prepared with DSPC:CHOL 5:1 w/w showed no significant 
change in size or zeta potential over the 28 days stability testing period (p>0.05, ANOVA post 
hoc Dunnett’s test)(Figure 4.8).From a starting size of 11.07± 0.99μm, there was no significant 
change in size after 28 days when stored at 4⁰C (10.01 ± 1.8 μm), 25⁰C (11.6 ± 1.6 μm) and 40⁰C 
(10.25 ± 1.9 μm) (Figure 4.8a). Similarly, the zeta potential remained around -2 to -6 mV 
irrespective of the temperature the vesicles were stored at (Figure 4.8b). With increasing 
concentration of cholesterol (DSPC:Chol 5:2w/w), the formulations were again stable with 
nosignificant change in size (Figure 4.8c) or zeta potential (Figure 4.8d) over the 28 days 
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stability testing period, with vesicles remaining around 10 microns in size and approximately -6 
mV. 
 
Similarly, glipizide containing liposomes showed no significant change in size or zeta potential 
over the 28 days stability testing period (Figure 4.9); with liposomes containing low levels of 
cholesterol (DSPC:Chol 5:1w/w) having a starting size of 7.7± 1.5 μm on day zero to 10.01 ± 1.8 
μm (4⁰C), 7.6 ± 0.7μm(25⁰C) and 9.2 ± 1.7μm (40⁰C) (Figure 4.9a). The zeta potential again was 
around -6 mV, with no significant difference (Figure 4.9b). With increased cholesterol 
(DSPC:Chol 5:2w/w), again there was no significant change in size (Figure 4.9c) or zeta potential 
(Figure 4.9d) over the 28 days stability testing period.  
 
One of the main reasons to induce charge on liposomal samples is to avoid aggregation. In this 
project, liposomes were not induced with charge and were prepared with neutral lipids. 
However, it was important to analyse the effect of formulation process or drug incorporation 
on liposomes, as incorporation of drug inside liposomes could produce charge on liposomes. As 
negatively charged liposomes have been reported to have a shorter half-life in blood 
(Immordino et al., 2006), such liposomes are not ideal for sustained release. From the results in 
figure 4.7, 4.8 and 4.9, it can be seen that the MLV systems loaded with either metformin or 
glipizide showed similar stability under the test conditions as liposomes without drug.  
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a)        b) 
 
c)        d) 
 
Figure 4.8 Comparison of particle characteristics obtained from analysis of formulation prepared with the drug metformin and with 
two cholesterol concentrations. Samples were stored at three different stability conditions. a & b) Size and zeta potential analysis 
representing formulations with ratio of DSPC:Cholesterol, 5:1 w/w (N= 3 ± SD). c & d) Size and zeta potential analysis representing 
formulations with ratio of DSPC:Cholesterol, 5:2 w/w (N= 3 ± SD). 
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a)        b) 
 
c)        d) 
s  
 
Figure 4.9 Comparison of particle characteristics obtained from analysis of formulation prepared with the drug glipizide and with 
two cholesterol concentrations. Samples were stored at three different stability conditions. a & b) Size and zeta potential analysis 
representing formulations with ratio of DSPC:Cholesterol, 5:1 w/w (N= 3 ± SD). c & d) Size and zeta potential analysis representing 
formulations with ratio of DSPC:Cholesterol, 5:2 w/w (N= 3 ± SD). 
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4.3.7 Co-encapsulation of metformin and glipizide in MLV 
After confirming the stability of the empty and single drug loaded liposomal formulations, 
further efforts were taken to co-encapsulate drugs of divergent solubility and study the 
maximum possible encapsulation for each drug. From the previous studies, it was also 
confirmed that different cholesterol concentrations did not notably change the size, zeta 
potential and drug loading. Therefore, from here on, all experiments were performed with 
using DSPC:Cholesterol 5:2 w/w.  
 
Formulations were prepared using the thin-film hydration method. All the samples were tested 
for size, zeta potential and drug encapsulation determination. Liposomes loaded with single 
drug were comparatively smaller than co-drug loaded liposomes; the average size for 
individually loaded glipizide and metformin liposomes was 9.6 ± 1.1 µm and 10.9 ± 2.2 µm, 
respectively (Figure 4.10). However, after co-encapsulation of both glipizide and metformin, 
liposomes with a significantly larger average particle size (13.6 ± 0.5 µm, p<0.05, t-test) were 
produced. In all cases, there was no surface charge development observed, with the zeta 
potential for all samples being around neutral. The drug loading for individually loaded glipizide 
and metformin was 40.5 ± 0.1% and 21.0 ± 0.1%, respectively. When co-encapsulated, the drug 
loading was calculated to be 41.5± 0.9 % and 22.0 ± 0.1 % for glipizide and metformin, 
respectively (Figure 4.10). It was observed that, when co-encapsulated, there was no significant 
difference in drug loading compared to liposomes where 1 drug alone was incorporated (Figure 
4.10).  
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Similar to above observations, recently Liu et al. (2014) have reported co-encapsulation of 
doxorubicin and paclitaxel. The percent encapsulation of doxorubicin or paclitaxel alone or the 
co-encapsulation does not differ significantly. It was also observed in their research that upon 
co-encapsulation, the in-vitro drug release of lipophilic drug is slightly faster than that of 
released alone.  
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Figure 4.10 Co-encapsulation of divergent solubility drugs into multi-lamellar liposomes. Comparison of effect of single and co-drug 
encapsulation on percent drug loading. a) % drug loading and b) size analysis representing the formulation with ratio of 
DSPC:cholesterol, 5:2 w/w (N=3, ± SD). 
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4.3.7.1 Drug escalation study 
In addition to the particle characteristics and stability studies, the liposomal system (DSPC:Chol, 
5:2 w/w) was evaluated for maximum drug encapsulation. Four different amounts of metformin 
(20, 40, 80 and 120 mg) and glipizide (10, 20, 30 and 50 mg) were chosen for this drug 
escalation study. Increases in the amount of metformin from 20 to 120 mg did not significantly 
influence the percent drug loading, with 20 to 29% loading and a maximum of 28 mg metformin 
loading achieved (Figure 4.11). Similarly, increasing the initial amount of glipizide from 10 to 50 
mg again made no significant difference on the percent drug loading (46 to 56 %) with a 
maximum of 28.1 mg being loaded (Figure 4.11). This demonstrates that a weight ratio of 
28:28:10:4 (DSPC:Chol:met:glip) can be achieved within appropriate lipid doses.  
It is described earlier (section 4.3.5) that addition of cholesterol reduces the movement of 
phospholipid hydrocarbon chains, giving stability to the bilayer as well as reducing the loss of 
hydrophilic drug. Eloy et al. (2014) have reported that the encapsulation of hydrophilic drug is 
dependent of aqueous volume of liposomes as well as cholesterol concentration (Eloy et al., 
2014). Similarly, it was discussed in this chapter that the lipid chain length can also favour the 
drug encapsulation of lipophilic drug (Mohammed et al., 2004), but it could also favour 
hydrophilic drug encapsulation, as longer lipid chains could generate greater van der Waal’s 
forces, resulting in stronger adhesion, thereby less drug loss (Hąc-Wydro et al., 2007; 
Moghaddam et al., 2011). Han et al. (2012), have also reported the effect of chain length on 
encapsulation of hydrophilic drug Alendronate (Han et al., 2012). Doxorubicin entrapment of 
approximately 14 %, with 1:1 (molar ratio) phosphocholine:Cholesterol MLV was also reported 
by Cullis et al. (Cullis et al., 1989).  
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a)            b) 
 
   c)          
 
Figure 4.11 Investigation of effect of drug amount escalation on a)%drug loading, b) % drug encapsulation and c) particle size, 
representing the formulation with ratio of DSPC:Cholesterol, 5 : 2 w/w (n=3, ±SD). 
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4.3.8 Co-encapsulation of metformin and glipizide in SUV 
Knowing that changes in size directly affect drug delivery (Kazi et al., 2010), and that smaller 
vesicles are less prone to clearance and reside longer in blood (Gregoriadis et al., 1996; 
Waterhouse et al., 2005), it was essential to reduce to the size of vesicles but co-encapsulate 
drugs at the same time. Therefore, MLV formulations were further subjected to probe 
sonication to reduce vesicle size and obtain SUV. Probe sonication is an easy and relatively 
quick method to produce SUV from MLV.  
 
Formulations were prepared using the thin-film hydration method followed by probe sonication 
to obtain SUV. All the samples were tested for size, zeta potential and drug encapsulation 
determination. SUV liposomes loaded with single drug were comparatively smaller than co-drug 
loaded liposomes (Figure 4.12; the average size for individually loaded glipizide and metformin 
SUVs was 143.9 ± 8.1 nm (PDI: 0.3 ± 0.06) and 137.6 ± 8.1 nm (PDI: 0.2 ± 0.05), respectively 
(Figure 4.12). Co-drug loading in these systems made no notable impact on vesicle size, with 
vesicles 147.6 ± 5.5 nm (PDI: 0.3 ± 0.03) in size (Figure 4.12).  
 
As discussed in chapter 1, liposomes are formed when the lipid layers are hydrated. The 
hydrated lipid sheets self assemble and form MLVs. Then, MLVs can be transformed to SUVs by 
sonication or extrusion. During the course of sonication, the field of sonic energy ruptures the 
bilayer and thereby forms SUVs. When the lipid bilayer is ruptured, the lipophilic drug 
entrapped into the bilayer becomes prone to leaving the bilayer and precipitates due to poor 
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water solubility. Similarly, this rupture of bilayer and removal of lipophilic drug creates the 
possibility for loss of co-entrapped hydrophilic drug. Therefore, size reduction using sonic 
energy can lead to reduction in drug entrapment. The sonication leads to formation of single 
compartment vesicles and, thereby, low internal volume, which directly affects the drug loading 
(Szoka and Papahadjopoulos, 1978).  
 
Similarly, this may have affected the co-encapsulation of glipizide and metformin, as the drug 
loading for individually loaded glipizide and metformin was 32.6 ± 0.4 % and 15.1 ± 0.1 % 
respectively; however, when co-encapsulated, the drug loading was calculated to be 29.7 ± 2.3 
% and 11.5 ± 0.3 %, respectively (Figure 4.12). It was observed that, when co-encapsulated, 
there is a significant (p<0.05, t-test) decrease in percent drug loading for both of the drugs 
(Figure 4.12). 
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a)         b) 
 
Figure 4.12 Co-encapsulation of divergent solubility drugs into small unilamellar liposomes. Comparison of effect of single and co-
drug encapsulation on a) percent drug loading (‘*’: suggesting p<0.05, t-test) & b) particle size, representing the formulation with 
ratio of  DSPC:cholesterol, 5:2 w/w (N=3, ± SD). 
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In all cases, there was no surface charge development observed; the zeta potential for all 
samples was between 0.0 and -10 mV (Table 4.4).  
Table 4.4 Zeta potential of empty and drug loaded liposomes. Results represent mean ± SD, n = 
3. 
Sample 
Zeta Potential, mV 
MLV SUV 
DSPC:cholesterol  
(5:1 w/w) 
DSPC:cholesterol  
(5:2 w/w) 
DSPC:cholesterol  
(5:1 w/w) 
DSPC:cholesterol  
(5:2 w/w) 
Empty -4.8 ± 0.9  -6.9 ± 1.3  -8.6 ± 1.7  -8.8 ± 2.1  
Metformin  -5.6 ± 2.1  -5.9 ± 1.5  -9.6 ± 2.2  -8.4 ± 1.8  
Glipizide -6.8 ± 0.9  -5.9 ± 0.8  -8.8 ± 1.9  -8.9 ± 0.5  
Co-drug -9.5± 0.9  -6.8 ± 0.6  -8.8 ± 1.9 -6.7± 0.2 
 
4.3.9 In-vitro drug release from MLV and SUV 
Data from the in-vitro drug release can be used to predict and develop the in-vivo behaviour of 
the drug. There are numerous predictive methods used to study the in-vitro release, but model 
dependent methods (e.g. zero order, first order, Higuchi etc.) are common (Dash et al., 2010). 
To study the zero order release kinetics, the data obtained from in vitro drug release studies 
can be plotted as cumulative amount of drug released versus time; whereas log cumulative 
percent drug release versus time can be used to study the first order release kinetics. However, 
in Higuchi model, the release is square root of time dependent process which follows Fickian 
diffusion (Gohel et al., 2000).  
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There are various models reported in past literature and it can be expected that any drug 
subjected for drug release would follow one or a mixture of these models (Ramteke et al., 
2014). Out of these, zero order and first order kinetics are widely discussed. Zero order is the 
process that happens at a constant rate independent of drug concentration (Costa and Lobo, 
2001), whereas first order is directly proportional to the drug concentration involved in the 
process (Jeong et al., 2000). However, drug in suspension can also experience diffusion where 
relationship between the cumulative percent drug released and square root of time is explored 
(Siepmann and Peppas, 2011).   
 
Metformin, due to its hydrophilic nature, was expected to be released faster. Thus, almost 60 % 
metformin was released within first 120 minutes and > 90 % released in 6 hours. On the other 
hand, it was observed that the initial release of glipizide was very slow compared to metformin, 
but within 12 hours >90 % glipizide was released and quantified successfully (Figure 4.13).  
When plotted the cumulative percent drug released versus time (h), it was observed that the 
release of drug is faster in first few hours (Figure 4.13a). Therefore, the release was further 
studied considering zero, first and Higuchi model of release (Figure 4.13 b & C).  
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a)         b) 
           
c)          d) 
                             
Figure 4.13 In-vitro release of glipizide and metformin in MLV. a) Drug release under physiological conditions from various formulations in 
aqueous buffer, pH = 7.4, at 37°C. b) Cumulative drug release (mg) representing data response under zero order model. c) Log cumulative 
percent drug remaining representing response under first order model. d) Cumulative percent drug release plotted using Higuchi model of 
drug release. (N=3, ± SD). 
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The release data from all formulations (Figure 4.13a and 14a) was again treated according to 
zero-order (cumulative amount of drug released vs time; Figure 4.13b and 14b), first-order (log 
cumulative percentage of drug released vs time; Figure 4.13c and 14c) and Higuchi (cumulative 
amount of drug released vs square root of time; Figure 4.14d and 14d) models. It has been 
reported that other drugs that are encapsulated into the liposome follow zero or first order 
kinetics (Ali et al., 2010; Hathout et al., 2007; Nounou et al., 2006). However; from the R2 values 
obtained from line of fit, it can be concluded that only when the metformin was co-entrapped 
with the glipizide has followed first order release but for all other samples there is strong 
correlation observed with Higuchi model compared to first order and zero order kinetics  
(Figure 4.13 c &b). However, in case of drug release from SUV obtained after sonication; where, 
all the metformin shown to fit good with Higuchi model but the glipizide shown to fit good with 
zero order having  difference in R2 values (Figure 4.14 b &d).  
Release of drug from liposomes has previously been shown to be dependent on cholesterol 
concentration, and relatively slow release has been observed when propofol (lipophilic drug) 
has been encapsulated within liposomes incorporating 11, 20 and 33 mole % total cholesterol 
concentration (Ali et al., 2010). Therefore, concentration of cholesterol could be a possible 
reason for the slow release of glipizide. Recently published research on the release of co-
encapsulated drug shows that the presence of lipophilic drug reduces the release rate of 
hydrophilic drug significantly (Cosco et al., 2012). However, here it was observed that, when co-
loaded, the initial release rate was higher for both drugs; in the case of metformin 
hydrochloride, the release was increased approximately 3 times that of release of individually 
entrapped metformin. Similarly, with glipizide, the release was increased approximately two 
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times that of release of individually entrapped glipizide (Figure 4.15). This may be a result of a 
burst effect (Calvagno et al., 2007); i.e. initial release of glipizide increased fluidity of the 
bilayer, which in turn had a pronounced effect on metformin hydrochloride release, as well as 
glipizide release, to a lesser extent. The initial quick release of metformin is a result of its 
solubility in PBS, which, along with the driving forces, made it to diffuse at a higher rate 
compared to glipizide. 
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a)         b) 
            
c)       d) 
               
Figure 4.14 In-vitro release of glipizide and metformin in SUV. a) Drug release under physiological conditions from various formulations in 
aqueous buffer, pH = 7.4, at 37°C. b) Cumulative drug release (mg) representing data response under zero order model. c) Log cumulative 
percent drug remaining representing response under first order model. d) Cumulative percent drug release plotted using Higuchi model 
of drug release. (N=3, ± SD).
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4.4 Conclusion 
Liposomal size is important when there is possibility of clearance by RES (Gregoriadis, 1995). 
The RES opsonise MLV faster than SUV; hence, the rate of RES uptake increases with 
increases in size and SUV have a longer circulation profile than MLV (Gregoriadis and Davis, 
1979; Sharma and Sharma, 1997). Therefore, in this chapter, individual and co-
encapsulation of metformin and glipizide was comparatively evaluated in MLV and SUV.  
Also, the results reported in this chapter have given an overview about the effect of varying 
concentration of cholesterol.  
 
In the case of the MLV formulation, individual encapsulation of metformin and glipizide 
brought no significant changes in the particle size, but the co-encapsulation increased the 
particle size significantly (approximately 44 %, p<0.05, t-test). The stability of the lipid 
formulation, with or without drug, was assessed at different stability environment and only 
the formulation stored at the elevated temperature and humidity (40°C/ 75 % RH) showed a 
significant increase (approximately 52 %, p<0.05, t-test) in the particle size of MLV (section 
4.3.4). Drug escalation studies performed with metformin as well as glipizidehas given an 
overall idea about the ability DSPC:Cholesterol 5:2 w/w system to accommodate the 
maximum possible amount of drug in the vesicle (section 4.3.5).From this study, it can also 
be concluded that approximately 40% glipizide and approximately 20% metformin gets 
encapsulated, no matter of the initial amount of drug.   In the case of SUVs, no significant 
changes were observed in the particle characteristics due to individual or co-drug 
encapsulation (Figure 4.12b). However, a significant decrease (approximately 25 % and 45 % 
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reduction for glipizide and metformin respectively, p<0.05, t-test) in % encapsulation of 
both the drugs has been observed after size reduction.  
With respect to the drug release, there is a distinct pattern observed in drug release of both 
MLV and SUV. The release of drugs from MLV is comparatively slower than SUV; where the 
burst release was not prominent in MLV formulations. Most of the formulations show good 
fit with Higuchi release except the glipizide in SUV which fit good with zero order release 
and metformin when co-entrapped in MLV obeys first order release.    
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Chapter 5: Microfluidics based manufacture of liposomes co-
encapsulating hydrophilic and lipophilic drugs 
 
 
 
 
 
 
 
 
 
 
 
Publication related to this chapter:  
Joshi, S., Hussain, M.T., Roces, C.B., Anderluzzi, G., Kastner, E., Salmaso, S., Kirby, D.J., Perrie, 
Y., 2016. Microfluidics based manufacture of liposomes simultaneously entrapping 
hydrophilic and lipophilic drugs. International journal of pharmaceutics 514, 160-168.  
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5.1 Introduction 
The field of microfluidics had notable developments in the 1990s (Harrison et al., 1992) and, 
since then, over 10,000 papers have been published on the topic (ISI Web of Science 2016). 
Microfluidics, in general, considers the use of channels having at least one dimension in the 
micron size range and exploits the flow of liquid through these micron sized channels.  
However, the exact nature of microfluidics is open to interpretation; some researchers have 
considered it as a technology in the form of ‘lab-on-chip’, others have considered it as a 
science to study the flow of liquid through these micro-channels and microfluidics has been 
used for extraction, purification, labelling, fractionation, droplet preparation, environmental 
analysis and drug metabolism analysis (Abdelgawad et al., 2009; Nge et al., 2013; Yang et al., 
2010). Glass, silicone and polymers like poly-dimethyl-siloxane (PDMS) have been used for 
microfluidics chip preparation.  PDMS is a transparent elastic polymer used widely in 
microfluidic technology, due to cost-effectiveness and easy moulding of the material. 
However, silicone was the first material used for the fabrication of microfluidic devices and 
has subsequently been replaced by glass and PDMS (Nge et al., 2013). This was primarily 
due to the fact silicone is transparent to infrared but not to visible light. However, a 
combination of glass or polymer with silicone was proposed as an alternative to silicone only 
systems and this was found to be more applicable in biological detection (Washburn et al., 
2009).  On the other hand, PDMS was first introduced in 1990s (Effenhauser et al., 1997a; 
Effenhauser et al., 1997b) and at present it is the more preferable material for the academic 
laboratories, due to ease of handling, preparation and storage (Nge et al., 2013).  
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As outlined within Chapter 1, in the preparation of liposomes, there is a range of methods 
including the thin film hydration method (Bangham et al., 1965), ethanol injection (Pons et 
al., 1993) and hot-melt extrusion (Repka et al., 2007). However many of these methods have 
limited scalability, and in recent years microfluidics has been investigated as a potential 
production method for liposomes(Yu et al., 2009). For clinical application, liposomes with 
size < 100 nm are generally used, as shown in Table 5.1. This is due to this size range 
offering improved drug delivery and targeting by avoiding recognition and clearance by the 
mononuclear phagocyte system (MPS) (Gregoriadis, 1993; Perrie and Rades, 2012a).  
Table 5.1 Liposomal systems in clinical use. 
Product name API Vesicle size range, nm 
Doxil Doxorubicin 80-100  
Myocet Doxorubicin 150-190  
Daunoxome Daunorubicin 45-50  
Ambisome Amphotericin B 80-100  
Marqibo Vincristine 90-100  
 
Formation of SUV is possible by two ways, either by preparing large vesicles followed by size 
reduction methods (e.g. homogenisation, microfluidisation, high-sheer mixing and 
sonication) or by using advanced techniques to form SUV directly from lipid monomers. In 
the case of licensed products, the majority of the systems have been prepared by 
microfluidisation followed by lyophilisation to remove the water content in the final product 
(Dua et al., 2012) and this does not map well with current laboratory research, where the 
vast majority of work still adopts basic methods, such as the thin film hydration first 
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developed by (Bangham et al., 1965). To address this, new methods that allow for the rapid 
translation from bench to clinic are required, with microfluidics offering strong potential.  
 
 
Figure 5.1 Illustration of the process of liposomal suspension production using microfluidics 
device. At different TFR (mL/min) solvent and aqueous phase run at different FRR through 
microfluidics channel having staggered herringbone micromixer. The resultant is a liposomal 
suspension having no drug, single drug or co-drug encapsulated. 
 
Microfluidics is a novel method to prepare liposomes (Fig 5.1) that is reproducible, a one-
step process and high throughput compared to the traditional thin film hydration method 
(Hood et al., 2014). More recently, microfluidics has been considered for the formulation of 
liposomes (Jahn et al., 2007; Kastner et al., 2014; Kastner et al., 2015). Microfluidics is 
presented by a low Reynold’s number ‘Re’, which is a non-dimensional number to 
determine whether the flow is turbulent or laminar. A threshold value for this is 2000 and 
‘Re’ below 2000 is considered as laminar flow. This ‘Re’ can be expressed as follow.  
                                         =



                                                                                    Equation 5.1 
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Here µ is the viscosity of the fluid, ρ is the density, V is velocity scale and D is the diameter 
of the pipeline. It is a promising way to obtain a monodisperse population of particles 
(Belliveau et al., 2012). Microfluidics allows distinct mixing organised exclusively by 
interfacial diffusion where multiple flow streams get injected into a microchannel (Pradhan 
et al., 2008). In other words, this is based on laminar fluid flow and involves diffusion mixing. 
Liposome formation is energetically favourable at a point in the system where 
concentration of solvent/buffer reaches a position where lipid solubility is low (Jahn et al., 
2004). Within the process, flow rates, aqueous to solvent ratios, total sample volumes, 
waste volumes can be manipulated as needed and should be optimised for a given system. 
 
5.2 Aim and objectives 
The work in this chapter aimed to prepare liposomes < 100 nm using microfluidics so as to 
effectively reduce the time and effort required in preparing liposomes with better drug 
encapsulation. To achieve this, the objectives were: 
1. Optimisation of the microfluidics parameters for the manufacturing of liposomes.  
2. Liposome purification by solvent and un-entrapped drug removal.   
3. Studying effect of simultaneous drug encapsulation on percent encapsulation and 
simultaneous drug release.   
To achieve this, initial studies focused on microfluidics parameter optimisation for the 
better quality and yield of SUV. This was followed by evaluation of effect of single and co-
drug encapsulation on particle characteristics. Into the optimised SUV formulation, the 
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maximum possible drug encapsulation was then studied and finally in-vitro drug release was 
analysed for the maximum single and co-drug drug loaded formulations. 
 
5.3 Results and discussion 
5.3.1 Optimisation of microfluidics method parameters 
An in depth investigation of the formulation is necessary when designing a colloidal carrier 
carrying two drugs of different physico-chemical properties. As described earlier in chapters 
1 and 4, to consider encapsulation of two drugs of different solubility, DSPC, a long chain 
phospholipid, was used, as previous studies demonstrate that greater drug loading (Ali et 
al., 2010; Mohammed et al., 2004) and retention (Gregoriadis and Davis, 1979) can be 
achieved using long chain phospholipids. An optimised ratio of DSPC:Cholesterol 5:2 w/w 
was used as previously adopted in Chapter 4. 
 
Initial studies investigated the impact of total flow rate (TFR) and flow rate ratio (FRR)on 
liposome attributes, given that previous studies have highlighted the importance of 
considering the effect of such parameters (Kastner et al., 2014). Liposomes produced after 
each run were tested for size and zeta potential analysis. At first, total sample volume of 1.0 
mL including the waste volume was considered for the formulation (Figure 5.2). 
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Figure 5.2 Comparison of the particle characteristics of DSPC:Cholesterol (5:2, w/w) liposomes produced by microfluidics at different flow rate 
ratios (FRR) and total flow rates (TFR) with a total sample volume 1.0 mL. Results represent mean ± SD, n = 3. (OR= organic, AQ= Aqueous, PDI= 
Poly dispersity index).  
175 
 
Although previous reports have shown that it is possible to control the size of liposomes 
with an increase in the aqueous stream volume (Kastner et al., 2015), it was not observed 
here with a sample volume of 1.0 mL. The results in figure 5.2 show that there is no notable 
trend observed at different TFR or FRR, with all parameters tested being able to produce 
liposomes in the range of 80 to 120 nm. The observed PDI for all samples is in the range of 
0.1 to 0.2, which also indicates that a change in solvent to aqueous ratio has no effect on 
particle heterogeneity. It was concluded that possibly the use of a sample volume of 1.0 mL 
does not give enough time for mixing, whilst it can also be possible that, due to less waste 
volume (0.1 mL), the larger particles are becoming part of the sample volume. Therefore, it 
was decided to repeat the experiment with a larger sample (1.6 mL) and initial waste (0.6 
mL) volume for subsequent experiments (Figure 5.3). 
 
Unlike the 1.0 mL sample volume, a substantial trend has been observed after increasing the 
sample volume as well the initial waste volume, with these differences in particle size with 
two different sample and waste volumes described with a multidimensional surface plot 
(Figure 5.4). Here, a change in particle size was studied considering the two dimensions, 
namely FRR and TFR.  
 
 
  
Figure 5.3 For total sample volume 1.6 mL including 0.6 mL waste volume
Cholesterol liposomes produced by microfluidics. Results represent mean ± SD, n = 3.
176 
, selection of flow rate and flow rate ratio for the production of DSPC: 
 
 
 a       
Figure 5.4 Effect of sample volume on particle size. a) Particle size when the total sample 1.0 mL b) Particle size when the total samp
1.6 mL. (n=3). 
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In the surface plot of a total volume of 1 mL (Figure 5.4a), a scattered particle size was 
observed at different TFR and FRR. Here, the particles were in the range of 50-150 nm and 
no effect was observed due to change in the TFR or FRR. However, unambiguous patterns 
were observed in the surface plot with the sample volume 1.6 mL (Figure 5.4b), where there 
is a decrease in particle size with an increase in TFR at any FRR. In other words, having more 
aqueous volume had a remarkable effect on particle size and it can be seen that particles 
are predicted in the range of 1-100 nm; whereas, when the aqueous content was lowered, 
the particle size increased up to the 300-400 nm range. 
 
The solvent to buffer ratio has a significant effect (p<0.05, ANOVA post hoc Dunnett’s test) 
on the particle size as well as PDI. The smallest particle size observed was 81 nm ± 6 nm with 
15 mL/min TFR at 1:5 FRR, whilst the largest observed was 308 nm ± 17 nm with the same 
process parameters 15 mL/min TFR at 1:1 FRR (Figure 5.3). A similar trend was observed 
with other TFRs, where at higher aqueous volume the size decreased, with increases seen at 
low aqueous volume.  
 
Preliminary analysis of the DSPC:Cholesterol liposomes suggest the potential of a 
microfluidic device to produce size controlled liposomes; although the microfluidics method 
is relatively new, the process of nanoprecipitation involved is quicker compared to the 
multi-step process of the thin film hydration method described in chapter4 (Hood et al., 
2014).  
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At high aqueous buffer content, the chaotic mixing of the phases was increased and it was 
presented previously that at higher TFR, the thickness of the solvent streams decreases and 
diminishes at a point (Kastner et al., 2014; Zook and Vreeland, 2010). Basically, FRR dictates 
the polarity of the fluid running in the microfluidic chamber, and this polarity is the basis of 
the precipitation reaction leading to liposome formation (Dong et al., 2012). Hence, it was 
observed that the smallest liposomes were produced at higher aqueous volumes. On the 
other hand, it was observed that FRR 1:1 produces the largest sized liposomes at any TFR 
(Figure 5.3 and 5.4). This is because increases in the aqueous portion of the FRR changes the 
polarity of solvent, which limits the production of large liposomes, resulting in the 
production of smaller sized liposomes (Jahn et al., 2010), whilst at lower FRR, the bilayer 
alcohol gets exhausted at a slower rate and, hence, produces larger liposomes as the bilayer 
gains more to time to stabilise (Zook and Vreeland, 2010).In all cases, the liposome 
formulations were near neutral in zeta potential, as would be expected for such 
formulations. When comparing FRR at different TFRs, it was observed and concluded that 
higher TFR and FRR 1: 5 (organic to aqueous) are comparatively better process parameters 
as smaller liposomes are produced. Hence, TFR 15 mL/min and FRR 1:5 (organic to aqueous) 
was adopted for further experiments. 
 
5.3.2 Separation of non-encapsulated drug and removal of residual solvent 
In the formulation of liposomes using microfluidics, both the removal of non-entrapped 
drug and residual solvent (in this case methanol) is a requirement. The ICH limit for 
methanol in formulation is 3000ppm; therefore, maximum removal of solvent from the 
sample is very important. As such, initially two methods (dialysis and spin-column 
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separation) were investigated for their ability to remove both non-incorporated drug and 
residual solvent. Both systems were compared using liposomes containing either metformin 
(Table 5.2) or glipizide (Table 5.3).  
Table 5.2 Analysis of metformin loaded liposomes subjected to dialysis as well as spin 
column filtration. All the experiments were performed in triplicates (n=3). 
Parameter Sample from 
dialysis 
Sample from spin 
columns 
Size, nm 64.6 ± 2.3  56.1 ± 3.5  
PDI 0.151± 0.02 0.211± 0.05 
Zeta Potential, mV -8.52 ± 1.6  -5.95 ± 2.4  
Metformin  % Encapsulation 19.3 ± 1  20.0± 1.8  
% Non encapsulation 79.9± 3.2  79.9± 2.5  
% Drug Recovery 99.2 99.9 
Solvent (ICH limit: 3000ppm), ppm 17 ± 2  34418 ± 576  
 
Table 5.3 Analysis of glipizide loaded liposomes subjected to dialysis as well as spin column 
filtration. All the experiments were performed in triplicates (n=3). 
Parameter Sample from 
dialysis 
Sample from spin  
Columns 
Size, nm 62.16± 2.6  73.04 ± 5.6  
PDI 0.272± 0.01 0.181± 0.06 
Zeta Potential, mV -4.96 ± 1.5  -7.06 ± 4.5  
Glipizide  % Encapsulation 43.1 ± 2.2  4.7 ± 1.1  
% Non-encapsulatioon 60.3 ± 3.5  14.6 ± 2.5  
% Drug Recovery 103.4 19.3 
Solvent (ICH limit-3000ppm), ppm 25 ± 6  49696 ± 970  
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Considering the metformin-loaded liposomes (Table 5.2), there was no notable difference in 
size, PDI or zeta potential observed for the liposome formulations after dialysis or filtration, 
with liposomes being 60 – 70 nm in size, with PDI of 0.2 and near neutral zeta potential. 
Similarly, metformin drug loading (as determined by HPLC analysis of both the liposome 
fraction and the eluent) were similar at approximately 20% (Table 5.2). However, it was 
observed that, whilst dialysis was able to reduce residual solvent levels to within ICH limits, 
the spin column method failed to remove residual solvent from the sample, with solvent 
levels at 34418 ± 576 ppm, which was much higher than the ICH limit (Table 5.2). 
 
Similar results were observed with liposomes incorporating glipizide, with no significant 
difference in the size (60 – 70 nm) and polydispersity (0.2 to 0.3) of the liposomes recovered 
after dialysis or spin column purification, and again the spin-column method was unable to 
remove residual solvent (Table 5.3). However, in the case of glipizide-loaded liposomes, only 
dialysis was able to give reliable information on drug loading. The results obtained from 
analysis of dialysed sample show drug loading of 43 % and approximately 100 %recovery of 
the drug. However, when liposomes were subjected to spin column filtration, a low (20 %) 
drug recovery was measured and, as such, the drug loading measurements could not be 
considered (Table 5.3). It may be possible that the glipizide was absorbed to the 
polyethersulfone (PES) membrane within the spin column instead of passing through along 
with eluted solution and, therefore, could not be adopted as a reliable method. Therefore, 
for all subsequent studies, removal of non-loaded drug was undertaken by dialysis. 
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5.3.3 Microfluidics assisted liposomal co-encapsulation of two divergent solubility drugs 
As discussed in section5.3.1, whilst TFR did not affect liposome size, FRR was shown to 
impact on the liposome attributes. Therefore, all formulations thereafter were prepared 
using TFR 15 mL/min and FRR 1:5 (organic to aqueous) and the effect of loading metformin 
and glipizide, both individually and in combination, was considered, with glipizide dissolved 
in the solvent phase and metformin in the aqueous stream. In terms of initial drug added, 
300 µg of glipizide dissolved in methanol (the maximal amount soluble in the solvent phase 
used; 300 µg in 0.27 mL i.e. 1.2 mg/mL) along with the DSPC and cholesterol (2.7 mg and 1.1 
mg, respectively), and 20 mg/mL of metformin was added to the PBS phase. Microfluidics 
had been previously used to prepare small unilamellar liposomes, but there is limited 
research performed on liposome preparation using long chain phospholipids (e.g. DSPC) 
(Young and Tabrizian, 2015) and no research has been reported regarding preparation of 
DSPC liposomes using  Precision system’s microfluidic device. 
 
Results in Figure 5.5 show that drug loading of glipizide within the liposomal bilayer was 
approximately 40% and metformin entrapment was approximately 20%. In all cases, it was 
found that >90 % glipizide and >95 % metformin was recovered (results not shown). 
Furthermore, the results show that loading of the drug individually or in combination had no 
significant impact on the loading capacity of the liposomes. However, the presence of either 
drug in the formulation tended to push the vesicle size down by approximately 20 nm, with 
the measured z-average particle size being 50 to 60 nm.  
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Figure 5.5 Comparison of DSPC:Cholesterol (5:2, w/w) liposomes z-average diameter, pdi 
and drug loading for liposomes with glipizide loading within the bilayer, with metformin 
loading within the aqueous phase, liposomes containing both glipizide and metformin and 
liposomes without drug present. Results represent mean ± SD, N=4. 
 
In terms of drug loading within these vesicles prepared using microfluidics, the loading was 
based on the principle of passive loading, where both drug and lipids are co-dispersed in the 
aqueous phase. Generally, encapsulation efficiency for passive loading is less than 10% 
(Cullis et al., 1989), whilst these studies show notably higher hydrophilic (metformin) drug 
loading of approximately 20% was achieved (Figure 5.5); indeed, loading for both drugs was 
high, despite the large differences in Log P (Figure 5.6). The use of microfluidics has been 
suggested to improve hydrophilic loading; for example, Jahn et al. (2008) reported 
unexpectedly high entrapment efficiencies of a hydrophilic moiety (sulforhodamine B 
dissolved in PBS) within nanometer-scale liposomes prepared using a continuous-flow 
microfluidics system. The authors suggest that the high encapsulation efficiency may be due 
to a spatial concentration enhancement induced by viscosity anisotropy in the microchannel 
(Jahn et al., 2008). In terms of bilayer loading, the simultaneous packaging of the lipids and 
 glipizide within the bilayer can promote drug loading of approximately 40%, similar to 
previous studies with propofol (Kastner et al., 
liposomes were formed in the presence of metformin and/or glipizide may be a result of 
changes in viscosity, miscibility and/or mixing at the interphase as the liposomes form
discussed by Jahn et al. (2008). 
             
Figure 5.6 The relation between lipophilicity (log P) and drug encapsulation. Liposomal 
composition= DSPC:Cholesterol (5:2 w/w) with/without glipizide and metformin 
hydrocholoride. (MET-CO: Metformin co
 
 
5.3.4 The role of drug concentration in drug loading
Considering the challenges associated with delivery of pharmacological agents, the 
possibility of liposomes as a carrier was co
al., 1971; Gregoriadis and Ryman, 1972a
first among the novel drug delivery systems to 
with the plethora of commercialisation can be seen with other drug delivery systems
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2015). The small decrease in size noted when 
-encapsulated, GPZ-CO: Glipizide co-encapsulated). 
 
ined more than four decades ago (Gregoriadis et 
) and liposomal drug delivery systems
be commercialised. No such development 
, as 
 
 
 became the 
, which 
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can be attributed to the innocuous nature of liposomes. As such, numerous updates have 
been made to extract the best from this outstanding drug delivery system.  
 
With passive diffusion using traditional production methods, it can only be possible to 
encapsulate up to 50 % of the lipophilic drugs and upto 15 % of the hydrophilic drugs (Cullis 
et al., 1989).  
 
Recently, it was reported that an increase in initial drug concentration increases 
encapsulation efficiency of liposomes (Kastner et al., 2015). Therefore, to study the 
maximum possible drug loading efficiency of the liposomes prepared using microfluidics, 3 
different concentrations of both glipizide and metformin were tested. Due to limited 
solubility of glipizide in methanol, it was only possible to go up to 0.3 mg total drug in 0.27 
mL organic phase of the aqueous to organic ratio 5:1 v/v. Therefore, solutions having  0.1, 
0.2 and 0.3 mg of glipizide in 0.27 mL of organic phase was investigated in combination with 
metformin 5, 10 or 20 mg/mL in the aqueous phase were tested for escalation study. In 
both cases, the initial drug concentration did not significantly impact on the percentage 
drug loading (Figure 5.7a), demonstrating that increasing doses of drug could be delivered 
within the liposome formulation. Furthermore, it can be observed in Figure 5.7b that, 
although the percent of drug loading has not changed at any given concentration of drug, 
the amount of drug loaded into the liposomes (final volume 1.0 mL) was increased gradually 
with the increase in initial drug concentration. 
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a)           b) 
                          
Figure 5.7 The role of drug concentration in drug loading for glipizide and metformin. Samples were prepared on microfluidic device and 
tested for percent loading using RP-HPLC (UV detector). a) % drug loading with respect to the drug concentrations. b) Drug loading presented 
as amount of drug loaded for respective drug concentration. (N=4, ± SD). 
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5.3.5 Microscopic elucidation of small unilamellar liposomes 
Cryo-TEM has significantly contributed to the understanding of complex structures like 
liposomes. Microscopy is usually used for liposomes to characterise their size and 
lamellarity. The liposomal bilayer can be spotted but, due to the limit of resolution, the 
arrangement of lipid within the bilayer cannot be spotted (Almgren et al., 2000). However, 
methods like small angle x-ray scattering (SAXS) or small angle neutron scattering (SANS) 
can be used for this purpose.  
 
To consider the morphology of the liposomes prepared by microfluidics, 4 formulations 
were considered by cryo-TEM: liposomes without drug, liposomes incorporating either 
metformin or glipizide and also liposomes incorporating both drugs. As described in chapter 
2 (section 2.3.7.1), the liposomal solution was applied to a microscopic grid, forming a thin 
film, which was then frozen by plunging into the cooling medium, such as ethane. Extra care 
was taken to avoid crystallisation during the process of freezing. Finally, the liposomal 
structures on the film were spotted and captured without dehydration.   
 
No variation has been observed between DLS results and cryo-TEM results with respect to 
the size and PDI of liposomes, with the average size of liposome observed on cryo-TEM for 
all liposome samples being around 60 ± 10 nm (Figure 5.8).  
 
Considering the speed of liposome preparation employed by the microfluidics system (i.e. 
15 mL/minute) and high proportion of aqueous content, there was a possibility that the 
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shear may cause elongation of liposomes or possibly breakage (Richardson et al., 2007).  
However, there was no such sign seen in any of the samples (Figure 5.8).  
 Figure 5.8 DSPC:Cholesterol (5:2, w/w) liposomes produced by microfluidics imaged by Cryo
liposomes with glipizide loading within the bilayer, C) liposomes with metformin loading within the
both glipizide and metformin. 
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5.3.6 In-vitro release study of liposome encapsulated and co-encapsulated glipizide and 
metformin. 
In-vitro drug release was studied using USP-4 (SOTAX, SOTAX Ltd., London, UK). Liposomal 
drug release studies have often been performed using large amounts of buffer and it was 
also observed that excess buffer can result in inaccurate analysis due to leakage of drug 
(Shabbits et al., 2002). Therefore, the in-vitro drug release was studied using USP-4, flow 
through cell based closed loop system (SOTAX, SOTAX Ltd., London, UK).  The USP-4 is well 
known for versatility, and has distinct advantages, such as requiring low volume of media, 
precise as well as auto-temperature control and most important is the adaptor, which is 
especially designed for the submicron sized delivery systems.   
 
Drugs encapsulated into liposomes exhibit the pharmacokinetic properties of the liposome 
drug carrier. These properties may include long circulation, reticuloendothelial clearance 
pathway as well as greater permeability and tumour site drug accumulation (Lee, 2006). 
Enhanced drug safety and efficacy can be achieved after the liposomal encapsulation.  Drug 
encapsulated into liposomes depends on the solubility of drug as well as components of 
liposomal system. Drugs co-encapsulated into liposomes may differ in the rate of release 
irrespective of region of encapsulation and/or drug solubility.  
 
When drugs with divergent solubility are encapsulated into two distinct regions of 
liposomes, it can be expected that the release rate may vary (Lee, 2006). This difference in 
drug release rate from co-drug encapsulated liposomes often creates complications in 
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determination of released drug concentration. In this case, if the concentration falls below 
the limit of detection, then approaches like spiking can be used to achieve precision in the 
quantification.  The drug release was observed in PBS flowing in closed loop system at flow 
rate of 8.0 mL/minute and at physiological temperature (37⁰C ± 1⁰C). Released drug was 
quantified using RP-HPLC, as mentioned in chapter 2 (section2.3.4.2). At predetermined 
intervals, a predetermined sample volume (1.0 mL) was taken and tested for drug release. 
The percent drug release was then calculated.  
 
The release profiles of both drugs encapsulated individually or together were similar to the 
liposomes produced by thin film hydration method in chapter 4. However; from the R2 
values obtained from line of fit, it can be concluded that for metformin there is strong 
correlation observed with Higuchi model and for glipizide there is strong correlation 
observed with zero order kinetics (Figure 5.9 b &d and table 5.4). Comparitively, no stong 
correlation with first order kinetics was observed for any of the drug release. Metformin, 
due to its hydrophilic nature, was expected to be released faster; thus, almost 60 % 
metformin was released within the first 60 minutes and > 90 % released in 6 hours. On the 
other hand, it was observed that, within the initial stages of release, glipizide was very slow 
compared to metformin, but within 12 hours >90 % glipizide was released and quantified 
successfully (Figure 5.9). 
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a) b) 
                      
c)                   d) 
        
Figure 5.9 USP-4 aided study in-vitro release of glipizide and metformin in SUV. a) Drug release under physiological conditions from various 
formulations in aqueous buffer, pH = 7.4, at 37°C. b) Cumulative drug release (mg) representing data response under zero order model. c) Log 
cumulative percent drug remaining representing response under first order model. d) Cumulative percent drug release plotted using Higuchi 
model of drug release. (N=3, ± SD). 
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Table 5.4 Kinetic values of release of glipizide and metformin from liposomal formulations using the correlation coefficient parameter. 
Glipizide 
 Zero Order First Order Higuchi Order 
 GPZ GPZ-CO GPZ GPZ-CO GPZ GPZ-CO 
TFH-MLV 0.797 0.913 0.867 0.934 0.917 0.947 
TFH-SUV 0.976 0.946 0.971 0.929 0.904 0.981 
MICF-SUV 0.927 0.99 0.922 0.986 0.887 0.938 
 
Metformin Hydrochloride  
 Zero Order First Order Higuchi Order 
 MET MET-CO MET MET-CO MET MET-CO 
TFH-MLV 0.889 0.710 0.934 0.902 0.966 0.847 
TFH-SUV 0.811 0.969 0.929 0.988 0.931 0.989 
MICF-SUV 0.951 0.84 0.981 0.885 0.99 0.915 
 
Based on the R
2
 values the applicable model is described in the table below 
 GPZ GPZ-CO MET MET-CO 
TFH-MLV Higuchi Order Higuchi Order Higuchi Order First Order 
TFH-SUV Zero Oder Zero Order Higuchi Order Higuchi Order 
MICF-SUV Zero Order Zero Order Higuchi Order Higuchi Order 
 
 
TFH-MLV Thin film hydration-Multi lamellar vesicles 
TFH-SUV Thin film hydration-Small Unilamellar vesicles 
MICF-SUV Microfluidics-Small Unilamellar vesicles 
* For all the 3 models only initial 3 hours were taken into consideration.   
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Release of drug is dependent on cholesterol concentration; relatively slow release was 
observed by Ali et al. (2010) when encapsulating propofol (lipophilic drug) within liposomes 
(Ali et al., 2010). Therefore, the concentration of cholesterol could be a possible reason for 
slow release of glipizide. 
 
Release of drug from a co-drug loaded liposomes is largely dependent of the water solubility 
of lipophilic drug. Recently published research on the release of co-encapsulated drug 
shows that the presence of lipophilic drug reduces the release rate of hydrophilic drug 
significantly (Cosco et al., 2012). However in our case, it was observed that, when co-loaded, 
the initial release rate is increased for both drugs; in the case of metformin hydrochloride, 
the percent drug release was increased approximately 6 times that of release of individually 
entrapped metformin. Similarly, with glipizide the release was increased approximately 4 
times that of release of individually entrapped glipizide. This may be a result of a burst 
effect (Calvagno et al., 2007) i.e. initial release of glipizide increased fluidity of the bilayer, 
which in turn had a pronounced effect on metformin hydrochloride release, as well as 
glipizide release, to a lesser extent. The initial quick release of metformin is result of its 
solubility in PBS; which along with the driving forces made it to diffuse at higher rate 
compared to glipizide. 
 
5.3.7 Influence of liposomal size on in-vitro drug release 
Liposomal systems have been designed to control drug exposure, aid the drug in crossing 
biological barriers and protect the active ingredient from premature elimination (Siegel and 
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Rathbone, 2012). Liposomal formulations can be developed to deliver drug with controlled 
release and represent the sanctified as well as spatial presentation of the active 
pharmaceutical ingredients in the body.  In the designing of controlled release systems, it is 
necessary to understand the kinetics of the drug release and factors affecting it.
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a)              b)  
 
c)                d) 
 
 
Figure 5.10 Drug release under physiological conditions from various formulations in aqueous buffer, pH = 7.4, at 37°C (n=4 ± SD). Comparison 
of drug release kinetics of the MV as well as SUV prepared by thin film hydration (TFH) and the SUV prepared by microfluidics. a) glipizide 
encapsulated individually, b) metformin encapsulated individually, c) glipizide co-encapsulated, d) metformin co-encapsulated. 
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The process of dissolution is the reverse of the precipitation (Rogers et al., 2004). Dissolution is 
a kinetic process dependent of the solubility and is a thermodynamic property of the drug.  
 
As per Noyes-Whitney equation, the dissolution rate can be increased by increasing particle 
surface, but stern application of this law is unlikely as the surface area of the drug-
encapsulating matrix changes over time and cannot be assumed constant (Perrie and Rades, 
2012a). Also, recently Siegel and Rathbone (2012), Hatzi et al. (2007) as well as Sridhar et al 
(2008) have observed that the rate of dissolution decreases with increasing particle size and 
increases with increase in the solubility of the active ingredient.  
 
Indeed, similar to the findings of Siegel and Rathbone (2012), it can be seen in figure 5.10 that 
the rate of release decreased as the particle size decreased (Release rate: MLV (approx.10 
µm)>SUV (approx. 150 nm) > SUV (approx. 70 nm).When comparing SUVs produced by thin film 
hydration versus SUVs produced by microfluidics, it was noticed that the dissolution rate did 
differ in both cases, but in the case of glipizide, the release rate was significantly slower 
(p<0.05, t-test)for SUVs prepared by microfluidics (Figure 5.10). This is possibly due to the 
efficient mixing of aqueous and organic phase in microfluidics that resulted in the production of 
liposomes with a very rigid structure providing better drug encapsulation as well as slower 
release.  
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Along with factor of size of the liposomes, another important factor is the solubility of the 
encapsulated drug. It was seen that the rate of metformin release is faster in all cases 
suggesting that the release rate is dependent on diffusion. Moreover, it can be seen in Figure 
5.10 that the rate of dissolution had more influence of size in the case of glipizide compared to 
metformin. This confirms that solubility of encapsulated drug is equally important in the 
process of dissolution.  
 
5.4 Conclusions 
For the first time, the co-encapsulation of divergent solubility drugs into liposomes prepared by 
microfluidics was investigated. Microfluidics was not only found to be efficient in producing co-
drug encapsulated liposomes, but also was a rapid liposome production method; microfluidics 
is a simple, one step method for producing small unilamellar liposomes. Furthermore, to a 
degree, size may be controlled by consideration of the interplay between alcohol diffusion and 
laminar convection, in line with previous reports (Jahn et al., 2007; Kastner et al., 2014). With 
regards to developing a drug carrier system, it is particularly important that the carrier system’s 
characteristics are reproducible and robust. This aspect can be achieved by use of microfluidics, 
which can reproduce formulation with robustness and in a limited amount of time. 
Microfluidics based liposomal encapsulation of a poorly water soluble drug was reported in past 
(Kastner et al., 2015) and the studies reported within this thesis demonstrate that high drug 
loading can be achieved with a range of drugs. Furthermore, for the first time, we have 
successfully prepared co-drug encapsulated liposomes using a microfluidic device, which may 
prove beneficial for drugs which are commonly used in combinational therapy and possess 
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divergent solubility, but also for the co-delivery of important anticancer drugs (Cosco et al., 
2012). Overall, microfluidics offers several advantages over several other methods in use for 
liposome preparation; in particular, the ability to manufacture a precise, robust and scalable 
liposome product several times quicker than other production methods for liposomes.   
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Chapter 6: Liposomes for the inhibition of respiratory syncytial 
virus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publication related to this chapter:  
S Joshi, D Kirby, Y Perrie, S R Singh. Novel nano-biomaterials for inhibition of respiratory 
syncytialvirus. TechConnect World Innovation Conference and Expo, Technical Proceedings of 
the 2017, Volume 3, p. 75-78. 
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6.1 Introduction 
Respiratory syncytial virus (RSV) as well as Rhinovirus (HRV) are the main causes of acute lower 
respiratory tract (LRTI) infections (Luchsinger et al., 2014), with noticeable increases in 
incidences of RSV infection during winter months, particularly in specific populations including 
foetus, infants, children and young adults (AR et al., 2005b; Borchers et al., 2013; JS and J, 2010; 
Rappuoli et al., 2011).  RSV is a prominent cause of bronchitis and pneumonia, and it is widely 
recognised that there is need for vaccine against RSV; natural infection is not capable of 
inducing life-long immunity and patients are prone to suffer repeating RSV infection (Kamphuis 
et al., 2012).  
RSV, which belongs to the Paramyxo virus community and Pneumoviridae subfamily (Wyde, 
1998), is a distinct serotype having two major antigenic circulating subgroups, of which one 
dominates (Borchers et al., 2013).  RSV has an RNA genome consisting of 15191 base pairs, 
which can be identified with 11 proteins, including 2-non-structural proteins (NS-1 and NA-2), 
3-surface proteins (glycoprotein-G, fusion protein-F, and hydrophobic protein-HP), two 
overlapping frames of M2 mRNA producing 2 distinct matrix proteins (M-1 and M-2) and 4 
other structural proteins (matrix protein-M, nucleocapsid-N, phosphoprotein-P and large 
protein-L) (Borchers et al., 2013) (Figure 6.1).Viruses of the Pneumoviridae subfamily fuse their 
membrane with the plasma membrane of the host, which results in cell fusion if added to the 
cell in large quantities (Haywood, 1978). The entry of RSV virus into the host cells happens with 
the aid of a fusion protein, which has two hepated-repeated regions that form a hairpin like 
structure, facilitating the entry of the virus into the cells (Zhao et al., 2000). 
 
 
 
                    
 
Figure 6.1 Diagrammatic illustration of the structure of respiratory syncytial virus (RSV), a member of the Paramyxo virus community 
and Pneumoviridae subfamily. (image modified from 
202 
(Redmond, 2013)) .
 
203 
 
 
Route cause analysis of any disease or disorder is at the foundation of treatment design. 
Infection of RSV can start with mild upper respiratory tract infection (URTI) and may lead to 
potentially precarious Lower respiratory tract infection (Borchers et al., 2013).  RSV 
transmission happens person to person, directly or indirectly;an RSV infected person, upon 
sneezing or coughing, can leave viral droplets suspended in the air, which have the potential for 
transmission of infection by entering healthy individual through the mouth, nose or eyes (CDC, 
2014; Diseases, 2014).  
 
First line treatment of RSV infection is the use of bronchodilators, such as α and/or β adrenergic 
agonist (Borchers et al., 2013). For paediatrics, since corticosteroids are not approved for 
treating RSV infected individuals less than 1 year old due to safety concerns (Piedimonte and 
Perez, 2014), the use of vaporub and non-aspirin formulations, such as paracetamol, are the 
treatments of choice prior to clinical attention. Of the very few options available for the 
treatment of RSV, ribavirin, a broad spectrum antiviral drug, is used, although this too comes 
with limitations and drawbacks (Bawage et al., 2013); despite several concept studies claiming 
effectiveness of ribavirin in significantly reducing the RSV load and minimising disease severity, 
the disadvantages of mutagenicity, teratogenicity and carcinogenicity subsequently resulted in 
FDA denial (Simões et al., 2015). Active prophylaxis would be better than passive prophylaxis 
but, unfortunately, there is no current vaccine developed for RSV infection. Formalin 
inactivated vaccine was launched in  the 1960s, but was later withdrawn due to poor 
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immunogenic response as well as an atypical TH2-type response, increasing chances of 
reinfection with similar or deadly infections (Piedimonte and Perez, 2014). 
Recently, a novel approach to inhibit RSV was the use of gold nanoparticles (GNPs). These GNPs 
can be functionalised with nucleic acid, antibodies, drugs as well as with peptides and these 
functionalised GNPs can then be applied in diagnosis or treatment (Tiwari et al., 2014). Indeed, 
anti-RSV fusion peptide RF-482 (Figure 6.2) has previously been used to functionalise GNPs, 
which resulted in significant RSV inhibition (Singh et al., 2014). Liposomes can also be 
conjugated in the same way, but very limited research has been performed using liposomes as 
a carrier system for the inhibition of RSV (Hendricks et al., 2015; Vabbilisetty and Sun, 2014). 
Therefore, considering the global need, the work in this chapter describes a combined 
approach; liposomes as a carrier system and conjugation of liposomes with the anti-RSV fusion 
peptide RF-482 for inhibition of RSV.  
 
Peptide RF-482 is structure built of 39 amino acids (VFPSDEFDASISQVNEKIN 
QSLAFIRKSDLLHNVNAGKK) with a total of 611 atoms (atomic formula: C192H303N53O63, molecular 
weight: 4361.8, theoretical iso-electric point: 4.95), having a net charge of -2 (acidic to near 
neutral). RF-482 is derived from a precursor of RSV fusion protein F0 (Figure 6.2).  
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Figure 6.2 Diagrammatic illustration of the amino acid regions of the RSV fusion protein 
precursor F0 from which the peptide RF482is derived. 
 
Considering published outcomes related to treatment, as well as the impact of RSV on global 
healthcare, a promising treatment or vaccine development remains a priority.  The genome of 
RSV codes immunogenic proteins, which creates scope for DNA vaccines, subunit vaccines and 
nano vaccines (Bawage et al., 2013). These vaccines can be designed as carrier based vaccines, 
through the use of nanoparticulate systems, such as liposomes, that can express adjuvant 
action by enhanced antigen delivery or inducing innate immune responses (Schwendener, 
2014). The potential of liposomes as  a carrier of active pharmacological agents was described 
decades ago (Gregoriadis et al., 1971; Gregoriadis and Ryman, 1972a, b), whilst liposomes have 
attracted much attention for their ability to carry antigens as well as immunomodulators (Perrie 
et al., 2013). Therefore, liposomes could be a potential candidate in vaccine development 
against the RSV. 
 
6.2 Aim and objectives 
The work in this chapter aimed to prepare liposomes < 100 nm using thin film hydration 
followed by sonication, to effectively conjugate the anti-RSV peptide RF-482 and investigate the 
efficiency of this formulation against RSV inhibition. To achieve this, the objectives were: 
4. Preparation of RF-482 conjugated GNP as well as liposomes and separation of non-
conjugated peptide. 
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5. Evaluate the toxicity of the formulations using HEP-2 cells. 
6. Study and compare the liposomal RSV inhibition in presence and absence peptide RF-
482, as well as with the GNP and RF-482 conjugated GNP. 
 
6.3 Results and discussion 
6.3.1 Conjugation of gold nanoparticles and peptide RF-482 
Carboxyl-polymer coated spherical GNPs (Nanopartz™, Loveland, CO, USA), 50 nm in size, were 
functionalised with RF-482 (Bachem Americas Inc., Santa Clara, CA, USA) with the aid of 1-Ethyl-
3-(3-dimethylaminopropyl) carbodiimide (EDC, Sigma Aldrich, St. Louis, MO, USA) chemistry.  
 
Confirmation of conjugation of peptide with GNPs was made after the data analysis of DLS, and 
US/Visible spectrometry. It has previously been reported that peptide conjugation of the GNP 
scan be confirmed by the increase in particle size and reduction in the surface potential (Tiwari 
et al., 2014). Similarly, DLS results here show that the hydrodynamic diameter of GNPs was 
changed from 58.14 ±0.3 nm to 85.85 ± 1.5 nm after conjugation with RF-482 (Figure 6.3), 
whereas the zeta potential of GNPs changed from -66.5±1.3 to -54.8 ±0.4 mV (n=3, ±SD). These 
changes in the particle characteristics confirm the conjugation of RF-482 with GNPs.  
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Figure 6.3 DLS analysis of non-functionalised and functionalised hours. The line at the bottom 
(size 85.85±1.5 nm) represents non-functionalised nanoparticles; whereas top line (size 
58.14±0.3 nm) represents functionalised gold nanoparticles. (n=3 ±SD). 
 
For further evidence of peptide conjugation, previous studies have also shown that attachment 
of the peptide on the surface of the particle, including functionalisation of GNPs, can cause a 
shift in the surface plasma resonance (Chithrani et al., 2006a; Joshi et al., 2004; Stover et al., 
2014).Similarly, the shift of spectra from520 to 517 nm (Figure 6.4) was observed here after 
UV/Visible analysis of GNPs followed by FGNPs, further supporting the previous results 
confirming functionalisation of GNPs. 
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Figure 6.4 UV/Visible scan of GNPs and FGNPs. 
 
Furthermore, the supernatant obtained after FGNPs washing was subjected to BCA assay and 
tested for quantification of the protein conjugated with GNPs, using an indirect approach. It 
was found that 53.6% (n=3, ±1.3 %) was found not conjugated and, hence, it can be concluded 
that 46.4 % protein was conjugated. 
 
6.3.3 Conjugation of liposomes and peptide RF-482 
Liposomes are one of the most flexible structures that can conjugate moieties like lactose and 
peptide (Nahar et al., 2014; Vabbilisetty and Sun, 2014). As discussed earlier in this chapter 
(Figure 6.2), RF-482 is a very small peptide and, therefore, a slight increase in the size of 
liposomes can be expected to confirm the conjugation; indeed, it has previously been reported 
that the adsorption of protein to negatively charged liposomes can increase the size of 
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liposomes by >10 nm, but thephosphocholine liposomes can experience the change in size<10 
nm (Brooksbank et al., 1993; Kozak et al., 2015).  
 
Similarly, after the conjugation with RF-482, there is a slight change in the size of liposomes 
(91.78 ± 0.3 nm (PDI 0.2 ± 0.01) and 96.91 ± 0.6 nm (PDI 0.19 ± 0.03) before and after 
conjugation, respectively).  However, unlike the FGNPs, there was little observed change in the 
zeta potential due to conjugation of RF-482 (-9.9 ± 1 mv and -12.2 ± 1.3 mv before and after 
conjugation, respectively) (Figure 6.5). This could be because the DSPC is neutral and the 
conjugation of RF-482 hasn’t brought any charge shading effect on the particle. Unlike GNPs, 
there is no chemical process involved with the conjugation of RF-482 with liposomes and the 
conjugation is dependent on electrostatic or hydrophilic interaction of the RF-482 with 
liposome. 
 
Figure 6.5 DLS measurement of liposomes before and after RF-482conjugation. (n=3 ±SD). 
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In order to support the results above indicating association of peptide with liposomes, further 
analysis employed fluorescent dye FITC labelled peptide RF-482 for the conjugation. After the 
separation of non-conjugated peptide, the liposomal suspension was dried, covered with 
phosphotungstic acid for better resolution and observed under the fluorescence microscope. 
After separation of non-conjugated peptide, the presence of peptide in the suspension suggests 
its association with the liposomes. The presence of RF-482 in the suspension was observed at 
low and high magnification (Figure 6.6a&b); the low magnification shows the omnipresence in 
the drop of the suspension, whereas at high magnification, the RF-482 appeared as clusters, 
possibly around the liposomes.  
 
Indeed, this ‘corona formation’ phenomenon was described recently following adsorption of 
protein on the surface of liposomal nanoparticles; a protein corona formation was observed 
around the liposomes, with no significant effect on the size of liposomes (Hadjidemetriou et al., 
2016; Hadjidemetriou et al., 2015). A similar phenomenon had also been reported for 
polymeric microparticles (Kirby et al., 2013). 
 
Also, previous studies have reported that, whilst negatively charged liposomes have better 
protein adsorption due to high binding affinity, neutral liposomes could also have protein 
adsorption onto their surface due to some electrostatic interaction (Price et al., 2001).  
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It is described earlier in this chapter that the RF-482 is a fusion protein. Given the cohesive 
nature of the RF-482 and the resemblance of the liposomal bilayer to the cell surface, it is likely 
that some interaction has occurred between the protein and the lipid bilayer, resulting in its 
adsorption on the surface of the liposomes. Thereby, this whole conjugation resembles the 
phenomenon of the ‘protein corona’ formation, where protein is adsorbed on the surface of 
the liposomes forming a corona (Hadjidemetriou et al., 2016; Hadjidemetriou et al., 2015).  
 
Knowing this, subsequently after the fluorescence microscopy, the empty liposomes as well as 
peptide conjugated liposomes were imaged under TEM. Presence of protein was again 
indicated by a cloudy environment observed around the conjugated liposomes and a change in 
morphology (Figure 6.7b), which was not observed in the case of empty liposomes (Figure 
6.7a). 
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(a)       (b) 
Figure 6.6 Fluorescence microscopy analysis liposomes conjugated with FITC labelled peptide RF-482 (Green). (a) 10X magnification 
and (b) at 40X magnification. 
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(a)        (b) 
 
Figure 6.7 Transmission electron microscopy analysis. Comparison between (a) empty liposomes and (b) RF-482 peptide associated 
liposomes Images taken at 50X magnification and 60kv HT. 
 
 
 
6.3.4 Evaluation of column efficiency to separate the non
The efficiency of the column to separate the RF
achieve maximum removal, the solution
separated protein may, thereby, be counted as conjugated protein. Also, to remove further 
doubt, three different concentrations of peptide RF
the same amount of time and the eluent was tested for recovery. It was observed that more 
than 97 ± 1% of protein passes through the column (Figure 6.8). This confirms that the column 
used to separate the non-conjugated protein is efficient for the purpose. 
 
Figure 6.8 Analysis of column efficiency to separate non
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Furthermore, this confirms that the liposomal sample obtained after separation of 
nonconjugated protein would have negligible amounts of non-conjugated protein present along 
with the liposomes in the suspension. In other words, only liposomes conjugated with the RF-
482 can be present in the suspension as almost all the non-conjugated RF-482 separates out 
from the column after centrifugation.  
 
6.3.5 Quantification of conjugation 
The exact mechanism of protein-liposome association is still unknown, although results above 
indicate that RF-482 is associated with the liposomes. However, it was necessary to quantify 
the amount of protein conjugated with the liposomes, whilst being equally important to 
achieve the mass balance to confirm the actual amount of conjugation of peptide. Hence, the 
BCA assay was performed for the analysis of both eluent as well as liposome samples. It was 
confirmed that 81.7 ± 0.1 % (n=3) was not-conjugated and 19.1 ± 0.4 % (n=3) was conjugated 
(Figure 6.9). This also confirms 100 % recovery of initial amount of peptide.  
 
The percent conjugation of GNPs was significantly higher than liposomes, since the conjugation 
of RF-482 and GNPs involves covalent bond formation, which contributes towards less loss of 
adsorbed (or conjugated) peptide upon centrifugation (Singh et al., 2014). Also, as mentioned in 
the previous section, the adsorption of peptides is higher in negatively charged particles than 
the neutral particles (Price et al., 2001). DSPC:cholesterol liposomes neither form any covalent 
bond with the peptide RF-482 nor have strong charges to absorb more peptide and, hence, the 
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percent conjugation of liposomes is significantly lower than GNPs.  Factors such as cohesive 
nature of peptide RF-482, potential electrostatic and hydrophilic interaction between peptide 
RF-482 and liposomes as well as the resemblance of liposomes with the cell membrane 
contributes in making liposomes a potential carrier of anti-RSV peptide RF-482.  
 
                
Figure 6.9 Liposomal conjugation with peptide RF-482 determined by BCA assay. Results 
presented as peptide conjugated determined after separation of non-conjugated peptide. (n=3 
±SD). 
 
6.3.6 Cell toxicity analysis 
The emerging problem of RSV treatment development is cell toxicity, as several compounds 
have failed to meet toxicity criteria in in-vivo testing, such as Pyrazofurin (Wyde et al., 1989), 
neplanocin (Shuto et al., 1992) and PALA (Wyde et al., 1995), which has made them 
unacceptable for clinical use. Peptide, GNPs and FGNPs are proven to be non-toxic up to certain 
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levels of concentration (Tiwari et al., 2014), whilst liposomes can carry an extensive range of 
molecules, and have low toxicity for therapeutic requirements (Storm and Crommelin, 1998a). 
 
A range of concentrations of peptide, GNPs, FGNPs, liposomes and peptide encapsulated 
liposomes were assessed for cell toxicityin human epidermoid type-2 (HEP-2) cells (American 
Type Culture Collection (ATCC), Manassas, VA 20110 USA). It was found that peptide upto 0.003 
mg, as well as GNPs and FNGPs upto 3 nM concentrations were non-toxic to HEP-2 cells (Figure 
6.10). It was also found that both empty and peptide encapsulated liposomes up to volume of 
150 µL (150µL is approximately 0.03 mg RF-482) was non-toxic to HEP-2 cells (Figure 6.10).  
 
Peptide, liposomes and peptide conjugated liposomes at two different concentrations were 
tested for their cell toxicity. There was no toxicity observed with both the concentrations of all 
samples. For all the chosen concentration of all the samples, more than 80 % (n=3 ± SD) cell 
viability was observed after 72 hours of incubation (Figure 6.10). 
 
Knowing that the toxicity is an emerging problem in RSV treatment (Wyde, 1998), it is one of 
the primary objectives when designing treatment for RSV infection. In this scenario, liposomes 
have shown their non-toxic nature for the chosen HEP-2 cells for 72 hours, reflecting their 
potential application in designing RSV treatment.  
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Figure 6.10 Toxicity profiling of peptide RF-482, Liposomes and RF-482 conjugated liposomes as well as GNPs and FGNPs presented 
through cell viability count performed using MTT assay (section 2.6.3). (72 hours, n=3 ±SD). 
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6.3.7 Investigation of viral inhibition 
The plaque assay is one of the most common and reliable methods of determination of 
viral/antiviral activity by counting plaques in the cell culture. Also, the plaque reduction assay is 
known as the optimum standard for antiviral activity analysis (Landry et al., 2000). The plaque 
assay was performed using HEP-2 cells (1.5×105/well) proliferated in MEM-10 for 48hours to 
achieve maximum confluence. During the plaque assay, the monolayer of HEP-2 cells was 
infected with the lytic RSV. The infected cells experience lytic cycles and eventually appear as 
plaques or, in other words, zones of cell death (Baer and Kehn-Hall, 2014). It was reported 
recently that surfactant phospholipids bound to RSV have markedly suppressed the infection 
through fusion inhibition (Numata et al., 2010).  
 
Here, liposomes and nanoparticles with and without their conjugation product with the RSV 
fusion protein were tested against RSV infection to the HEP-2 cells. When these plaques were 
counted, it was observed that, in the presence of peptide RF-482/liposomes/peptide 
conjugated liposomes, the total number of plaques are significantly less than in the absence of 
the same (Figure 6.11; p<0.005 ANOVA, post hoc-Dunnett’s multiple comparison test). This 
confirms that liposomes/peptide RF-482 alone or as conjugation product is capable of inhibiting 
the virus.  
 
Indeed, liposomes have recently gained attention for the treatment of viral infections 
(Hendricks et al., 2015); moreover, it has recently been shown that 1-stearoyl-2-arachidonoyl-
220 
 
 
sn-glycero-3-phospho-L-serine (SAPS) liposomes can inhibit human rhinovirus (HRV) (Stokes et 
al., 2016). Thus, the findings presented here similarly confirming the inhibition of RSV in the 
presence of DSPC-cholesterol liposomes is of interest and corroborates research elsewhere in 
the field. The results also confirm that RSV percent inhibition is significantly increased 
(approximately 9 %, p<0.005, ANOVA, post hoc-Dunnett’s multiple comparison test) for RF-482 
conjugated liposomes compared to RF-482 and liposomes alone (Figure 6.11). 
 
On the other hand, GNPs as well as FGNPs were efficient in inhibiting virus and have shown 
more than 60 % viral inhibition through the plaque assay. However, when a comparison was 
made between functionalised gold nanoparticles and functionalised liposomes, it was found 
that the liposomes have a significantly greater RSV inhibitory effect (P<0.05, t-test).  
 
Although, the liposomes have less percent RF-482 conjugation compared to GNPs, it was 
observed that the toxicity index of liposome alone or functionalised liposomes is equal or better 
than the GNPs or FGNPs. Also, the plaque assay results represent a significant difference in RSV 
inhibition by liposomes compared to GNPs alone (P<0.05, t-test) and there was also a significant 
difference in RSV inhibition by functionalised liposomes compared to GNPs and FGNPs (p<0.05, 
ANOVA, post hoc-Dunnett’s multiple comparison test). This suggests that liposomes are a 
better candidate for inhibiting RSV compared to GNPs alone, whilst functionalised liposomes 
are a better candidate for RSV inhibition compared to GNPs and FGNPs.  
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Figure 6.11 Screening of Peptide, Liposomes and gold nanoparticles with and without peptide conjugated against RSV. Plaques were 
counted and the mean count of each sample was compared against control to determine the percent inhibition. (n=3 ±SD). 
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It was important to post-investigate the findings of the plaque assay, in order to validate the 
results and provide a qualitative and quantitative assessment. Therefore, immunofluorescence 
imaging was used as a qualitative tool and PCR as a quantitative tool. For the 
immunofluorescence analysis, the HEP-2 cells were incubated for 48 h with peptide RF-482, 
empty liposomes and functionalised liposomes, as well as GNPs and FGNPs, followed by fixing 
in paraformaldehyde-glutaraldehyde and washing with buffer (1X PBS). An appropriate 
chamber from the 8-chambered slide was observed under the fluorescence microscope for the 
RSV activity. The observation made from this analysis matches the results obtained from the 
plaque assay and confirm that peptide RF-482, liposomes and peptide conjugated liposomes, as 
well as GNPs and FGNPs, are capable of inhibiting RSV (Figure 6.12). 
Recently, reports have shown that  phosphatidylinositol (PI) inhibits the respiratory syncytial 
virus (RSV), as the PI binds the RSV with high affinity, inhibiting its fusion to the epithelial cells 
(Numata et al., 2010; Numata et al., 2015). There are five derivatives of phospholipids including 
the PI and the phosphocholine (PC). Although the exact mechanism of RSV inhibition by PC is 
not confirmed, it is possible that, similarly to the PI, the PC could have affinity towards the RSV, 
inhibiting its fusion to the epithelial cells.  
Presence of virus can be clearly marked with the green dye (FITC) and HEP-2 cells with the blue 
dye (DAPI). This microscopic investigation confirms that, not only GNPs and FGNPs, but also 
liposomes as well as functionalised liposomes are efficient in inhibiting RSV spread. With RF-482 
alone, the effect is less prominent, as green dye (FITC) can still be observed in some places 
(Figure 6.12). 
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Figure 6.12 Fluorescence microscopy analysis. FITC (Green): RSV and DAPI (Blue): HEP-2 Cell nucleus.  In liposomes and RF-482 
liposomes the blue colour represents survived cells and green colour represents presence of RSV.
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Polymerase chain reaction (PCR), one of the basic techniques available in the modern biological 
research, was employed for the quantification of the target sequence using real time, by 
detecting the number of amplicons generated at the end of every amplification cycle 
(Watzinger et al., 2006).  The whole experiment was a set of small experiments starting from 
cell culture to gene quantification. Having confirmation from the microscopic observation of 
viral inhibition, it was necessary to validate, numerically, the plaque assay results. 
qRT-PCR provides rapid and quantitative data for analysis of viral presence. However, prior to 
amplification of cDNA via RT-PCR, the RNA was extracted from the samples and cDNA was 
synthesised using the superscript. After amplification, the obtained cycle threshold ‘Ct’ values 
were used as a tool for the comparison between the samples.  
Significant differences (p<0.005, ANOVA, post hoc-Dunnett’s multiple comparison test) were 
observed between the Ct value of virus samples and samples having 
peptide/liposomes/conjugated liposomes/GNPs/FGNPs (Figure 6.13). Although there is no 
significant difference (p>0.05, t-test) observed between peptide/liposome alone and 
conjugated liposomes, the conjugated liposome samples displayed a slight trend for higher Ct 
values, further suggesting more inhibition when used in combination (Figure 6.13).   
GNPs as well as FGNPs were efficient in inhibiting virus and have shown the cycle threshold 
significantly higher than the virus alone (p<0.05, ANOVA, post hoc-Dunnett’s multiple 
comparison test). This confirms the anti-RSV effect of GNPs and FGNPs observed through the 
plaque assay and immunofluorescence imaging. However, when a comparison was made 
225 
 
 
between GNPs and liposomes, it was found that the liposomes have a significantly increased 
inhibitory effect towards the RSV inhibition (P<0.05, t-test) (Figure 6.13). 
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Figure 6.13 Screening of RSV-F gene amplicon dilution with water as negative control. Water represents blank or sample with no 
gene amplicon. Blue line: indicating the threshold of virus samplehas higher gene amplicon than the gene amplicon of standard 
10^4. Comparison of viral gene amplicon (V) and Peptide (P1 & P2), Liposomes (L1 & L2), Functionalised liposomes (LP1 & LP2), gold 
nanoparticles (N2) and functionalized gold nanoparticles (NP2). (* and ** in the figure represents p<0.05 and p 0.01 respectively). 
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6.4 Conclusion 
With the quest of finding an alternative carrier for delivering the anti-RSV peptide RF-482, a 
liposome formulation has been prepared and tested for the inhibition of RSV infection. Similar 
to the GNPs and FGNPs that have previously been reported (Singh et al., 2014; Tiwari et al., 
2014), the functionalisation of liposomes was confirmed through dynamic light scattering 
(Figure 6.5), change in the surface charge, fluorescence imaging (Figure 6.6) and transmission 
electron microscopy (Figure 6.7).  The cytotoxicity of various concentrations of these liposomes 
was tested by MTT assay and it was found that liposomes of two different concentrations of 
lipids with and without protein conjugation did not render any cytotoxic effect and molecular 
effect on the host HEP-2 cells (Figure 6.10).   The anti-RSV effect was then confirmed in plaque 
assay (Figure 6.11), immunofluorescence imaging (Figure 6.12) as well as in qRT-PCR. In qRT-
PCR, the cycle threshold (Ct) for liposomes of two different concentrations of lipids with and 
without protein conjugation was observed significantly higher (P <0.005, t-test performed 
individually) than the virus cycle threshold (Ct) (Figure 6.13). 
Overall, the observed potential of GNPs and FGNPs to inhibit RSV infection matches the past 
research (Tiwari et al., 2014). However, liposomes as a new candidate for RSV inhibition was 
tested and the inhibitory effect of liposomes was shown to be better compared to GNPs alone, 
whilst functionalised liposomes were shown to be a better candidate for RSV inhibition 
compared to both GNPs and FGNPs. However, this has generated another quest to unveil the 
exact mechanism of RSV infection inhibition by the use of liposomes or functionalised 
liposomes, which could lead to commercialisation of the formulation. 
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Chapter 7: Overall discussion and conclusion 
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7.1 RP-HPLC based simultaneous determination of metformin and glipizide 
In this thesis, liposomes have been explored as a delivery vehicle to improve the delivery of 
drugs that require advanced strategies when considering their formulation. Consideration was 
given to improving the solubility and delivery of low-solubility drugs that could be co-
encapsulated with hydrophilic drugs, and also liposomes were considered for their ability to 
deliver biopharmaceutical systems.  
 
To achieve this, robust methods for drug quantification are required. Therefore, to determine 
drug encapsulation, as well as drug loss, an RP-HPLC based method was developed, where the 
separation was based on the affinity of the compound towards the stationary phase in the 
column and the quantification was performed using UV detection. This method was then 
evaluated using a range of parameters, such as specificity, accuracy, linearity, precision and 
intermediate precision, fulfilling ICH criterions for method validation (FDA, 1994). This method 
is based on isocratic elution, which makes the method simple and the retention time observed 
is less than 3 minutes. With this method, not only free drug, but also encapsulated as well as 
released drug was determined. The method was not compatible with the simulated medium 
used for drug release studies. 
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7.2 Production of liposomes co-encapsulating drugs of divergent solubility 
As mentioned previously, the liposomal size is important given the possibility of clearance by 
RES (Gregoriadis, 1995), but size reduction to produce SUVs can lead to the formation of single 
compartment vesicles, thereby lowering internal volume, which directly affects the drug 
loading (Szoka and Papahadjopoulos, 1978). Therefore, both MLVs as well as SUVs were 
produced and evaluated for their potential of co-drug delivery.  
 
Initially, the significance of cholesterol concentration was determined, where liposomes with 
two different concentrations of cholesterol were prepared. With low fractions of cholesterol in 
the formulations (below 33 mole %), no change in the size of the liposomes can be expected 
(Melzak et al., 2012) and the bulky appearance of cholesterol is responsible for the immobility 
of hydrophobic tails (Deol and Khuller, 1997), which can impact on drug loading within the 
bilayer. However, with the formulations tested within this thesis, no cholesterol concentration 
induced change was observed in size, surface potential, drug loading and retention capacity of 
liposomes. Simultaneously, the effect of drug encapsulation on particle characteristics was 
studied and it was found that neither metformin nor glipizide have any significant effect on 
MLV characteristics, irrespective of cholesterol concentration. Furthermore, the formulations 
were stable for 28 days, having particle sizes around 10 microns, surface charge < ± 10 mV and 
< 12% drug loss of entrapped drug. 
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Knowing that the presence of cholesterol makes bilayers rigid (Eloy et al., 2014) and an increase 
in cholesterol concentration did not make any difference in particle characteristics – including 
drug loading or retention – DSPC:Cholesterol concentration of 5:2 w/w was finalised for further 
studies. Subsequently, co-encapsulation of two drugs simultaneously was evaluated. Here, no 
significant difference (p>0.05, t-test) in drug loading was observed; however, the particle size of 
co-drug loaded MLVs was significantly increased (P<0.05,t-est) compared to the single-drug 
loaded liposomes. To evaluate liposomes for the maximum possible encapsulation, a drug 
escalation study was performed. Although there was no difference observed in size or drug 
loading capacity of MLVs, there was a gradual increase in encapsulation efficiency observed for 
both metformin and glipizide.  
 
MLVs can be transformed into SUVs by methods including sonication or extrusion, but 
sonication is broadly used because of ease of the method as well as cost effectiveness. 
However, during the course of sonication, the field of sonic energy ruptures the bilayer and 
forms SUVs. During this rupture process, the lipophilic drug becomes prone to leakage and the 
likelihood of loss of hydrophilic drug increases. To study this possibility, MLVs were transformed 
into SUVs by sonication and their particle size, drug loading as well as in-vitro drug release was 
compared with the MLVs. There was no significant difference (p>0.05 ANOVA post hoc 
Dunnett’s test) found in the particle characteristics (i.e. size and zeta potential) of empty, 
individual or co-drug loaded SUVs. However, the percent loading was significantly decreased 
(approximately 25 % for glipizide and 52 % for metformin, p<0.05, t-test) in SUVs compared to 
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MLVs. However, drug release was comparatively slower in SUVs than MLVs and SUV are less 
prone to a burst effect, possibly due to the rigid bilayer packing achieved. 
 
7.3 Microfluidics based simultaneous co-encapsulation of lipophilic and hydrophilic drugs 
Unlike probe sonication, the microfluidics process of SUV production is less disruptive as well as 
less prone to contamination (Batzri and Korn, 1973; Wagner and Vorauer-Uhl, 2010). Moreover, 
it is a rapid, one step liposome production method. Use of microfluidics for the encapsulation 
of poorly water soluble drug propofol was reported recently (Kastner et al., 2015), but in this 
thesis, for the first time simultaneous encapsulation of lipophilic and hydrophilic drug was 
demonstrated.  
 
Initially, the impact of FRR and TFR was studied on the formation of SUVs composed of the long 
chain lipid, DSPC, in combination with cholesterol (5:2, w/w). Decreased availability of solvent 
for lipid solubilisation as well as decreased distance for diffusion impacts vesicle closure time 
and results in production of smaller vesicles (Zook and Vreeland, 2010). At higher TFR (15 
mL/min) and high aqueous volume (5:1 aqueous: organic), production of smaller liposomes was 
observed in comparison with lower TFR and high organic content. The solvent to buffer ratio 
has a significant effect (p<0.05, ANOVA post hoc Dunnett’s test) on the particle size as well as 
PDI. 
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Size and lamellarity are the main points that confirm the formation of SUVs. The less than 100 
nanometer size range of liposomes produced by microfluidics was confirmed by DLS and, to 
examine the structure of liposomes closely, cryo-electron microscopy was also undertaken. No 
significant variations have been observed between DLS results and cryo-TEM results with 
respect to the size and PDI of liposomes; the average size for all liposome samples was around 
60 ± 10 nm. The presence of organic solvent over the permitted limit may deteriorate the 
formulation; therefore, dialysis was used for the removal of organic phase of liposomes 
obtained after the chaotic mixing of aqueous phase and organic phase having lipids dissolved. 
Only 25 ± 6 ppm of organic solvent was found remaining in the sample, which was far below the 
ICH limit (3000 ppm). 
 
In terms of drug loading within these vesicles prepared using microfluidics, the loading was 
based on the principle of passive loading, where both drug and lipids are co-dispersed in the 
aqueous phase. Generally, encapsulation efficiency for passive loading is < 50% for lipophilic 
drugs (Cullis et al., 1989) and 1 to 15 % for hydrophilic drugs (Cullis et al., 1989; Sharma and 
Sharma, 1997), whilst these studies have shown notably higher hydrophilic (metformin) drug 
loading of approximately 20% was achieved. Subsequently, the maximum possible 
encapsulation was determined through a drug escalation study. Here, similar to the MLVs, 
although there was no difference observed in size or drug loading capacity of SUVs, there was a 
gradual increase in encapsulation efficiency observed for both metformin and glipizide. 
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Finally, the release of drugs was performed using the USP-4 dissolution apparatus. There are 
various models reported in past literature and it can be expected that any drug subjected for 
drug release could have strong releation with these models (Ramteke et al., 2014), with both 
zero order and first order kinetics being common; zero order is independent of drug 
concentration (Costa and Lobo, 2001), whilst first order is directly proportional to the drug 
concentration (Jeong et al., 2000). However; from the R2 values obtained from line of fit, it can 
be concluded that only when the metformin was co-entrapped with the glipizide has followed 
first order release but for all other samples there is strong correlation observed with Higuchi 
model compared to first order and zero order kinetics. However, in case of drug release from 
SUV obtained after sonication; where, all the metformin shown to fit good with Higuchi model 
but the glipizide shown to fit good with zero order having  difference in R2 values. The initial fast 
drug release is possibly due to the burst effect, where release of glipizide increased the fluidity 
of the bilayer, which in turn had a pronounced effect on metformin hydrochloride release, as 
well as glipizide release, to a lesser extent. Also, the hydrophilic nature of the metformin may 
be responsible for its initial quick release.  
 
7.4 Liposomal inhibition of respiratory syncytial virus 
RF-482 was reported as an inhibitor of RSV fusion and, to date, gold nanoparticles are the only 
reportedcarrier of RF-482 (Singh et al., 2014).Given the potential of liposomes and the studies 
conducted in chapters 4 and 5, liposomes were considered as an alternative carrier for 
delivering the anti-RSV peptide, RF-482. 
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RF-482 is a small fusion peptide with 39 amino acids with a total of 611 atoms. Since it is fusion 
peptide and hydrophilic in nature, it was expected that the RF-482 may get entrapped in the 
hydrophilic core as well as it may adsorb on the surface of liposomes. The exact mechanism of 
protein-liposome association is still unknown, although results presented in this thesis indicate 
that RF-482 is associated with the liposomes. The functionalisation was confirmed by a small 
increase in the size of liposomes from 91.8 ± 0.3 nm (PDI 0.2 ± 0.01) to 96.9 ± 0.6 nm (PDI 0.2 ± 
0.03), whilst association of peptide with liposome was also observed when FITC labelled 
peptide RF-482 was used for the conjugation and when the empty liposomes as well as peptide 
conjugated liposomes were imaged under TEM; the presence of the peptide was confirmed by 
the cloudy environment observed around the conjugated liposomes. In the case of the GNPs, 
the conjugation of RF-482 happens through a covalent bond, making the protein less 
susceptible to separation upon centrifugation, but in the case of DSPC:Cholesterol liposomes, 
the adsorption of peptides could be result of electrostatic interaction due to small amount of 
negative charge (< -10mV) present on the liposomes as well as due to the fusogenic nature of 
RF-482 and its interaction with the polar heads. 
 
To test the drug delivery efficacy of the liposomes with the RF-482, a plaque assay was used. 
This is one of the most common and reliable methods of determination of viral/antiviral activity 
by counting plaques in the cell culture (Landry et al., 2000). The results suggest that, although 
the liposomes have less percent RF-482 conjugation compared to GNPs, the toxicity index of 
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liposomes alone or functionalised is equal or better than the GNPs or FGNPs and were also 
superior in RSV inhibition compared to GNPs and FGNPs (p<0.05, ANOVA).  
 
However, it is necessary to validate the results of the plaque assay and provide a qualitative as 
well as quantitative assessment. Therefore, immunofluorescence imaging was used as 
qualitative tool and PCR as quantitative. The microscopic investigation confirmed that, not only 
GNPs and FGNPs, but also liposomes as well as functionalised liposomes are efficient in 
inhibiting RSV spread. Furthermore, the q-RT-PCR results suggest that, upon comparing GNPs 
and liposomes, it was found that the liposomes have a significantly increased inhibitory effect 
towards the RSV inhibition (P<0.05, t-test), where the cycle threshold observed is significantly 
higher than GNPs. Overall, the liposomes as a new candidate for RSV inhibition was tested and 
the inhibitory effect of liposomes was better compared to GNPs alone and functionalised 
liposomes were better candidate for RSV inhibition compared to both GNPs and FGNPs. 
 
7.5 Overall conclusion 
In relation to the aims and objectives in this thesis, the studies show that:  
1. Appropriate analytical methods for the preparation, quantification and characterisation 
of a range of liposomal formulations were developed and validated.  
2. The potential of liposomes as a carrier of hydrophilic, lipophilic (alone or co-entrapped) 
and peptide drugs were demonstrated. 
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3. A new high-throughput one-step process for the manufacture of liposomes 
simultaneously entrapping hydrophilic and lipophilic drugs was developed, and the 
formulations were evaluated in comparison with the formulations produced by the 
conventional thin film hydration method. 
4. Liposomes were shown to effectively deliver peptides and act as an anti-RSV protein 
carrier. 
7.6 Future work 
1. Knowing the multifaceted potential of liposomes make it a versatile drug delivery 
system. Co-encapsulation can be utilised as one of the routes to deliver the drugs used 
in the combinational therapy. For example, glipizide and metformin, paclitaxel and 
doxorubicin, gemcitabine and tamoxifen etc.  
2. In the quest for a time saving and easy approach of liposome production, microfluidics 
has brought a revolution. It will be interesting to study the scalability of liposomal co-
drug encapsulation using microfluidics as a method of production. Here, use of 
continuous production through a series of microfluidic devices could help to achieve the 
target of scalability.   
3. Adsorption of anti-RSV protein RF-482 was an example of the multifaceted nature of 
liposomes. Further development such as a potential vaccine against the respiratory 
syncytial virus infection possible. Whereas the system can apt for imaging, diagnostic 
and therapeutic applications and this can be achieved by using cell specific markers 
which could provide targeted as well as enhanced intracellular delivery. However, the 
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mechanism of interaction of the fusogenic RF-482 with liposomes, and the mechanism 
of liposomes to inhibit the RSV can be further explored using techniques like enzyme 
linked immunosorbent assay (ELISA), western blot, qRT-PCR; where factors like stress 
conditions etc can be explored. 
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